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Abstract  
Intestinal phosphate absorption occurs via a sodium-dependent mechanism, 
known to be NaPi-IIb-mediated, and a sodium-independent mechanism, thought 
to be mediated via the paracellular pathway. Emerging evidence suggests that 
the paracellular pathway is likely to be more dominant and that this pathway is 
regulated by NHE3. Studies in rats, mice and humans have shown some species 
differences in the efficacy of both NaPi-IIb and NHE3 inhibitors on intestinal 
phosphate absorption, thus, the suitability of rodents as experimental models to 
study phosphate absorption is uncertain. Furthermore, recent reports suggest 
that alterations in iron levels influence phosphate homeostasis, although there 
are conflicting reports regarding how it affects intestinal phosphate absorption. In 
this study, the mechanisms of phosphate absorption in the small intestine of rats, 
mice and humans were compared, and the effect of diet-induced iron deficiency 
on these mechanisms was investigated. The result showed a similar profile for 
intestinal NHE3 in rats and humans, suggesting that the rat is a more appropriate 
model to study the mechanisms of paracellular phosphate absorption. Using in 
vivo and in vitro uptake experiments, iron deficiency was demonstrated to 
significantly inhibit phosphate absorption in the duodenum and jejunum of rats. 
The findings of this study demonstrated that NaPi-IIb expression or activity was 
unaffected by iron deficiency. However, while the sodium-independent phosphate 
transport pathway was most affected in the duodenum, NHE3 activity was 
inhibited in the jejunum, in response to iron deficiency. Interestingly, iron 
deficiency resulted in increased expression of duodenal claudin 3, while also 
causing the expected upregulation of DMT1 in the duodenum and jejunum. It is 
therefore hypothesised that increased DMT1 expression, in addition to the 
inhibition of jejunal NHE3 activity by iron deficiency, may locally impact phosphate 
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absorption by a mechanism involving the accumulation of intracellular protons 
leading to the sealing of the paracellular pathway. 
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Impact statement  
This study aims to improve our understanding of intestinal phosphate absorption 
and address the potential discrepancies in the efficacy of NaPi-IIb and NHE3 
inhibitors in the inhibition of intestinal phosphate absorption in rodents and 
humans. The recently reported negative clinical outcomes from the use of NaPi-
IIb inhibitors in the treatment of hyperphosphataemia in CKD patients may be 
because this transporter was found to be most highly expressed in the shortest 
segment of the human small intestine, the duodenum, known to have the shortest 
sojourn time of food. In addition, under normal phosphate concentration in the 
intestinal lumen, NaPi-IIb would likely become saturated and therefore, its 
function would be limited.  
NHE3 has recently been linked to paracellular phosphate transport, and the 
findings of this study confirm its role in mediating phosphate absorption in rats, 
but not in mice. Interestingly, this is the first study to show that the regional 
expression of NHE3 in the small intestine of rats and humans are similar. This 
may explain why the findings that tenapanor, an NHE3 inhibitor that effectively 
inhibits phosphate absorption in rats translate into improved management of 
hyperphosphataemia in humans with CKD. Based on these findings, pre-clinical 
studies and future experiments aimed at discovering new compounds for 
inhibiting intestinal phosphate absorption in patients with hyperphosphataemia 
should be carried out using rats. 
This study is the first to show that diet-induced iron deficiency inhibits intestinal 
phosphate absorption, and this is potentially why iron deficiency, the most 
common micronutrient deficiency globally, has recently been linked to bone 
disease. The reduction of intestinal phosphate absorption in iron deficient 
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conditions may cause a potential dip in postprandial serum phosphate levels and 
this may result in the breakdown of bone mineral to buffer the change in serum 
phosphate. Increased bone resorption may be one of the causes of bone disease 
in iron deficient individuals. Therefore, it is important to educate the public to 
consume iron-rich diets to prevent not only iron deficiency anaemia, but also 
rickets in children or osteoporosis in adults.  
The findings of this study provide the first evidence that diet-induced iron 
deficiency inhibits intestinal phosphate absorption by a mechanism that 
potentially involves the upregulation of DMT1 and claudin 3 in the duodenum. In 
addition, diet-induced iron deficiency also causes jejunal DMT1 upregulation and 
inhibits NHE3-regulated paracellular phosphate absorption in this intestinal 
segment. The hypothesis is that DMT1 not only mediates iron absorption, but 
also activates mechanisms that result in the inhibition of intestinal phosphate 
absorption. These findings linking DMT1 and the inhibition of intestinal phosphate 
absorption may present a significant breakthrough in the management of 
hyperphosphataemia in CKD patients. To bring about the impact of this potential 
breakthrough, further studies in collaboration with pharmaceutical companies 
should be aimed at identifying compounds that can increase DMT1 levels in the 
small intestine of CKD patients. These compounds, if identified, will potentially 
increase intestinal iron absorption and reduce that of phosphate, thus, correcting 
two major clinical problems in CKD patients, iron deficiency anaemia and 
hyperphosphataemia. 
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1.0. Introduction to phosphate homeostasis and mechanisms of 
phosphate transport  
Inorganic phosphate is essential for the following physiological processes: 
generation of adenosine triphosphate (ATP), biosynthesis of nucleotides and 
proteins, cell signalling and bone mineralisation. Phosphate is also known to be 
a major component of the phospholipid bilayer of cell membranes. Because of 
these important functions, the maintenance of phosphate balance is necessary 
for survival. Phosphate imbalance is seen in inherited disorders such as X-linked 
hypophosphataemic rickets and tumoral calcinosis 1, and in acquired disorders 
like chronic kidney disease (CKD) 2,3. In addition, consistent consumption of 
excess phosphate from natural and processed food may increase serum 
phosphate levels, and this poses significant risks to the health of the general 
population. High serum phosphate levels (hyperphosphataemia) in healthy 
individuals and CKD patients have been linked to increased risk of cardiovascular 
diseases 2,4. With the high global prevalence of CKD 5, a condition associated 
with hyperphosphataemia, studies into understanding the mechanisms of 
phosphate homeostasis are gaining significant attention. A better understanding 
of these mechanisms will be invaluable in generating new management therapies 
for the management of phosphate imbalance. 
1.1. Phosphate homeostasis 
Phosphate homeostasis is the maintenance of extracellular phosphate levels 
within narrow physiological limits. In healthy adults, serum phosphate ranges 
from 0.8 – 1.45 mmol/l (2.5 – 4.5 mg/dl) 6. It is generally accepted that three key 
systems regulate phosphate balance: the bone-phosphate buffering system, the 
gastrointestinal system and the renal system, and the interaction between these 
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systems is regulated by a complex hormonal axis 7–11. While the bone rapidly 
buffers acute changes in serum phosphate, the renal system plays a more 
significant role in the long-term regulation of phosphate levels. The 
gastrointestinal system is involved in the digestion of phosphate-containing food 
and the subsequent absorption of phosphate into the circulation. Therefore, this 
system contributes to phosphate homeostasis by replenishing the extracellular 
phosphate pool during negative phosphate balance. The renal system acts as the 
major regulator of phosphate homeostasis by adjusting the levels of phosphate 
in the extracellular fluid in response to changes in phosphate absorption by the 
small intestine and phosphate shuttling from bone (Figure 1.1).  
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Figure 1.1. Systems involved in phosphate homeostasis. To maintain phosphate 
homeostasis, dietary phosphate intake is the same as the sum of the amount of 
phosphate excreted in urine and faeces. Bone acts as a reservoir for phosphate, where 
it is deposited and subsequently mobilised into the extracellular fluid when necessary.  
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The regulation of phosphate balance by the renal system involves changes in the 
expression of specific membrane transporters that facilitate proximal tubular 
reabsorption of phosphate. Two families of transporters mediate the transport of 
phosphate in the renal proximal tubule, of which the solute carrier, SLC34 family 
or type II phosphate transporters are known to be the major players, while the 
SLC20 or type III phosphate transporters only play a minor role (reviewed in 12,13). 
During positive phosphate balance, which could result from excessive intake of 
dietary phosphate, the expression of these transporters is downregulated 
resulting in an increase in urinary phosphate excretion. In contrast, these 
transporters are upregulated to conserve phosphate when extracellular 
phosphate levels are below normal physiological limits, or when intestinal 
phosphate absorption is significantly reduced during the intake of a low 
phosphate diet 14–17.  
Intestinal phosphate absorption is mediated by both transcellular and paracellular 
mechanisms 18. Like the renal system, transcellular or active phosphate transport 
in the small intestine is mediated by two families of phosphate transporters:  type 
II and type III phosphate transporters (reviewed in 12,13). Although the expression 
of the transcellular phosphate transporters changes in response to high or low 
dietary phosphate content 17,19, there is still a debate as to the overall contribution 
of the transcellular phosphate transport pathway in comparison to the paracellular 
pathway. Paracellular or passive phosphate transport is thought to involve the 
diffusion of phosphate across intestinal tight junctions. In contrast to the 
extensively studied transcellular phosphate absorption pathway, the paucity of 
information on the regulation of the paracellular pathway makes the small 
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intestine an area of intense focus in the search for management therapies for 
phosphate imbalance. 
There is a body of evidence supporting the interaction between the systems 
involved in phosphate homeostasis 20,21. In addition to the role of the small 
intestine in the absorption of phosphate, it has been speculated that the small 
intestine interacts with the kidneys by releasing an unknown phosphaturic factor 
22. However, due to the lack of evidence to support this hypothesis, it is now 
believed that this interaction between the small intestine and the kidneys may be 
as a result of changes in the levels of the systemic regulators of phosphate in 
response to postprandial phosphate levels 23,24. More importantly, the accepted 
osteo-renal interaction involving the action of the bone-derived phosphaturic 
factor fibroblast growth factor-23 (FGF-23), on the renal phosphate transporters 
is responsible for the maintenance of phosphate homeostasis 25. The release of 
FGF-23 in response to elevated extracellular phosphate levels following dietary 
phosphate intake links the small intestine to the osteo-renal mechanism of 
phosphate metabolism, and these interactions maintain phosphate balance.  
1.2. Na+-dependent phosphate cotransporters 
Three families of Na+-dependent phosphate cotransporters have been identified: 
type I, type II, and type III transporters 26–28. These transporters are integral 
membrane proteins, which are involved in the active transport of phosphate 
across epithelial cells. The mechanism driving this active transport process 
involves the action of the Na+/K+ ATPase in the basolateral membrane of the 
epithelia cells. The Na+/K+ ATPase generates the Na+ gradient required for the 
downhill transport of Na+ coupled to phosphate. A large body of evidence 
suggests that the type II phosphate transporters are the most important 
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transporter family involved in the maintenance of phosphate homeostasis 
(reviewed in 20), while there is no significant evidence for the contribution of the 
type I and type III transporters. 
1.2.1. Na+-dependent phosphate cotransporter type II 
The Na+-dependent phosphate cotransporter type II (NaPi-II) have been shown 
to be vital for the reabsorption of phosphate in the renal proximal tubules 29,30 and 
the small intestine 31. The SLC34 genes encode this family of transporters, and 
the transport proteins derived from these genes are inserted on the brush border 
membrane (BBM) of the cell to mediate phosphate transport. The members of 
the SLC34 gene family of phosphate transporters are SLC34A1 (NaPi-IIa), 
SLC34A2 (NaPi-IIb) and SLC34A3 (NaPi-IIc) 32. Although these transporters 
belong to the same family and share similar structural homology, their tissue 
distribution (Table 1.1.) and transport kinetics show transporter-specific features 
(Table 1.2). 
Table 1.1. Tissue distribution of the Na+-dependent phosphate cotransporter type 
II 
Transporter Tissue distribution References 
NaPi-IIa Kidney, Brain and osteoclasts. 33–37 
NaPi-IIb Small intestine, salivary gland, mammary gland, 
Lungs, liver, thyroid gland, uterus, ovary, prostate 
gland and testes.  
37–41 
NaPi-IIc Kidney, spleen, testes, brain, colon, skin and 
ovary. 
33,34,37 
 
1.2.1.1. Localisation of the type II Na+-dependent phosphate transporters 
Under normal dietary conditions, NaPi-IIa is localised in all segments (S1-S3) of 
the proximal tubule, while NaPi-IIc is localised only in the S1 segment (Figure 
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1.2) 33,34. In rodents, the expression and localisation of NaPi-IIa and -IIc proteins 
changes with age 42,43. Compared to weaned rats, preweaned rats show higher 
levels of the renal NaPi-II proteins, with similar levels in both superficial and 
juxtaglomerular nephron 42. However, in weaned and adult rats, renal NaPi-II 
proteins are higher in the juxtaglomerular nephron 42. Studies have shown that 
the relative distribution of NaPi-IIa and -IIc in the different segments of the 
superficial and juxtaglomerular nephrons is affected by dietary phosphate levels 
44. During dietary phosphate restriction, there are higher levels of these 
transporters in superficial nephrons compared to the juxtaglomerular nephrons 
44. In addition to the kidney, NaPi-IIa protein has also been identified in the brain 
35 and bone cells 36, while only NaPi-IIc mRNA has been found in the spleen, 
testes, brain, colon, skin and ovary 37 (Table 1.1). 
NaPi-IIb protein is expressed in the BBM of intestinal epithelial cells in rodents 
and humans (Figure 1.3). The distribution of this transporter throughout the whole 
length of the small intestine varies in different species 38,39. In the mouse small 
intestine, NaPi-IIb is highly expressed in the ileum, with low expression levels 
detected in the duodenum and jejunum, unlike in rat where the jejunum shows 
the highest levels of NaPi-IIb 17,39. The mouse ileum and rat jejunum have been 
demonstrated to have the highest expression of NaPi-IIb, and this protein is 
correlated with the highest rate of Na+-dependent phosphate absorption in these 
intestinal segments 38,39,45. Because of this correlation of intestinal NaPi-IIb with 
phosphate transport in these species, a higher rate of Na+-dependent phosphate 
absorption in the human jejunum compared to the ileum 46 suggests that the 
expression levels of NaPi-IIb protein in rats and humans are similar. There is 
evidence for an age-dependent variation in the expression of NaPi-IIb in the small 
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intestine of rodents, with the highest expression observed in preweanling animals 
compared to adults 47,48. The expression of NaPi-IIb protein has also been 
detected in the lungs, liver, salivary gland, thyroid gland, mammary gland, testes, 
ovary and the uterus 37,40,41. 
             
Figure 1.2. Phosphate transport in the renal proximal tubule. The type II (NaPi-IIa 
and NaPi-IIc) and type III (PiT-2) transporters mediate the transport of phosphate across 
the BBM of the proximal tubule (S1-S3 segments). These transporters are activated by 
the energy generated by the downhill transport of Na+ across the BBM, with the 
concentration gradient of Na+ maintained by the Na+/K+ ATPase pump at the basolateral 
membrane. The mechanism underlying the transport of phosphate across the 
basolateral membrane is currently unknown (?).                         
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Figure 1.3. Phosphate transport in the small intestine. NaPi-IIb and PiT-1 mediate 
the active transport of phosphate across the BBM of the small intestine. These 
transporters are activated by the energy generated by the downhill transport of Na+ 
across the BBM, with the concentration gradient of Na+ maintained by the Na+/K+ ATPase 
pump at the basolateral membrane. The mechanism underlying the transport of 
phosphate across the basolateral membrane is currently unknown (?). Phosphate also 
diffuses passively through tight junctions, indicated by the dotted arrows. 
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1.2.1.2. Molecular structure of the type II Na+-dependent phosphate 
transporters 
The NaPi-II proteins are integral membrane proteins with 8 – 12 transmembrane 
domains (TMDs), with both the C- and N-terminal regions situated in the 
intracellular compartment 13,27,29,49. Human NaPi-IIa is a protein with 639 amino 
acid residues 32 and has a molecular weight of approximately 70 kDa 50. In 
comparison, the rat NaPi-IIa has been predicted to have a molecular weight of 
approximately 90 kDa, with 637 amino acid residues 51. Human NaPi-IIb protein 
is made up of 689 amino acids, and its molecular weight varies between 77 – 108 
kDa based on the degree of glycosylation 52, with the fully glycosylated protein 
known to have a molecular weight of 108 kDa 27,40. Human NaPi-IIc is formed by 
599 amino acid residues 32, with a molecular weight of approximately 75 kDa 27. 
The structural topology of NaPi-IIa has been studied extensively in the last two 
decades. Using an in vitro translation approach, NaPi-IIa protein has been shown 
to have a large hydrophobic extracellular loop, situated between the 5th and 6th 
TMDs 53. Two regulatory sites have been identified in the NaPi-IIa protein; the K-
R motif, which interacts with PTH and a triglyceride-rich lipoprotein motif, which 
interacts with the PDZ proteins (discussed in more detail in section 1.2.1.5.2): 
NHERF1, NHERF2, NHERF3, NHERF4 and SHANK2E 54–56. NaPi-llc has been 
shown to interact with two PDZ proteins;  NHERF1 and NHERF3 57, with no 
convincing evidence for its interaction with the other PDZ proteins. Although 
NaPi-IIb has also been shown to interact with NHERF1, unlike NaPi-lla and -llc, 
evidence suggests that NaPi-llb does not interact with NHERF3 58. The detailed 
structure of NaPi-IIb and NaPi-IIc is still under investigation; however, 
bioinformatics analysis suggests that the NaPi-IIb protein has at least 8 TMDs, 4 
extracellular loops and 5 intracellular domains, with the N- and C-terminal regions 
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situated in the intracellular compartment 59, while NaPi-IIc has been predicted to 
have 8 TMDs 29. 
Genetic mutation studies involving specific modifications in selected TMDs have 
revealed the relationship between the structural components of the transporters 
and their function. Mutation at Ser-460 (by replacing with Cysteine), a site at the 
top of the 9th TMD of NaPi-IIa, has shown that this site is critical for its cotransport 
function (reviewed in 13). Similar sites in NaPi-IIb (Ser-448) and NaPi-IIc (Ser-
437) have also been shown to play a role in the Na+-phosphate cotransport 
function of these proteins 60,61. The linker regions between TMD1 and 2, and 
TMD7 and 8 have been implicated in the voltage-activated structural changes 
necessary for their cotransport function 62. The structural position of the N- and 
C-terminal regions of the NaPi-II proteins make both regions suited for interacting 
with regulatory molecules, both intracellular regulatory proteins and systemic 
regulators 13,27,49,63. 
1.2.1.3. Transport Kinetics of the type II Na+-dependent phosphate 
transporters 
NaPi-II proteins transport divalent phosphate ion (HPO42-) via an active transport 
process that involves the downhill movement of Na+ 64. NaPi-IIa and NaPi-IIb 
transport phosphate with a Na+: phosphate stoichiometry of 3:1 61, while NaPi-IIc 
transports phosphate with a 2:1 stoichiometry (Table 1.2) 65. The transport of 
phosphate by NaPi-IIa and NaPi-IIb results in the influx of a net positive charge 
into the cell, making both transporters electrogenic. However, no net positive 
charge is deposited in the intracellular compartment by NaPi-IIc-mediated 
phosphate transport, making this transporter an electroneutral phosphate carrier. 
Unlike NaPi-IIa and NaPi-IIb, the presence of charged aspartate as a member of 
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a conserved trio of amino acids at the bottom of the 4th TMD in NaPi-IIc confers 
the electroneutrality of this transporter 64,66. Heterologous expression studies in 
Xenopus oocytes have shown that the process of activation of NaPi-IIa and -IIb 
involves the binding of 2Na+, which exposes the phosphate binding site, after 
which another Na+ binds to cause a conformational change that results in the 
transport of phosphate into the cell 61. In contrast, for NaPi-IIc, the binding of 1Na+ 
to an allosteric or immobile site on the extracellular region of the transporter 
catalytically exposes the phosphate and Na+ binding sites, thus, allowing the 
binding of 2Na+ and divalent phosphate ion 60. The binding of these ions causes 
a conformational change resulting in the transport of the bound divalent 
phosphate ion and 2Na+ 60. The affinity for Na+ and phosphate is similar in all 
NaPi-II proteins, with an affinity constant (Km) of approximately 40 mM for Na+ 
and < 100 μM for phosphate 32. However, there is slight variations between the 
transporters (Table 1.2). These affinities are representative for the NaPi-II 
proteins at pH 7.4, which is the pH at which the transporters function optimally 67. 
The kinetic properties of the NaPi-II proteins are significantly affected by changes 
in proton (H+) concentration or pH 68. Early findings suggested that changes in 
pH alter the interaction of the NaPi-II proteins with Na+ due to an increase in the 
Km for Na+ 69. Additionally, their transport function may also be affected by the 
reduction of HPO42- to H2PO4-  by a decrease in pH, thus, reducing the 
concentration of HPO42-  available for binding with the NaPi-II proteins 68. It is now 
believed that the overall effect of H+ on the function of the NaPi-II proteins is the 
sum of the effects due to changes in the Km for Na+ and the divalent-monovalent 
phosphate ion shuttling 70.  
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Table 1.2. Kinetic features of the Na+-dependent phosphate cotransporter type II 
 
1.2.1.4. Inhibitors of the type II Na+-dependent phosphate transporters 
To understand the role of the renal and intestinal NaPi-II proteins, studies into 
generating experimental inhibitors of the activities of these proteins have been 
carried out extensively. Among the inhibitors examined, phosphonoformic acid 
(PFA), which is a competitive inhibitor, remains the most potent, readily available 
and widely accepted inhibitor of the function of these transporters 71. Like PFA, 
nicotinamide has been shown to inhibit the function of both intestinal and renal 
type II transporters 72,73. In addition, arsenate has been reported to act as a 
competitive inhibitor of NaPi-IIb, with high affinity of NaPi-IIb for arsenate due to 
the structural similarity of arsenate to HPO42-  74. Both arsenate and nicotinamide 
are known to negatively affect cellular metabolism and are therefore not 
commonly used as experimental inhibitors of NaPi-II proteins. Azaindole 
analogues, especially PF-06869206, have been recently shown to be a new 
group of orally bioavailable NaPi-IIa specific inhibitors 75. In addition, there is 
Properties NaPi-IIa NaPi-IIb NaPi-IIc 
Stoichiometry 
(Na+: HPO42-) 
3:1 3:1 2:1 
Km for Na+ (mM) ~ 45 ~ 30 ~ 45 
Km for HPO42- (µM) ~ 50 ~ 50 ~ 70 
Electrogenicity Electrogenic 
(+1) 
Electrogenic 
(+1) 
Electroneutral 
(0) 
Effect of pH on activity Reduces in 
low pH 
Increases in 
low pH 
Reduces in low 
pH 
Transport capacity  High High Low 
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evidence in rodents showing that two new compounds ASP3325 76 and NTX9066 
77 potently inhibit NaPi-IIb.  
1.2.1.5. Regulation of the type II Na+-dependent phosphate transporters  
The regulation of the levels of NaPi-II proteins at the BBM of renal and intestinal 
cells involves both systemic and cellular regulators. The cellular regulators 
include protein kinases such as protein kinase A (PKA), protein kinase C (PKC) 
and protein kinase G (PKG); and the scaffolding proteins (e.g. NHERF1 and 
NHERF3) associated with the C-terminal of the NaPi-II proteins. These 
scaffolding proteins are widely known to mediate the effects of the systemic 
regulators on the levels of the NaPi-II proteins at the BBM. 
1.2.1.5.1. Systemic regulators of the type II Na+-dependent phosphate 
transporters 
A large body of evidence supports the role of parathyroid hormone (PTH), FGF-
23, α-klotho, 1,25-dihydroxycholecalciferol (1,25(OH)2D3), and dietary phosphate 
in the regulation of the expression of the NaPi-ll proteins. In addition, dopamine, 
atrial natriuretic peptide (ANP), Insulin-like growth factor 1 (IGF-1), matrix 
extracellular phosphoglycoprotein (MEPE), secreted frizzled-related protein-4 
(sFRP-4), fibroblast growth factor-7 (FGF-7), estrogen, glucocorticoids and 
metabolic acidosis affect the expression or activity of these transporters 
(reviewed in 20).  
1.2.1.5.1.1. PTH 
PTH is an 84 amino acid polypeptide hormone, which is synthesised and released 
from the parathyroid gland in response to changes in circulating calcium (Ca2+), 
phosphate, 1,25(OH)2D3 and FGF-23 levels 78,79. This hormone has been shown 
to downregulate the expression of NaPi-IIa within minutes after binding to its 
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receptor in the renal proximal tubule 79–81. The mechanisms underlying this role 
of PTH in the downregulation of NaPi-lla has been reported to involve post-
translational shuttling of the protein from the BBM to intracellular sites where the 
protein is degraded 80. It has been hypothesised that the regulation of the 
transcription of NaPi-IIa by acute exposure of renal  proximal tubular epithelial 
cells to PTH does not contribute to its role in the reduction of the abundance of 
this transporter at the BBM 54, however, it is possible that persistently elevated 
PTH levels may inhibit the transcription of NaPi-IIa mRNA. PTH acts by binding 
to the PTH-type 1 receptor (PTHR1) 82, which is a G-protein coupled receptor 
localised at both the BBM and basolateral membrane of the renal proximal tubular 
cell 83. The binding of PTH to PTHR1 activates both phospholipase C (PLC)-Ca2+ 
and adenylate cyclase-cyclic adenosine monophosphate (cAMP) second 
messenger pathways. PTH binds to the basolateral membrane PTH-receptors to 
activate the cAMP-PKA pathway leading to an increase in the cellular levels of 
active PKA 37. PKA has been shown to phosphorylate NHERF1 at Ser-77 84 and 
ezrin 85, and this phosphorylation destabilises the NHERF1-ezrin network 
resulting in the internalisation of NaPi-IIa. In contrast, PTH binding to PTHR1 at 
the BBM preferentially activates the PLC-PKC signalling pathway, resulting in an 
increase in the cellular levels of active PKC 86,87. PKC phosphorylates NHERF1 
at Ser-77 resulting in reduced interaction between NHERF1 and NaPi-IIa at the 
BBM 84. In addition to the downregulation of NaPi-lla by PTH, there is evidence 
that PTH reduces the activity of the NHE3 88, and this may contribute to the PTH-
induced loss of NaPi-lla function in the renal proximal tubules. It is plausible that 
the activity of NHE3 is directly linked to the cellular activity of NHERF1, such that 
when NHE3 activity is reduced the activity of NHERF1 is also affected, and this 
may result in the internalisation of NaPi-IIa. Internalised NaPi-IIa is rapidly 
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degraded in the lysosomes 80,89, and the recovery of apical NaPi-IIa levels 
following the removal of PTH signalling requires the biosynthesis of new NaPi-IIa 
protein 89. The mechanism underlying the role of PTH on NaPi-llc internalisation 
is still under investigation, however, studies by Segawa and colleagues suggest 
that like NaPi-IIa, PKA and PKC signalling pathways may be responsible 90. 
Unlike the rapid internalisation of NaPi-lla by PTH, NaPi-llc internalisation is a 
slow process, which occurs within several hours 91, and the internalised protein 
is left undegraded and may recycle back to the apical membrane in the absence 
of PTH 90. 
In addition to its role in regulating renal phosphate transporters, the role of PTH 
in the maintenance of phosphate homeostasis involves its actions on bone 
resorption, and interaction with other hormones of phosphate homeostasis, 
notably FGF-23 and 1,25(OH)2D3. In bone, specifically osteoblasts, PTH-
mediated resorption increases extracellular Ca2+ and phosphate levels by 
increasing the expression of the receptor activator of nuclear factor kB ligand 
(RANKL) via PKA, PKC and extracellular signal-regulated kinase (ERK) 
mechanisms 92. PTH has been shown to increase FGF-23 synthesis by 
enhancing FGF-23 gene expression in osteocytes 11. In addition, PTH binds to its 
receptors in the kidney to activate the renal 25-hydroxyvitamin D-1-α hydroxylase 
enzyme, which mediates the conversion of 25(OH)D3 to 1,25(OH)2D3 93–95, a 
steroid hormone that upregulates NaPi-IIb expression. These actions of PTH, 
including the FGF-23 permissive effects, suggest that PTH decreases the total 
body phosphate levels in the short-term while activating the synthesis of 
1,25(OH)2D3 to replenish the body’s phosphate levels in the long-term. 
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1.2.1.5.1.2. FGF-23 and α-Klotho 
FGF-23 is a member of the fibroblast growth factor family, which is made up of 
251 amino acid residues 96. It is synthesised in osteocytes and transported in the 
blood to its target organs, mainly the kidney. Two forms of FGF-23 have been 
detected in the circulation: full length or intact FGF-23 and c-terminal FGF-23 
fragments (cFGF-23), which is known to be the inactive form of intact FGF-23 
97,98. FGF-23 is released in response to increased extracellular phosphate levels 
and it acts mainly in the kidney where it downregulates the proximal tubular 
expression of NaPi-lla and -llc, and inhibits the synthesis of 1,25(OH)2D3 99. A 
large body of evidence suggests that FGF-23 is the major regulator of phosphate 
homeostasis 100. Overexpression of FGF-23 in mouse models results in 
hypophosphatemia and low circulating levels of 1,25(OH)2D3 101. In contrast, 
persistently high extracellular phosphate and 1,25(OH)2D3 levels as well as 
suppressed PTH levels were observed in mice following FGF-23 ablation 8,98,102. 
Genetic disorders characterised by excessive levels of FGF-23 in humans such 
as autosomal dominant hypophosphataemic rickets, autosomal recessive 
hypophosphataemic rickets and X-linked hypophosphataemia are associated 
with persistently low circulating phosphate levels 103–105, thus, indicating the 
essential role of FGF-23 in phosphate homeostasis in humans.  
Recent studies have shown that in the renal proximal tubule, FGF-23 
predominantly binds to FGF-23 receptor (FGFR) type 1, in the presence of its 
membrane co-receptor α-klotho, to cause the downregulation of NaPi-IIa and -IIc 
106,107. Evidence from α-klotho-deficient mice demonstrates a critical role of this 
protein in FGF-23 function as these mice have been shown to exhibit a phenotype 
identical to FGF-23 knock-out mice 108. Specifically, α-klotho knock-out mice have 
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increased NaPi-IIa levels at the proximal tubular BBM and are unable to regulate 
circulating phosphate levels following phosphate loading, thus, developing 
hyperphosphataemia under this condition 108. There is evidence that FGF-23-
mediated internalisation of NaPi-lla involves the phosphorylation of NHERF1 by 
the ERK1/2 pathway and serum glucocorticoid-regulated kinase-1 (SGK1) 
mechanism 109. The role of FGF-23 in regulating the synthesis of 1,25(OH)2D3 
involves the interaction of FGF-23 with FGFR3 and FGFR4 in the kidney 110. Even 
though it is known that the actions of FGF-23 on renal phosphate transporters 
and 1,25(OH)2D3 involve different receptors, it is still unknown whether the FGF-
23-mediated NaPi-lla internalisation and inhibition of 1,25(OH)2D3 secretion have 
different cellular mechanisms. However, emerging evidence in Janus kinase 3 
(JAK3) knock-out mice suggests that an FGF-23 related-JAK3 regulation of renal 
25-hydroxyvitamin D-1-α hydroxylase activity is a key mechanism involved in the 
regulation of 1,25(OH)2D3 synthesis by FGF-23 111. 
Unlike α-klotho, which is known to play a vital role in increasing the affinity of 
FGFR for FGF-23 and the potency of bound FGF-23 112,113, studies in Xenopus 
oocytes have shown that circulating klotho may directly downregulate the apical 
expression of renal NaPi-IIa and intestinal NaPi-IIb 114. Circulating or soluble 
klotho is synthesised from the cell surface of the extracellular domain of 
membrane α-klotho by membrane-bound proteolytic enzymes and released into 
the extracellular fluid 115. This form of klotho has been shown to stimulate the 
synthesis of FGF-23 in osteocytes 116 and this may be the mechanism by which 
circulating klotho downregulates NaPi-IIa. Whether circulating klotho interacts 
with specific receptors to activate cellular signalling pathways in its target organs 
remains to be seen. Moreover, it has been reported that circulating klotho 
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downregulates NaPi-IIa due to its glucuronidase activity in the renal proximal 
tubule 117.  
Interestingly, a putative link between FGF-23 and PTH secretion has been 
suggested 118–120. However, the underlying mechanism is still unclear. The 
identification of abundant membrane α-klotho expression in the parathyroid gland 
suggests that FGF-23 may affect PTH secretion by a klotho-dependent 
mechanism 121. There is evidence that FGF-23 inhibits the secretion of PTH 120, 
and because PTH increases the release of FGF-23 from osteocytes, the 
interaction of these hormones creates a negative feedback loop for the regulation 
of phosphate balance (Figure 1.4). In addition, the direct link between FGF-23-α-
klotho complex and circulating PTH and 1,25(OH)2D3 levels (Figure 1.4), suggest 
that FGF-23 can directly or indirectly impact phosphate balance by regulating the 
expression of both renal and intestinal NaPi-ll proteins. 
1.2.1.5.1.3. 1,25(OH)2D3 
1,25(OH)2D3 is a steroid hormone predominantly synthesised from a precursor 
steroid on the skin. Its synthesis involves a series of physiological processes in 
the liver and kidney resulting in the release of the active 1,25(OH)2D3, which is a 
hormone primarily involved in bone mineralization. Active 1,25(OH)2D3 is 
released into the circulation from the kidney by the action of 25-hydroxyvitamin 
D-1-α hydroxylase (encoded by Cyp27b1 gene) on 25(OH)D3 122. In the early 
1970s, the release of 1,25(OH)2D3 was reported to be stimulated by PTH in 
response to low extracellular Ca2+ levels 123. Soon after, evidence that rats 
maintained on a low phosphate diet had significantly elevated 1,25(OH)2D3 levels 
despite high levels of extracellular Ca2+, indicated that circulating phosphate and 
consequently, renal tubular cell phosphate, affects 1,25(OH)2D3 secretion 124. 
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Treatment of rats with 1,25(OH)2D3 has been demonstrated to directly stimulate 
the upregulation of intestinal NaPi-IIb 39,48. Previous findings that jejunal Na+-
dependent phosphate absorption was significantly upregulated following 
1,25(OH)2D3 administration to 1,25(OH)2D3-deficient rodents 125,126 provide 
additional evidence for the stimulatory role of 1,25(OH)2D3 on NaPi-IIb.  
As a steroid hormone, 1,25(OH)2D3 acts by interacting with its intracellular 
receptor, VDR, to activate NaPi-IIb gene promoter activity and modulate NaPi-IIb 
gene expression 48. The effect of 1,25(OH)2D3 on NaPi-IIb expression and the 
underlying mechanism in rodents has been reported to be age-dependent 48. In 
preweaning rats, the effect of 1,25(OH)2D3 on NaP-llb has been shown to be 
mediated partly by an alteration in NaPi-llb gene expression and partly by 
posttranslational modification of the protein 48. However, reports from 8-week old 
VDR knock-out mice suggest that VDR-mediated effects of 1,25(OH)2D3 on NaPi-
llb levels occur by posttranscriptional mechanisms 127. While NaPi-llb mRNA 
expression levels are unaffected in adult VDR knock-out mice, its protein levels 
and transport activity were significantly suppressed in the knock-outs compared 
with wild-type mice 127. Taken together, this suggests that in young animals with 
high circulating levels of 1,25(OH)2D3, this hormone interacts with its receptor to 
increase the expression of NaPi-IIb by both transcriptional and posttranslational 
mechanisms, hence, this is why there are relatively higher levels of NaPi-IIb in 
young animals compared to adults. To understand the mechanism underlying the 
posttranslational effect of 1,25(OH)2D3 on NaPi-IIb levels, evidence from cell 
culture studies suggests the presence of caveolae-associated VDRs, which when 
activated by 1,25(OH)2D3 binding, initiate multiple G-protein dependent-
intracellular second messenger systems, leading to the generation of PKC and 
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MAP/RAS kinases 128–131. These mechanisms may be responsible for the 
posttranslational modification of NaPi-llb protein in response to 1,25(OH)2D3. 
However, there is a paucity of information to support this mechanism in vivo, thus, 
its physiological role is still in doubt.  
Furthermore, there is evidence for the presence of a 1,25(OH)2D3 response 
element in rodent NaPi-IIa 132 and human NaPi-IIc 133 gene, suggesting that this 
regulator may have a direct effect on the mRNA expression levels of these 
transporters. However, unlike the action of PTH on the renal phosphate 
transporters, there is lack of convincing evidence to support a direct effect of 
1,25(OH)2D3 on NaPi-lla and -llc protein levels 134. Moreover, increased 
circulating FGF-23 levels in response to high levels of 1,25(OH)2D3 135 suggests 
that the later indirectly downregulates renal NaPi-lla and -llc proteins. 
Interestingly, mice lacking VDR have been shown to be associated with low levels 
of renal NaPi-IIa and NaPi-IIc protein in the renal proximal tubular BBM, 
suggesting that the loss of 1,25(OH)2D3 signalling or low levels of this hormone 
may negatively impact the levels of these transporters 136. Since PTH is known 
to cause NaPi-IIa and -IIc downregulation, the low protein levels of these 
transporters in VDR knock-out mice may be due to the feedback stimulation of 
PTH release by the lack of 1,25(OH)2D3 signalling 136. Although the exact effect 
of 1,25(OH)2D3 on NaPi-IIa and -IIc has not yet been determined, the fact that 
high or low levels of 1,25(OH)2D3 results in the feedback release of FGF-23 or 
PTH suggests that 1,25(OH)2D3 indirectly causes the downregulation of renal 
NaPi-IIa and -IIc protein levels. 
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1.2.1.5.1.4. Dietary phosphate 
The intake of a high phosphate diet has been shown to induce renal BBM NaPi-
lla and -llc downregulation in a manner similar to PTH 137,138. The effect of high 
phosphate diet on NaPi-IIa and -IIc levels appears to be relatively rapid compared 
to that of FGF-23 138. It was previously proposed that this effect of dietary 
phosphate on the renal NaPi-ll proteins was independent of PTH, 1,25(OH)2D3 
and FGF-23 139,140 and that the release of a gut-derived factor may be a key driver 
22. However, recent evidence indicates that changes in the levels of renal NaPi-II 
proteins following an oral phosphate load require changes in circulating PTH 
levels, and there is still no evidence for a gut-derived phosphaturic factor 
suggested to be involved in regulating renal NaPi-II proteins following an oral 
phosphate load 23,24. In contrast to the effect of a high phosphate diet, low dietary 
phosphate significantly upregulates the expression of the NaPi-ll proteins 16,44. 
The upregulation of NaPi-IIa and -IIc does not require de novo synthesis of the 
proteins but has been demonstrated to involve posttranslational mechanisms, 
which is likely to be as a result of shuttling of the proteins from intracellular stores 
to the renal BBM 141,142. Taken together, these findings suggest that high dietary 
phosphate increases circulating phosphate levels leading to an increase in PTH 
and a consequent downregulation of renal NaPi-IIa and -IIc (Figure 1.4), while a 
low phosphate diet causes the activation of mechanisms within the renal epithelial 
cells involved in the shuttling and anchoring of the renal NaPi-II transporters on 
to the BBM. There is evidence that the adaptation of renal NaPi-IIa and -IIc to 
changes in dietary phosphate levels requires the interaction of the transporters 
with the PDZ proteins, NHERF1 and NHERF3, which are associated with the C-
terminal of the transporters 16,141,142. Specifically, NHERF1 is known to be mainly 
responsible for the upregulation of NaPi-IIa in response to low dietary phosphate 
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levels 16,141,142, while NHERF3 has been shown to be the PDZ protein involved in 
the adaptation of NaPi-IIc to a low phosphate diet 141. Therefore, these PDZ 
proteins are the key players involved in the intracellular mechanisms underlying 
the anchoring of NaPi-IIa and NaPi-IIc to the BBM in response to a low phosphate 
diet. 
Dietary phosphate concentration is considered the major regulator of NaPi-IIb 
expression in the small intestine 17,19,38,127,143,144. Like 1,25(OH)2D3, dietary 
phosphate restriction has been shown to upregulate NaPi-IIb levels, while a high 
phosphate diet is known to cause NaPi-IIb downregulation at the BBM of 
enterocytes 17,19,38,58,127,143–146. Because a low phosphate diet stimulates the 
synthesis of 1,25(OH)2D3 147,148,  it was previously thought that this hormone was 
responsible for the adaptation of intestinal NaPi-IIb to changes in dietary 
phosphate levels 149. However, it is now known that the upregulation of NaPi-IIb 
in response to a low phosphate diet is independent of 1,25(OH)2D3 and VDR 
signalling 19,127. In these studies, the authors demonstrated that the adaptation of 
NaPi-IIb under this dietary condition was unaffected in VDR and 25-
hydroxyvitamin D-1-α hydroxylase knock-out mice. There are conflicting reports 
on the mechanisms underlying the upregulation of intestinal NaPi-IIb by low 
dietary phosphate levels. While an early report indicated that the upregulation of 
NaPi-IIb in response to a low phosphate diet had no effects on NaPi-IIb mRNA 
143, more recent reports have shown that changes in both NaPi-IIb mRNA and 
protein are observed under this dietary phosphate condition 19,38,127.  
It is still unclear if the regulation of NaPi-IIb by a low dietary phosphate is 
manifested at transcriptional level or mediated solely by posttranslational 
mechanisms. Evidence from the adaptation of NaPi-llb to acute and chronic 
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administration of a low or a high phosphate diet suggests the possibility of the 
involvement of both mechanisms, but with intestinal-segment specificity in rats 17. 
Giral and Colleagues 17 showed that chronic administration of a low phosphate 
diet resulted in the upregulation of rat jejunal NaPi-llb protein and mRNA, with no 
effect observed in the duodenum. However, when the rats that had been 
chronically adapted to the low phosphate diet were acutely switched to a high 
phosphate diet, there was a significant upregulation of duodenal NaPi-llb protein 
only, with no change observed in the jejunum. Taken together, these findings 
suggest that the adaptation of jejunal NaPi-llb to dietary phosphate involves the 
de novo synthesis of NaPi-llb, while posttranslational modification of already 
synthesised NaPi-llb may be responsible for NaPi-llb upregulation in the 
duodenum. 
Furthermore, there are speculations that a low phosphate diet activates 
intracellular mechanisms, which involves the PDZ proteins that play important 
roles in NaP-llb trafficking to and from the enterocyte BBM 32,58,150. Studies have 
shown that the regulation of NaPi-IIb by a low phosphate diet requires the 
expression of NHERF1 58. Giral and colleagues demonstrated that the 
upregulation of NaPi-IIb in response to dietary phosphate restriction is impaired 
in NHERF1 knock-out mice 58. Myosin VI protein has also been implicated in the 
regulation of NaPi-IIb expression by low phosphate intake 150. Changes in NaPi-
IIb in response to high or low phosphate intake is significantly blunted in myosin 
VI knock-out mice compared to the wild-type mice 150. Taken together, these 
reports suggest that NHERF1 and myosin VI are key targets in the regulation of 
NaPi-IIb by dietary phosphate levels (See section 1.2.1.5.2 for more detail)  
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Figure 1.4. Systemic regulation of renal NaPi-IIa and -IIc, and intestinal NaPi-IIb by 
dietary phosphate, FGF-23-α-klotho axis, PTH and vitamin D. High dietary phosphate 
intake stimulates (+) increased PTH and FGF-23 release. PTH and the activation of FGF-
23-α-klotho axis cause the downregulation of NaPi-IIa and -IIc levels. High dietary 
phosphate intake inhibits (-) the release of 1,25(OH)2D3 and this cause the 
downregulation of intestinal NaPi-IIb. Dietary phosphate also directly downregulates 
intestinal NaPi-IIb levels. 
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1.2.1.5.1.5. Acid-base status  
The phosphate buffer system is known to be one of the major renal tubular 
mechanism for the secretion of excess H+, and as a result of this, there is 
increased urinary excretion of phosphate in metabolic acidosis 151. To cause this 
response, it is expected that the expression of the proximal tubular phosphate 
transporters, NaPi-IIa and -IIc will be altered during acid-base imbalance. There 
are conflicting reports on the effect of metabolic acidosis on NaPi-lla and -llc. 
There is evidence to suggest that the mRNA and protein levels of NaPi-lla are 
downregulated during metabolic acidosis 152, while other studies have failed to 
demonstrate this effect despite a significant increase in urinary phosphate 
excretion 151,153. Since NaPi-lla and -llc are known to preferentially transport 
divalent phosphate, which is readily reduced to monovalent phosphate at low 
luminal pH, it has been hypothesised that the transport activity of these proteins 
is significantly reduced during metabolic acidosis 68. Moreover, there is evidence 
that the Km of the NaPi-II proteins is increased at low pH, and this affects the 
interaction of the transporter with Na+ and phosphate, thus, causing a significant 
reduction in renal phosphate reabsorption 68,69. 
As a compensatory mechanism to increased renal excretion of phosphate in 
acidosis, intestinal NaPi-IIb and phosphate absorption have been shown to be 
upregulated 151 and the mobilization of phosphate from bone increases to buffer 
serum phosphate levels 154. The mechanism underlying this upregulation of 
intestinal phosphate absorption in metabolic acidosis has been attributed to an 
increase in NaPi-llb protein, with no change in its mRNA expression 151.  
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1.2.1.5.1.6. IGF-1  
In humans and weanling rats, insulin-like growth factor-1 (IGF-1) has been 
reported to reduce renal phosphate excretion by increasing proximal tubular Na+-
dependent phosphate transport 155. IGF-1 has been reported to increase renal 
proximal tubular phosphate reabsorption leading to increased circulating 
phosphate, known to be necessary for the growth and development of the skeletal 
system in young animals  155. IGF-1 has been implicated in the regulation of the 
expression or activity of renal NaPi-II proteins 156. Activation of the tyrosine kinase 
receptor by IGF-1 upregulates the protein levels and increases the membrane 
stability of the type II Na+-dependent transporter in OK cells 157. 
1.2.1.5.1.7. Dopamine 
Dopamine has been implicated in the renal adaptation to a high phosphate diet, 
with increased levels of dopamine shown to be associated with an increase in 
urinary phosphate excretion 158. Reports by Bacic and colleagues have 
demonstrated that acute dopamine administration causes NaPi-IIa internalisation 
by activating the dopamine type 1 receptor 159. Interaction of dopamine with this 
receptor in the proximal tubule activates the cAMP-PKA and PLC-PKC signalling 
pathways, leading to increased intracellular levels of PKA and PKC, which both 
initiate NaPi-IIa internalisation 159,160. 
1.2.1.5.1.8. ANP 
ANP has been shown to increase the fractional excretion of phosphate by 
inhibiting Na+-dependent phosphate transport in the renal proximal tubule 161. 
ANP has been demonstrated to downregulate NaPi-IIa protein levels at the BBM 
of the renal proximal tubular cell via the activation of the guanylate cyclase-
cGMP-PKG signalling cascade 162.  
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1.2.1.5.1.9. Estrogen 
Recent evidence demonstrates that estrogen downregulates the mRNA and 
protein levels of NaPi-IIa in a dose-dependent manner in ovariectomised rats, but 
had no effect on NaPi-IIc levels in the renal proximal tubules 163. This effect of 
estrogen has been shown to be mediated by the activation of two estrogen 
receptor subtypes (ERα and ERβ) 163. In parathyroidomised rats, estrogen has 
also been shown to downregulate NaPi-IIa levels indicating that the effect of 
estrogen is independent of PTH 164. This effect of estrogen causes significant 
phosphate wasting and hypophosphataemia 163,164. In contrast, there is evidence 
that estrogen upregulates the expression of NaPi-IIb protein at the BBM of the 
small intestine by increasing NaPi-IIb gene transcription 165. In cell culture 
experiments, estrogen has been reported to increase the activity of the NaPi-IIb 
gene promoter 165, indicating that estrogen has a direct effect on the de novo 
synthesis of NaPi-IIb protein. In addition, estrogen has also been demonstrated 
to stimulate the production of 1,25(OH)2D3 166. Thus, the effect of estrogen on 
1,25(OH)2D3 synthesis is an additional mechanism through which estrogen 
upregulates NaPi-IIb protein levels. 
1.2.1.5.1.10. Glucocorticoids  
Elevated levels of circulating glucocorticoids, for example, following 
glucocorticoid administration or in Cushing’s disease, are associated with 
hypophosphataemia and phosphaturia 167. Chronic treatment with glucocorticoids 
has been shown to downregulate NaPi-lla mRNA and protein levels in the renal 
proximal tubule 168. It is speculated that glucocorticoids interact with SGK-1 
receptor to cause the phosphorylation of NHERF1 and this initiates NaPi-IIa 
endocytosis and the resultant downregulation of NaPi-IIa at the BBM 37. Studies 
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in preweaning animals have shown that glucocorticoids affect the expression of 
intestinal NaPi-IIb, as glucocorticoid injection in these animals has been shown 
to downregulate the mRNA expression and protein levels of NaPi-IIb in the small 
intestine 47. 
1.2.1.5.1.11. Thyroid hormones 
There are indications that thyroid hormones affect NaPi-lla expression and its 
transport activity 169,170. Euzet and colleagues demonstrated that acute 
administration of 3,5,3’-triiodothyronine, a form of thyroid hormone, in rats, 
increases the expression of NaPi-lla mRNA and protein, while also increasing the 
affinity and capacity of the transporter 169.  
1.2.1.5.1.12. Phosphatonins 
Phosphatonins were first suggested when the Na+-dependent transport of 
phosphate was significantly affected in opossum-kidney cells that were cultured 
in a conditioned medium obtained from the tumour of a patient with oncogenic 
osteomalacia, a disorder characterised by renal phosphate wasting and low 
serum phosphate levels 171. Although FGF-23 (discussed in detail in section 
1.2.1.5.1.2) was later identified as the major phosphatonin responsible for 
maintaining phosphate homeostasis 103–105,172,173, other phosphatonins such as 
MEPE, sFRP and FGF-7 have also been demonstrated to play a role in the 
maintenance of phosphate balance by regulating the expression and functions of 
the NaPi-II proteins (reviewed in 139). 
1.2.1.5.1.12.1. MEPE 
MEPE was first cloned and characterised from an oncogenic hypophosphataemic 
osteomalacia tumour 174 and has been demonstrated to inhibit renal and intestinal 
Na+-dependent phosphate transport in a dose-dependent manner resulting in an 
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increase in fractional phosphate excretion in rats 175,176. Studies by Marks and 
colleagues have shown that MEPE significantly downregulates renal NaPi-IIa 
protein levels, but has no effect on NaPi-IIc levels 176. Although the effects of 
MEPE on intestinal NaPi-IIb levels has not been reported, the role of MEPE in 
the reduction of phosphate absorption in the rat jejunum, a region with high NaPi-
IIb expression 176, suggests that this phosphatonin may downregulate NaPi-IIb 
protein levels. Even though a link between FGF-23 and MEPE has been reported 
177, and clinical data has also established a positive correlation between serum 
MEPE and PTH levels 178, the acute effect of MEPE on renal NaPi-IIa levels and 
intestinal phosphate absorption was shown to be independent of PTH and FGF-
23, suggesting a direct effect of MEPE on the levels of the NaPi-II proteins 176. 
1.2.1.5.1.12.2. sFRP-4 
sFRP-4 has been shown to increase renal phosphate excretion in rats by a PTH 
independent mechanism 179. This effect of sFRP-4 on renal phosphate excretion 
occurs due to its role in NaPi-IIa internalisation and the consequent 
downregulation of NaPi-IIa protein levels in the renal proximal tubule 180. There 
is limited information on the effect of sFRP-4 on intestinal NaPi-IIb expression, 
however, sFRP-4 is known to reduce circulating 1,25(OH)2D3 levels 181 and via 
this mechanism, sFRP-4 may inhibit intestinal NaPi-IIb levels.  
1.2.1.5.1.12.3. FGF-7 
Like MEPE, reports from oncogenic hypophosphataemic osteomalacia, a 
phosphate-wasting syndrome, have identified FGF-7 as a potent phosphatonin 
182. High levels of FGF-7 in conditioned medium obtained from cell cultures of 
tumours associated with oncogenic osteomalacia has been shown to be 
responsible for the inhibition of phosphate uptake by renal epithelial cells 182. This 
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effect was reversed by an FGF-7-neutralising antibody, suggesting that FGF-7 
may inhibit the activity of the renal NaPi-ll proteins.  
1.2.1.5.2. Cellular regulators of the type II Na+-dependent phosphate 
transporters 
Common intracellular protein kinases, PKA, PKC and PKG, have been reported 
to play key roles in mediating the shuttling of NaPi-II proteins to and from the 
BBM of epithelial cells in response to changes in dietary phosphate levels and 
some of the systemic regulators, like PTH (discussed in section 1.2.1.5.1.1) 
37,87,90,160,162,183. These cellular enzymes are also known to mediate the effect of 
the PDZ proteins on the expression of NaPi-II proteins at the BBM of epithelial 
cells 160,184,185. Structurally, the C-terminal region of the NaPi-II proteins bears a 
PDZ-recognition sequence, which interacts with cytoplasmic regulatory proteins 
such as the NHERF family and Shank 2E, to alter the stability and expression of 
the proteins on the BBM 186–188. Among the NHERF family involved in the local 
regulation of NaPi-II proteins, NHERF1 and NHERF3 have been identified in the 
PDZ domain; however, while NHERF1 has been demonstrated as a key regulator 
of NaPi-IIa expression 37,189, NHERF3 is known to be involved in NaPi-IIc 
regulation 141. The loss of NHERF1 function in NHERF1 knock-out mice results 
in the internalisation of NaPi-IIa from the renal proximal tubular BBM 189. Evidence 
in NHERF1 knock-out mice and NHERF1 mutations in humans have shown that 
the mutation or deletion of the NHERF1 gene results in hypophosphataemia, a 
consequence of the lack of NaPi-IIa expression in the renal proximal tubule 189,190. 
Another protein, ezrin, has been implicated in the function of NHERF1 and the 
overall expression of NaPi-IIa 191–193. It has been hypothesised that ezrin interacts 
with NHERF1 to form a complex, which anchors NaPi-IIa to the apical membrane 
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32,185. Furthermore, the actions of the systemic regulators of NaPi-IIa protein, for 
example, PTH, increases the intracellular levels of kinases such as PKA and 
PKC, and these enzymes interfere with the interaction of NHERF1 and ezrin, 
thus, causing the internalisation of NaPi-IIa 184. PKA has been shown to 
phosphorylate ezrin, while both PKA and PKC are known to phosphorylate 
NHERF1, and this phosphorylation destabilises the NHERF1-ezrin network, 
leading to the loss of NaPi-IIa expression at the apical membrane 85,160,184,185. 
Moreover, the cGMP-PKG signalling pathway has also been suggested to induce 
the internalisation of NaPi-IIa by unknown mechanisms 162. It remains to be seen 
if PKG phosphorylates ezrin or NHERF1 like the other protein kinases. 
Shank 2E is highly concentrated on the BBM and closely localised with high levels 
of NaPi-IIa under low dietary phosphate conditions 188,194. Under a high dietary 
phosphate condition, the degradation of shank 2E has been speculated to be 
associated with the well known downregulation of NaPi-IIa 188,194. Although the 
mechanism underlying the role of Shank 2E on NaPi-IIa stability on the BBM is 
still under investigation, the interaction of Shank 2E with NHE3 and the 
consequent regulation of NHE3 trafficking by this regulatory protein 195 may 
impact NHERF1 activity, thus, affecting BBM NaPi-IIa stability. In addition, a 
GTPase enzyme, dynamin II, which is known to be involved in the internalisation 
of clathrin-coated vesicles has been shown to interact with Shank 2E 196. 
Furthermore, mounting evidence suggests that a PDZ-independent protein, 
Gamma-aminobutyric acid (GABA) receptor-associated protein (GABARAP) is 
also involved in the intracellular signalling pathways regulating the expression of 
NHERF1 and NaPi-IIa protein 197. The deletion of GABARAP gene in GABARAP 
knock-out mice has been shown to be associated with reduced NaPi-IIa 
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expression and a consequent increase in urinary phosphate excretion, indicating 
that GABARAP causes the upregulation of NaPi-IIa protein 197.  
Recent evidence demonstrates that like NaPi-IIa, NaPi-IIb also interacts with 
NHERF1, and this interaction regulates the expression of NaPi-IIb at the BBM 58. 
Studies in NHERF1 knock-out mice have shown that the adaptation of NaPi-IIb 
to changes in dietary phosphate is impaired in the absence of NHERF1 protein, 
suggesting a key role for NHERF1 in the anchoring of NaPi-IIb to the BBM of 
enterocytes 32,58. In addition, myosin VI has also been implicated in the regulation 
of NaPi-IIb by dietary phosphate 150. Unlike NaPi-IIa, GABARAP downregulates 
the expression of NaPi-IIb 198. The mechanism underlying the role of GABARAP 
in the downregulation of NaPi-IIb is still unknown. However, it is plausible that this 
effect of GABARAP on NaPi-IIb is not a direct effect, but only secondary to its 
action on renal NaPi-IIa, thus, compensating for the increased retention of 
phosphate by the kidneys to maintain systemic phosphate balance. 
Emerging evidence suggests that SPS1-related proline/alanine-rich kinase 
(SPAK) and oxidative stress-responsive kinase 1 (OSR1) are also regulators of 
NaPi-IIa and NaPi-IIb expression and activity in the renal proximal tubular cell 
and enterocyte BBM 199–201. In Xenopus oocyte expressing NaPi-IIa, OSR1 co-
expression has been demonstrated to increase NaPi-IIa-mediated phosphate 
transport activity 199. Under normal dietary phosphate condition, reduced 
circulating phosphate levels as a result of the downregulation of NaPi-IIa protein 
abundance and activity has been shown in OSR1-knock-in mice, heterozygously 
carrying a with-no-lysine protein kinase (WNK)-insensitive mutation 199. The 
adaptation of these mice to a low phosphate diet was also reported to be 
significantly impaired, suggesting a key role for this kinase in NaPi-IIa function 
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199. In addition, Xiao and colleagues have demonstrated the presence of SPAK 
and OSR1 expression in the intestine of mice 202, and that the co-expression of 
these kinases in Xenopus oocytes causes the upregulation of NaPi-IIb, resulting 
in an increase in NaPi-IIb-mediated phosphate current 200. The increased NaPi-
IIb-mediated phosphate current was speculated to be due to SPAK and OSR1 
induced phosphorylation of NaPi-IIb-regulating signalling proteins such as AMP-
activated kinase, serine/threonine-protein kinase B-Raf and SGK1 200. 
1.2.2. Na+-dependent phosphate cotransporter type I 
The type I Na+-dependent phosphate cotransporter (NPT) is encoded by the 
SLC17 gene and has been shown to be expressed in a number of tissues 
including the small intestine, colon, liver, pancreas, kidney, brain, bone and lung 
203–205. Among the different homologues of NPT identified previously, only the 
type A1 to A4 (NPT1, Na+/HPO42- homologue, NPT3 and NPT4) have been 
shown to be involved in transcellular phosphate transport 205. NPT1 (encoded by 
SLC17A1) is mainly expressed in the renal proximal tubular brush border 
membrane 206,207 and to a lesser extent in the sinusoidal membrane of liver cells 
208. Northern blot analysis has shown that NTP3 (encoded by SLC17A2) is highly 
expressed in the heart and muscle cells and found at relatively low levels in the 
lungs, placenta, liver and brain 205. RT-PCR and northern blot analysis have 
shown that NPT4 (encoded by SLC17A3) expression is localised in the small 
intestine, kidney, testes and liver, while the Na+/HPO42- transporter homologue 
(encoded by SLC17A4) have been shown to be expressed in the liver, pancreas, 
small intestine and colon 205. Other members of the NPT family (type A5 to A8, 
encoded by the SLC17A5-8) have been reported to mediate the transport of other 
anions such as glutamate and sialin in different organs 205.  
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The NPT transporter is a 465 amino acid protein, which is predicted to have 6-12 
TMDs 205. Early findings suggest that the members of the NPT family share 
approximately 20% structural homology with the type II and type III Na+-
dependent phosphate cotransporters 33. Further studies are required to 
understand the detailed topology of these transporters. In addition, there is limited 
information available on how the structure of these transporters is adapted to the 
transport of phosphate across the membrane of cells. Although the kinetic 
properties and ionic coupling of Na+ and phosphate by the NPTs have not been 
extensively studied, studies of human NPT1 have shown that the transport of 
phosphate and organic anions is electrogenic and not significantly affected by pH 
208,209. 
Inorganic phosphate transport in bone has been suggested to be mediated by a 
Na+-dependent cotransport mechanism in mammals 203. During bone resorption, 
released phosphate may be transported into the osteoclast via all the identified 
Na+-dependent phosphate cotransporters, including the type I cotransporter.  
Even though this class of phosphate transporters has been identified in bone 
cells, kidney and intestine, its contribution to systemic phosphate homeostasis is 
poorly understood. Concerning the regulation of the NPT transporters in various 
tissues, studies by Soumounou and colleagues 210 suggest that the expression 
of NPT1 is regulated by hepatocyte nuclear factor (HNF)–1α and HNF-3β, with 
HNF-1α reported to upregulate NPT1 and NPT4 expression 211. This regulation 
of the NPT1 by the HNFs is suggested to be at the transcriptional level 210. At 
least in the brain, high phosphate diet increases the expression of the NPTs 212, 
but whether dietary phosphate affects the expression of NPTs in different tissues 
remains to be seen. 
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1.2.3. Na+-dependent phosphate cotransporter type III 
The type III phosphate transporters (PiTs) have been identified to be involved in 
the BBM transport of phosphate in epithelial cells 17,213,214. Two members of the 
PiT family, which are encoded by the SLC20 genes have been characterized in 
mammals; PiT-1 (encoded by SLC20A1) and PiT-2 (encoded by the SLC20A2) 
12. The molecular structure of PiT-1 and PiT-2 is similar to the NaPi-II proteins in 
that they are proposed to have 12 TMDs, but unlike the NaPi-II proteins, both the 
N- and C- terminal tails are in the extracellular region 215,216. Bai and colleagues 
217 predicted that PiT-2 has 653 amino acid residues, while the amino acid 
sequence of PiT-1 has been suggested to be 59% identical to PiT-2 218. Cell 
culture and human PiT expression studies in Xenopus oocytes have identified the 
presence of a histidine residue (H502) in the C-terminal, which is shown to confer 
the phosphate transport function of these proteins 215. This phosphate transport 
function was shown to be unaffected following the removal of the large 
intracellular domain and its associated TMD 215, suggesting that the intracellular 
region and TMDs may not contribute to the transport properties of PiT proteins.  
1.2.3.1. Transport kinetics of the type III Na+-dependent phosphate 
cotransporters 
Studies into the kinetic properties of PiT proteins using Xenopus oocyte have 
revealed their electrogenic nature 218; they transport monovalent phosphate 
(H2PO4-) coupled with Na+ in a 2:1 Na+: phosphate stoichiometry 219. To activate 
the PiT proteins, one Na+ molecule binds to the transporter followed by a 
conformational change that allows the random binding of phosphate and another 
Na+ 219. This substrate interaction with the transporter results in a net influx of a 
positive charge, which confers the electrogenicity of this transporter. In the 
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absence of Na+, Li+ can drive the transport of phosphate, but with markedly 
slower transport rate 49. Like NaPi-II proteins, the affinity of PiT proteins for 
phosphate and Na+ is approximately 100 µM and 50 mM respectively 140. The 
sensitivity of this transporter has been shown to be stable between pH 3 to 6, and 
unlike NaPi-II proteins, their transport function is not drastically affected by pH 
changes 140. In a Na+ free medium, lowering the pH from alkaline to acidic state 
did not abolish PiT-2 mediated phosphate uptake in Xenopus oocyte suggesting 
that H+ may also drive PiT transport activity 140. Presently, other than PFA, which 
is a very poor inhibitor of the activity of PiT proteins, no specific inhibitors have 
been identified for this class of transporters 71. 
1.2.3.2. Localization of the type III Na+-dependent phosphate cotransporters 
Although PiT-1 and PiT-2 mRNA have been reported to be ubiquitously 
expressed in several tissues in humans and rodents (reviewed in 12), evidence 
for the role of PiT proteins in phosphate transport has been shown in the small 
intestine, kidney and brain 14,17,146,213,214,220,221. Immunohistochemistry and 
Western blot analysis have shown that PiT proteins are localised in the kidney 
and small intestine of both rats and mice 17,146,198,213,214. Even though both PiT-1 
and PiT-2 mRNA have been detected in the kidney (reviewed in 20) and small 
intestine 17, only PiT-2 protein has been shown to be present at the BBM of the 
proximal tubule of the kidney, mainly in the S1 segment (Figure 1.2) 91,198,213, 
while PiT-1 protein is mainly present in the rat small intestine 17. In the small 
intestine, PiT-1 mRNA has been reported to be highest in the ileum of rats, 
however, like the intestinal localisation of NaPi-llb, PiT-1 protein expression is 
mainly detected in the duodenum and jejunum 17. Surprisingly, PiT-2 protein has 
recently been reported to be present in all three segments of the rat small 
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intestine 146. There is limited information on the regional expression of PiT-1 in 
the small intestine of mice and humans. Even though PiT proteins have been 
detected in the kidney and small intestine, their overall contribution to phosphate 
transport in these organs is negligible. In contrast, recent evidence suggests that 
PiT-1 and PiT-2 mRNA and protein are highly detected in the brain and have 
been speculated to be the major phosphate transporters in the brain of humans 
and rodents 220,221.  
1.2.3.3. Regulation of the type III Na+-dependent phosphate transporters 
There are conflicting reports on the regulation of intestinal PiT-1 by dietary 
phosphate levels. While PiT-1 protein and mRNA levels have previously been 
shown to be unaffected by dietary phosphate manipulations 17, recent evidence 
has demonstrated that PiT-1 protein in the duodenum and jejunum is chronically 
regulated by dietary phosphate content, as its levels were upregulated in these 
segments following a 5-10 day administration of a phosphate-deficient diet 146. 
However, there is still a lack of convincing evidence for a significant role of PiT-1 
in intestinal phosphate absorption. Importantly, in NaPi-IIb knock-out mice, the 
observation that more than 90% of Na+-dependent phosphate transport is 
abolished 31,222, supports the claim that PiT-1 plays little or no role in intestinal 
phosphate absorption. In the kidney, the abundance of PiT-2 protein has been 
demonstrated to be regulated by dietary phosphate 214. In the renal proximal 
tubule, even though PiT-2 is normally localised in the S1 segment, its expression 
spreads throughout the S1 – S3 segments in rat fed a phosphate-deficient diet 
213. In addition, PiT-2 at the BBM of the proximal tubular epithelial cell is 
upregulated in rats fed with a phosphate-deficient diet over time 214. While NaPi-
IIa downregulation in rats switched from a chronically low phosphate to a high 
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phosphate diet is seen within 2 hours, PiT-2 is downregulated only after 24 hours 
214. It is interesting to note that dietary K+ restriction also affects the expression 
of PiT-2 in the BBM of the renal proximal tubule, with significantly low levels of 
PiT-2 protein observed during dietary K+ restriction in rats 213. This suggests a 
significant link between renal phosphate transport and K+ homeostasis since K+ 
restriction has been shown to cause phosphaturia as a result of NaP-IIc and PiT-
2 downregulation 213. Like NaPi-lla and NaPi-llc, PTH and FGF-23 downregulate 
PiT-2 expression in the proximal tubule 30,91. Metabolic acidosis and pH have also 
been reported to regulate PiT-2 expression and activity, with acidosis 
demonstrated to upregulate renal PiT-2 expression and increased PiT-2 activity 
was shown at low pH 14. Even though there was residual phosphate uptake in 
renal BBM vesicles prepared from NaPi-IIa and -IIc double knock-out mice, 
severe hypophosphataemia and bone abnormalities were shown in these mice, 
suggesting that the role of PiT-2 in renal phosphate reabsorption is minimal 223. 
However, further studies are required to clarify the precise contribution of the 
described changes in renal PiT-2 to phosphate homeostasis under various 
conditions. 
1.3. Renal phosphate handling 
The kidney controls the excretion of phosphate in the circulation by selectively 
reabsorbing phosphate from the glomerular filtrate as it travels down the different 
segments of the nephron. Although a small amount of plasma phosphate is bound 
to plasma proteins, more than 90% of total plasma phosphate is filtered into the 
proximal tubule 224. With a normal glomerular filtration rate of approximately 125 
ml/min in humans, the kidney under physiological conditions filters 4500-8000 mg 
of phosphate daily. In the proximal tubules, approximately 70% of the filtered 
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phosphate is reabsorbed 225, while a small but significant proportion is reabsorbed 
in the distal nephron 225,226. In total, 80% - 90% of phosphate in the glomerular 
filtrate is reabsorbed in the nephron and only 10% - 20% is excreted in urine 227. 
In addition, the rate of phosphate reabsorption in the renal proximal tubule has 
been shown to be higher in deep nephrons compared to superficial nephrons 228. 
The reabsorption of phosphate in the proximal tubule is a transcellular process, 
mediated by the previously discussed Na+-dependent phosphate cotransporters: 
NaPi-IIa, NaPi-IIc and PiT-2. The control of phosphate reabsorption is determined 
by the expression levels of NaPi-lla, NaPi-llc and potentially PiT-2 227. Studies in 
NaPi-IIa knock-out mice have shown that NaPi-IIa plays a key role in the renal 
regulation of phosphate homeostasis as these mice were characterised by 
hypophosphataemia and significant renal phosphate wasting, while NaPi-IIc 
knock-out mice showed normal plasma phosphate levels with no phosphate 
wasting 223. NaPi-IIc levels have been shown to be upregulated in NaPi-IIa knock-
out mice to compensate for the excessive loss of phosphate 223. Additionally, 
NaPi-IIa and -IIc have been reported to play synergistic roles in mediating renal 
phosphate reabsorption as NaPi-IIa and IIc double knock-out mice have been 
demonstrated to display a more severe hypophosphataemia and renal phosphate 
wasting 223. Nevertheless, NaPi-IIa is known to contribute approximately 70% to 
proximal tubular phosphate transport, while NaPi-IIc accounts for less than 30% 
30,223,229. Taken together, this suggests that NaPi-IIc plays a contributory role in 
renal phosphate reabsorption, but mainly becomes important when NaPi-IIa 
function is impaired in rodents. As described previously, NaPi-IIa is expressed in 
all three segments of the proximal tubule (S1-S3), with relatively higher 
expression in the S1 and S2 segments of the proximal tubule 230. This suggests 
63 
 
that a large proportion of phosphate in the glomerular filtrate is reabsorbed in the 
S1 and S2 segments compared to the S3 segment of the proximal tubule 227.  
There is a large body of evidence suggesting the existence of differential 
phosphate handling in humans and rodents 231. Unlike in mice, clinical reports 
from phosphate-related genetic disorders have suggested that NaPi-IIc, encoded 
by the SLC34A3, is the major proximal tubular phosphate transporter in humans 
29,232–234. Specific point mutations in human SLC34A3 gene, but not SLC34A1 are 
associated with severe phosphate wasting and hypophosphataemia 29,234. 
However, the recent identification of an autosomal-recessive mutation in the 
NaPi-IIa gene, SLC34A1, and its associated defect in Ca2+ and phosphate 
metabolism, suggest a significant role for NaPi-IIa in phosphate homeostasis, at 
least in human infants 235. In addition, a loss-of-function mutation in human NaPi-
IIa with Falconi syndrome has also been reported to cause hypophosphataemia, 
suggesting that NaPi-IIa and NaPi-IIc may be playing a synergistic role in renal 
phosphate reabsorption in humans 236 and that NaPi-IIc likely plays a more 
significant role (reviewed in 20). Immunohistochemistry data have shown that 
while the BBM of the renal proximal tubules of rodents stains strongly for NaPi-
IIa and faintly for NaPi-IIc, the opposite pattern was observed in humans 231. 
Unlike in rodents, NaPi-IIc has also been detected in the renal distal tubules of 
humans 231. Taken together, these findings suggest that in addition to its high 
expression and key role in the renal proximal tubular phosphate transport, human 
NaPi-IIc mediates distal tubular phosphate reabsorption and is therefore 
considered the major renal phosphate transporter in healthy humans.  
As previously described, the regulation of proximal tubular reabsorption of 
phosphate involves hormonal and dietary factors that affect the expression of the 
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phosphate transporters at the BBM. Among the factors regulating renal 
phosphate handling, FGF-23, dietary phosphate, α-klotho and PTH are the key 
players (reviewed in 237). There is evidence that the signalling pathway for α-
klotho-mediated FGF-23 action on the renal phosphate transporters occurs in the 
distal tubule, which is spatially separated from proximal tubular NaPi-IIa and -IIc 
238. Thus, since the FGF-23-klotho axis is regarded as a key mechanism in the 
regulation of phosphate homeostasis, further studies are required to examine the 
exact role of this distal tubular FGF-23-klotho signalling in the regulation of overall 
renal phosphate transport. 
1.4. Intestinal phosphate handling 
Early studies investigating the site of phosphate absorption in the gastrointestinal 
tract revealed that phosphate is absorbed in all three segments of the small 
intestine and the colon of rodents and humans 239–242. Chyme containing 
inorganic phosphate and other nutrients travel along the different segments of the 
small intestine spending two-thirds of the total transit time in the jejunum and 
ileum while lasting only a few minutes in the duodenum 243. The relatively longer 
transit time of chyme and the features of villi in the jejunum and ileum support the 
widely accepted dogma that these segments are the major sites of intestinal 
phosphate absorption. Although phosphate absorption in the colon has not yet 
been reported to play a significant role under normal conditions, during excessive 
phosphate intake, the absorption of phosphate in the colon can significantly affect 
serum phosphate levels 239. Moreover, there is evidence that the administration 
of phosphate-containing enemas results in hyperphosphataemia in humans 242. 
Taken together, these findings suggest that under certain conditions, the 
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absorption of phosphate across the colonic epithelia significantly affects systemic 
phosphate levels. 
At least two mechanisms account for the absorption of phosphate in the small 
intestine; paracellular and transcellular phosphate transport 18. Early studies 
aimed at understanding the mechanisms underlying intestinal phosphate 
absorption reported an active transcellular component, which is known to be Na+-
dependent and a passive paracellular process, mediated by the simple diffusion 
of phosphate 244. This passive paracellular component of intestinal phosphate 
absorption was shown to be a linear process that is driven by the electrochemical 
gradient of phosphate across the intestinal epithelial membrane 46,240,245. It is 
generally accepted that the passive paracellular phosphate transport process is 
Na+-independent 45,245,246, but a very early report in the rat small intestine 
indicated that this passive phosphate transport process is significantly dependent 
on Na+ 240. Interestingly, recent studies suggest that Na+ absorption via NHE3 
regulates paracellular phosphate transport in the small intestine 77,247, and this 
may account for an important component of paracellular phosphate absorption. 
Furthermore, It is widely known that NaPi-llb and PiT-1 are the active Na+-
dependent phosphate transporters at the BBM of the small intestine of mice, rat 
and humans, however, NaPi-llb is thought to be the major transporter responsible 
for transcellular phosphate absorption in the small intestine of these species 
17,18,31,39,248–250. Studies on the kinetics of NaPi-IIb have shown that NaPi-IIb is a 
high affinity and a low capacity transporter, with a Km of approximately 50 µM 
40,70. Even though it has been predicted to have a higher concentrating capacity 
compared to the PiT proteins 49, its overall contribution to intestinal phosphate 
transport is still being debated.   
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Using NaPi-IIb knock-out mice, two very recent studies reported conflicting data 
concerning the contribution of NaPi-IIb to intestinal phosphate absorption in the 
mouse small intestine 77,251. In the ileum of NaPi-IIb knock-out mice, while NaPi-
IIb was shown to contribute more than 90% to phosphate uptake using in situ 
intestinal loop techniques and 10 mM phosphate solution 77,  Ikuta et al 251, 
employed the everted sac technique and 4 mM phosphate solution to show that 
NaPi-IIb contributed approximately 30% to phosphate uptake. In a previous study 
in NaPi-IIb knock-out mice chronically maintained on a low phosphate diet, 
phosphate absorption following a 500 mM oral phosphate gavage was shown to 
consist of approximately 50% NaPi-IIb-mediated component,  with the remaining 
50% mediated by a NaPi-IIb-independent mechanism, suggested to be the 
passive paracellular transport pathway 31. The differences in the findings obtained 
in these studies may be due to the lack of consistency in the techniques 
employed. Additionally, there is evidence that NaPi-IIb knock-out mice 
maintained on a normal or a high phosphate diet exhibited normal serum 
phosphate levels, and NaPi-IIb was reported to be important for intestinal 
phosphate transport only in mice chronically fed a low phosphate diet 145,222,251. 
In rats, most of the early studies investigating the relative contribution of the Na+-
dependent and Na+-independent mechanisms of phosphate absorption showed 
that the saturable Na+-dependent component, now known to be NaPi-IIb 
mediated, is regulated by 1,25(OH)2D3 is 39,126,149,252. As discussed previously, 
NaPi-IIb protein is highest in the rat jejunum, where it has been suggested to 
contribute approximately 30-35% of total transepithelial phosphate transport in 
rats maintained on a normal phosphate diet, suggesting a dominant role for the 
Na+-independent component of phosphate transport 45.  
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Studies on the levels of postprandial luminal phosphate in the gastrointestinal 
tract of rats and mice have shown that the physiological concentration of free 
phosphate in the lumen of the small intestine is in the millimolar range, 
considerably higher than the Km of NaPi-IIb 45,251. Thus, this high phosphate levels 
in the intestinal lumen following a normal phosphate diet appears to be 
unfavourable for NaPi-IIb as the transporter will likely become saturated, 
suggesting that the passive Na+-independent component may be the dominant 
pathway for phosphate absorption in the small intestine of rats and mice 45,251. 
Considering the low Km of NaPi-IIb and the report that it mediates a saturable 
phosphate transport process, it has been speculated that under physiological 
conditions, when intestinal phosphate levels are expected to be in the millimolar 
range, passive Na+-independent phosphate transport mechanism is the 
predominant pathway for phosphate absorption in rats and mice 45,145.   
In comparison to rodents, there is limited information on the regional expression 
and functions of the Na+-dependent transporters, NaPi-IIb and PiT protein in the 
human small intestine, thus, the contribution of the Na+-dependent and Na+-
independent transport pathways to total transepithelial phosphate absorption in 
humans is unclear. However, NaPi-IIb mRNA has been shown to be highest in 
the human duodenum, with low expression levels in the ileum, while the jejunum 
showed the lowest expression 253. Functional studies in humans have shown that 
the jejunum is the major segment responsible for phosphate absorption and that 
in this segment phosphate transport is mainly Na+-dependent, while passive 
concentration-dependent phosphate transport has been reported in the ileum 46. 
Interestingly, a significant component of this passive concentration-dependent 
phosphate transport in the human ileum has been shown to be dependent on 
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transepithelial water movement 46. The human small intestine is known to be 
highly permeable to water, permitting rapid movement of water through 
paracellular pores due to osmotic gradient 254. Because of this, the transport of 
water-soluble phosphate by solvent drag would be expected to contribute to this 
passive mechanism of phosphate absorption. However, based on the evidence 
that the passive transport mechanism in the human small intestine is independent 
of intestinal transepithelial Na+ gradient 245, the major osmotically active solute in 
intestinal luminal content, solvent drag is, therefore, an unlikely driver for passive 
phosphate transport.  
Furthermore, a recent cell culture study investigating the mechanism underlying 
passive phosphate transport using Caco-2 brush border epithelial (BBE) cell line 
revealed that the rate of phosphate influx through the BBE membrane was 
unaffected by the Na+ gradient across the membrane 246. Another potential 
mechanism responsible for the passive Na+-independent component of 
phosphate absorption is phosphate transport via a passive transcellular 
transporter (carrier protein). There is evidence that the changes in the Na+-
independent passive phosphate transport in Caco-2 BBE cells in response to 
increasing phosphate concentration in the uptake solution requires de novo 
protein synthesis 246. Whether a passive transcellular carrier protein is involved 
in this adaptive response remains to be seen. Although pH has been reported to 
affect the passive phosphate transport process in rodents 126 and in Caco-2 BBE 
cell lines 246, there is no evidence suggesting that this effect involves a passive 
carrier protein or a facilitated transporter. Thus, the mechanism underlying 
passive phosphate transport remains unresolved. Using electrophysiological 
techniques, the paracellular pathway has been shown to mediate the passive 
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Na+-independent transport of phosphate in the small intestine 255, and because 
intestinal claudins are known to be involved in paracellular ion permeability, it is 
possible that these claudins may play a role in controlling the passive paracellular 
phosphate absorption process. 
1.5. Intestinal claudins 
Enterocytes are attached to one and other by the aggregation of tight junction 
proteins, of which claudins have been shown to be a key component. These 
claudins have been shown to play important roles in the paracellular transport of 
electrolytes and water 256–259. Other components of intestinal tight junctions are 
occludin, tricellulin and junctional adhesion molecules 260. Studies in occludin 
knock-out mice 261 and genetic mutations in the tricellulin gene 262 suggest that 
these proteins play minor roles in intestinal barrier function. Moreover, the 
junctional adhesion molecules have been shown to be activated during immune 
response 260,263 and thus, may play a less significant role in maintaining tight 
junction integrity under normal conditions.  
Claudins are transmembrane proteins encoded by the claudin (CLDN) genes. In 
humans, 23 CLDN genes have been identified, while a total of 24 CLDN genes 
have been reported for rats and mice 264. Most claudins are made up of at least 
120 amino acid residues, with molecular weight between 20 – 27kDa 264,265. 
Structurally, claudins span the membrane 4 times, with 2 extracellular loops and 
the N and C terminals facing the cytoplasm 265. Functionally, intestinal claudins 
can be classified into those that mediate the barrier functions of the intestine 
(tightening or pore-sealing claudins) and those that mediate channel formation 
(pore-forming claudins) for electrolytes and water transport 266. Among the 
claudins that have been detected in the intestine of mice, rats and humans, 
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claudins 2, 12, and 15 have been shown to play vital roles as paracellular pores 
or channels for electrolytes (pore-forming claudins), while claudins 1, 3, 4, 5 and 
8 are known to strengthen tight junction integrity, thus, classified as pore-sealing 
claudins 267. There is still some controversy concerning the classification of 
claudin 7 as either a pore-sealing or a pore-forming claudin 267,268. There is 
evidence that claudin 7 can function as both a pore-sealing and a pore-forming 
claudin since this protein has been shown to play a significant role as a Na+ pore 
as well as a barrier for anions, mainly Cl- 269. The pore-forming claudins are known 
to be predominantly distributed in leaky epithelia like the renal proximal tubule 
and small intestine, while the large intestine is characterised by the presence of 
pore-sealing claudins 270. A better understanding of the localisation and 
distribution of the intestinal claudins, their functions, charge selectivity and 
regulatory mechanisms will be essential in identifying a potential role for any of 
the claudins in mediating intestinal phosphate absorption. 
1.5.1. Localisation and distribution of intestinal claudins  
Intestinal Claudins are generally localised at the junction between the BBM and 
lateral membranes of enterocytes. Immunohistochemistry and 
immunofluorescent analysis have shown that most of these claudins exist in 
gradients along the intestinal crypt-villus axis 271,272. The pore-forming claudins 
are more concentrated in the crypts and their expression levels diminish towards 
the villus 271–273. However, the most highly expressed pore-sealing claudin in the 
small intestine, claudin 3, shows no crypt-villus gradient, while claudin 4 has been 
reported to be highest on the epithelial cells on the villus surface 271. As 
summarised in Table 1.3, the highest expression of claudin 1 in the intestine of 
rodents and humans has been shown in colonic epithelia 268,273,274. Claudin 2, 
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which is localised in the BBM, has been shown to be highest in the ileum of all 
three species, while low levels are observed in the duodenum of rat and humans, 
and the jejunum of mice  268,275,276. In the rat intestine, claudin 3 is localised on 
the BBM, and has its highest levels in the duodenum and colon 268, while in mice 
and humans, the ileum shows the highest levels of claudin 3 272,275,276. In addition 
to their localisation in the apical membrane, claudin 4 and 7 have also been 
shown to be localised in the lateral and basolateral membranes 273. In mice, 
claudin 4 levels appear to be similar in all the segments of the small intestine and 
colon, while its levels in rats and humans are highest in the colon 268,273,275,276. In 
rats and mice, claudin 7 has been reported to be highest in the ileum 268,276, while 
in humans, claudin 7 is highest in the colon 275. Claudin 8 levels in mice and 
humans increase down the intestine 272,276, with the lowest levels seen in the 
duodenum 275,276, while claudin 8 in the rat intestine is highest in the colon, with 
moderately high levels in the duodenum 268. Claudins 12 and 15 have been 
shown to be localised in the apical-most surface of the lateral membrane 272. In 
humans, the levels of claudin 12 are similar in all the segments tested, while 
claudin 15 is highest in the duodenum 275. The levels of these claudins in the 
human jejunum have not been reported. In mice, claudin 12 is most highly 
expressed in the ileum, while relatively higher levels of claudin 15 have been 
reported in the proximal segments of the intestine; duodenum and jejunum 272,276. 
In the rats, the jejunum shows the highest levels of claudin 12 268, while the 
regional expression of claudin 15 in this species has not yet been documented.
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Table 1.3. Expression profile of intestinal claudins in rats, mice and humans 
Claudins Species Duodenum Jejunum Ileum Colon References 
Claudin 1 Mice 
Rats 
Humans 
+ 
+ 
+ 
+ 
++ 
nd 
+ 
+ 
- 
++ 
+++ 
++ 
276 
268 
273,275 
Claudin 2 Mice 
Rats 
Humans 
++ 
+ 
+ 
+ 
++ 
nd 
+++ 
+++ 
+++ 
++ 
- 
- 
276 
268,271,273 
273,275 
Claudin 3 Mice 
Rats 
Humans 
+ 
+++ 
+ 
++ 
+ 
nd 
+++ 
+ 
+ 
+++ 
+++ 
+++ 
276 
268,271 
275 
 
Claudin 4 Mice 
Rats 
Humans 
+ 
++ 
+ 
+ 
+ 
nd 
+ 
+ 
+ 
+ 
+++ 
+++ 
276 
268,273 
275 
73 
 
Claudin 7 Mice 
Rats 
Humans 
+ 
+ 
++ 
++ 
+ 
nd 
+++ 
+++ 
+ 
+ 
++ 
+++ 
272,276 
268 
275 
Claudin 8 Mice 
Rats 
Humans 
+ 
++ 
- 
+ 
- 
nd 
++ 
+ 
+ 
+++ 
+++ 
+++ 
276 
268 
275 
Claudin 12 Mice 
Rats 
Humans 
+ 
+ 
+ 
+ 
+++ 
nd 
++ 
++ 
+ 
+ 
+ 
+ 
272,276 
268 
275 
Claudin 15 Mice 
Rats 
Humans 
+++ 
nd 
+++ 
+++ 
nd 
nd 
++ 
nd 
++ 
+ 
nd 
+ 
272,276 
 
275 
Expression levels are represented as very low or not detected (-), mild (+), moderate (++), high (+++) and not determined (nd)
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1.5.2. Physiological functions and regulation of intestinal claudins   
As the names imply, the pore-sealing claudins 1, 3, 4, 5 and 8 are known to inhibit 
the diffusion of electrolytes and water molecules through the paracellular 
pathways 274,277–280, while the pore-forming claudins play important roles in the 
selective transport of cations, anions and water 256,257,259,281. Amongst the pore-
sealing claudins, claudin 3 is known to be the most highly expressed claudin in 
the small intestine and colon 273,276,282,283 and has been shown to be significantly 
downregulated by prolactin and vitamin D 284,285. Zinc (Zn2+) has recently been 
reported as an important intracellular regulator of claudin 3, with low levels of Zn2+ 
in the enterocytes demonstrated to cause the downregulation of claudin 3 mRNA 
expression and protein levels 286. Claudin 4, another highly expressed pore-
sealing claudin, has been shown to act as a selective barrier to the diffusion of 
Na+ 280. Quercetin, the most abundant flavonoid, has been shown to strengthen 
tight junction barrier properties by upregulating claudin 4 levels in Caco-2 cells 
287. Moreover, claudin 8, has also been reported to act as a barrier for both 
monovalent and divalent cations, and its levels are regulated by aldosterone 
279,288. Although claudin 1 and claudin 5 expression have been detected in the 
intestine, their physiological roles have not been studied in detail in this tissue. 
However, claudin 1 is known to be the major tight junction protein in the epidermis 
of the skin as mice lacking claudin 1 die of dehydration few hours after birth 289, 
while claudin 5 has been shown to be a major component of the blood brain 
barrier 278. 
Pore-forming claudins 2 and 12 have been shown to be primarily involved in 
1,25(OH)2D3-dependent paracellular Ca2+ absorption 257. Additionally, claudin 2 
in leaky epithelia like the jejunum, has also been reported to act as a channel for 
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monovalent cations like Na+ and K+; and water, driven by the osmotic gradient 
generated by Na+ transport through the channel 270. Studies in claudin 7 knock-
out mice have shown that claudin 7 selectively acts as a barrier for Cl- and organic 
solutes 290, while also mediating paracellular Na+ transport 269. There is a paucity 
of information on the hormonal regulation of intestinal claudin 7, however 
estrogen has been shown to significantly upregulate claudin 7 levels in the 
luminal epithelial cells of the uterus in rats 291. A large body of evidence supports 
the role of claudins 2 and 15 as the major pore-forming claudins in the small 
intestine (reviewed in 292). Studies in claudin 2 and 15 double knock-out mice 
have shown that these claudins are the major pathway for the paracellular 
transport of Na+ 293. Interestingly, the transport of Na+ via these claudins 
significantly impacts the transcellular transport of glucose, amino acids and lipids 
293. Additionally, studies have demonstrated that the loss of Na+ and glucose 
absorption in the small intestine of the claudin 2 and 15 double knock-out mice 
was mainly due to the absence of claudin 15 256. It is worth noting that mice 
lacking NHE3 are characterised by reduced claudin 2 and 15 levels compared to 
wild-type mice 294, suggesting a role for NHE3 in the regulation of claudin 2 and 
15 expressions.  
Furthermore, intestinal claudins have been shown to change with age 273,276. 
While the levels of claudin 3, 4, 7 and 15 have been shown to increase with age, 
claudin 8 is unaffected 276. Claudin 2 levels have been shown to be significantly 
higher in newborn and suckling animals, and its levels decrease with increasing 
age 276. The high levels of claudin 2 in young animals may be because of the 
significant need for Ca2+ during bone development since claudin 2 is primarily 
involved in paracellular Ca2+ absorption. Intestinal claudins have been reported 
76 
 
to be regulated acutely by posttranslational modifications, including 
phosphorylation, glycosylation and palmitoylation of the proteins 295. Because 
most claudins have been shown to have a PDZ-binding motif at their intracellular 
C-terminal 260, phosphorylation of these proteins appears to be the most common 
posttranslational regulatory pathway. Notably, PKA and PKC have both been 
reported to control paracellular permeability by phosphorylating pore-sealing 
claudins within the enterocyte 265. PKA–mediated phosphorylation of claudin 3 
has been shown to affect its anchoring to tight junctions 296, while PKC-δ-induced 
phosphorylation of claudin 4 has been demonstrated to facilitate the assembly of 
this pore-sealing claudin into intestinal epithelial tight junctions 297. Other 
enzymes that have been reported to phosphorylate claudins in order to alter tight 
junction properties are: WNK4, tyrosine kinase, mitogen-activated protein kinase 
(MAPK) and c-Jun N-terminal kinase (JNK) 260. For instance, JNK has been 
shown to upregulate claudin 2 expression 298, while MAPK has been 
demonstrated to play a role in the downregulation of claudin 2 expression 299. 
1.5.3. Charge and size selectivity of pore-forming claudins  
Based on the electrical charge and the molecular size of the solutes in luminal 
content, the pore-forming claudins in the small intestine are designed to 
selectively permit the diffusion of both organic and inorganic solutes. Increasing 
evidence suggests that a charged amino acid side chain in the first extracellular 
loop of the protein structure of claudins is responsible for the charge selectivity of 
pore-forming claudins 300. Claudins are hypothesised to be lined by charged 
amino acid residues, which create a charge selective filter such that electrolytes 
with the same electrical charge as the amino acid side-chain are repelled and are 
unable to diffuse through the claudin channel, hence, why most pore-forming 
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claudins are cation selective 295. Genetic studies involving the introduction of a 
single positive charge at position M2 of the first extracellular loop of claudin 15 
reverses the preference of this claudin from being a Na+ pore to a Cl- channel 301. 
There is limited information on the respective pore sizes of all the intestinal pore-
forming claudins. However, a recent study investigating the permeability of 
claudin 15 to organic and inorganic solutes of different sizes have revealed some 
size-dependent differences in the permeability of positively charged solutes 
through this claudin in Madin-Darby canine kidney (MDCK) cells 302. Tanaka and 
colleagues 302 showed that the pore size of claudin 15 is approximately 5.6 Å in 
diameter and that the permeability of large organic cations like methylammonium, 
ethylammonium tetramethylammonium, tetraethylammonium, arginine, and N-
methyl-D-glucamine through this claudin is significantly less than that of Na+. In 
addition, the pore size of claudin 2 has been reported to be approximately 6.5–
7.5 Å in diameter 303, thus, only cations that are less than this pore diameter are 
likely to diffuse freely through this claudin. It is worth noting that in addition to the 
presence of pore-forming claudins mediating paracellular transport of cations in 
the small intestine, there are also leak pores between enterocytes that are up to 
50-60 Å in radius in the crypts, and less than 6 Å in the upper portion of the villus 
304. These pores have been shown to be relatively permeable to all solutes, with 
no charge-selectivity 304.  Evidence from cell culture studies suggests that 
increased expression of the pore-sealing claudins, for instance, claudin 3, may 
significantly seal these leak pores between enterocytes and thus, reduce the 
paracellular transport of both charged and uncharged solutes 277. 
78 
 
1.6. Iron and the regulators of phosphate homeostasis 
Increasing evidence from both clinical and animal studies suggests a link 
between iron deficiency and phosphate homeostasis 305–308. In autosomal 
dominant hypophosphataemic rickets (ADHR), the mutation within the FGF-23 
pro-protein convertase site affects the physiological cleavage of the intact FGF-
23 within the osteocytes 307. This results in elevated levels of intact FGF-23 in the 
circulation, responsible for the hypophosphataemia seen in ADHR. The 
observation that low serum iron levels are associated with high intact FGF-23 
concentrations during the active phase of this disease 309 suggests a link between 
iron homeostasis and intact FGF-23.  
In addition, there is evidence that iron deficiency affects the transcription of FGF-
23 in osteocytes 310. Unlike in ADHR, FGF-23 is continuously cleaved within 
osteocytes in iron deficient humans with normal renal function, resulting in the 
presence of excess cFGF-23 in the circulation, while intact FGF-23 levels are 
unaffected 305. In the same study, treatment of the iron deficiency significantly 
reduced the transcription of FGF-23, resulting in lowered levels of cFGF-23 and 
unchanged phosphate levels in the circulation. Additionally, intravenous iron 
injection in healthy subjects with normal serum iron levels had no impact on intact 
FGF-23 311. In rodents, neonatal iron deficiency has been shown to increase 
intact FGF-23 levels in both normal and ADHR mice 307, but not in adult mice 310. 
Moreover, iron deficiency has also been linked to 1,25(OH)2D3 deficiency in 
neonatal mice, which was reported to be as a result of significantly increased 
levels of intact FGF-23 associated with iron deficiency 307. Clinical evidence in 
iron deficient children suggests that an association between iron deficiency and 
1,25(OH)2D3 deficiency exists 312. The exact impact of iron deficiency on the 
79 
 
functions of the hormones of phosphate homeostasis, particularly how iron 
deficiency affect intestinal phosphate absorption and renal phosphate 
reabsorption remains to be determined.  
1.7. Aims of study 
Rats and mice are widely used as experimental models to study the mechanisms 
of intestinal phosphate absorption. Although the transporters mediating 
phosphate absorption in rats and mice are known to show significant variations 
in different segments of the small intestine 17,39, there is limited information on the 
segmental profile of these transporters in the human small intestine. Therefore, 
the aim of the experiments described in chapter 3 was to understand the regional 
differences in the expression of the transcellular phosphate transporters, NaPi-
IIb and PiT-1 and the mediator of paracellular phosphate absorption, NHE3, in 
mice, rats and humans. Since previous evidence suggests that there may be 
some variations between the mechanisms underlying phosphate absorption in 
different segments of the small intestine in rodents 17,38,39,45, the contribution of 
NaPi-IIb and NHE3 to phosphate absorption in the proximal and distal small 
intestine of mice, and the duodenum and jejunum of rats, was investigated. 
Furthermore, the aim of the experiments in subsequent chapters was to 
investigate the link between diet-induced iron deficiency and phosphate 
homeostasis, with a particular focus on how iron deficiency impacts the 
mechanisms of phosphate absorption in the rat duodenum and jejunum. The 
inhibition of intestinal phosphate absorption by phosphate binders is a major 
treatment strategy for managing hyperphosphatemia in CKD patients 313,314. 
Therefore, understanding the mechanisms of intestinal phosphate absorption and 
the differences that exist in different intestinal segments will provide more insights 
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into the generation of a segment-specific method for inhibiting intestinal 
phosphate absorption. 
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Chapter Two 
2.0. General Methods 
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2.1. Animals 
Male animals, C57BL/6 mice and Sprague-Dawley rats, both 6 – 8 weeks’ old 
and intestinal specific NaPi-IIb homozygous knock-out and wild-type mice of 8 – 
10 weeks of age were used for the study. The Sprague-Dawley rats were 
obtained from Charles River Laboratories (Harlow, UK), and the NaPi-IIb knock-
out and wild-type mice were generated in Professor Carsten Wagner’s laboratory, 
Institute of Physiology, University of Zurich, Switzerland. These animals were 
transferred to the Comparative Biology Service Unit at UCL Medical School, 
Royal Free Hospital, London. All animals were allowed free access to drinking 
water and standard rodent diet (RM1, SDS Ltd, Witham, UK) or custom iron diets 
(Harlan Laboratories, Inc. Madison, WI, USA). A maximum of three rats or six 
mice were housed in a single cage, maintained on a 12-hour light/dark cycle. All 
procedures were conducted in accordance with the UK legislation (Animal 
Scientific Procedures Act, 1986, Amendment regulations 2012). 
2.2. Intestinal tissue collection 
Rat and mouse intestinal mucosa scrapes were obtained from the duodenum 
(between the pylorus and ligament of Treitz), jejunum (from the ligament of Treitz 
to the halfway point through the small intestine) and ileum (between the halfway 
points to the ileocecal junction). All tissues were immediately frozen in liquid 
nitrogen and stored at -80 °C until required. Human tissue biopsies were taken 
from the small intestine of healthy adult volunteers that arrived at the endoscopy 
unit of Sahlgrenska University Hospital, Gothenburg, Sweden in the morning after 
an overnight fast. Following conscious sedation with midazolam and alfentanil, 
an endoscope was introduced into the gastrointestinal tract and the biopsies were 
harvested from the duodenum, proximal jejunum and ileum, and the tissue was 
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put in RNA STAT-60 (Amsbio, Abingdon, U.K) after which they were immediately 
frozen in liquid nitrogen and transferred to a -80 °C freezer. All human tissue 
samples were packaged in Professor Lars Fandriks Laboratory at the University 
of Gothenburg, Sweden, and shipped on dry ice to me in London, where they 
were used for the current study. All volunteers gave written consent, and the 
Regional Ethical Review Board of Gothenburg, Sweden, approved the study. 
2.3. Measurement of mRNA levels 
2.3.1. RNA extraction and Quantification 
All materials used for RNA extraction were sterilised using an autoclave. Total 
RNA was isolated from intestinal and kidney tissues using TRIzol (Life 
Technologies, Paisley, UK). Whole tissue samples or intestinal tissue scrapes 
were ground in liquid nitrogen using a mortar and pestle. Approximately 50-100 
mg of the ground tissue sample was then mixed with 1 mL TRIzol, shaken 
vigorously and incubated at room temperature for 5 minutes. Phase separation 
was done by adding 0.2 mL of chloroform to the tissue – TRIzol mixture and 
shaken vigorously by hand for 15 seconds. The mixture was incubated for 3 
minutes at room temperature, following which it was centrifuged at 12000 g for 
15 minutes at 4 ˚C. The aqueous phase of the sample was transferred to a fresh 
tube. RNA was isolated by adding 0.5 mL of 100 % isopropanol to the aqueous 
phase and the mixture was incubated at room temperature for 10 minutes. To 
obtain the RNA pellet, the mixture was centrifuged at 12000 g for 10 minutes at 
4 ˚C, after which the supernatant was removed. The RNA pellet was washed 
using 1 ml of 75 % ethanol and centrifuged at 7500 g for 5 minutes at 4 ˚C. The 
supernatant was removed and the RNA pellet was dried briefly at room 
temperature. The dried RNA pellet was resuspended using an appropriate 
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volume of DEPC-treated water. The concentration and purity of the extracted 
RNA sample were measured using the NanoDrop spectrophotometer (LabTech 
international). To further assess the purity of the RNA, electrophoresis of the RNA 
was carried out on a 2% agarose-TAE gel, which was stained with ethidium 
bromide and run at 50 V for 1 hour. The bands of the RNA were visualised under 
UV light using a transilluminator (Peqlab Biotechnologie GmbH, Germany). The 
RNA samples were stored at -80 °C until required. 
2.3.2. cDNA Synthesis 
The RNA sample was treated with deoxyribonuclease I (Life Technologies, 
Paisley, UK) according to the manufacturer’s instructions. 1 µL each of 10X 
DNase I reaction buffer and DNase I, Amp Grade (1 U/µL) was added to 1 µg of 
the RNA sample. DEPC-treated water was added to the sample mixture to obtain 
a total volume of 10 µL. The mixture was vortexed and incubated at room 
temperature for 15 minutes. To inactivate the DNase I enzyme, 1 µL of EDTA 
was added to the reaction mixture and heated at 65 °C for 10 minutes. 
Complementary DNA (cDNA) was then synthesised by the reverse transcription 
of the pretreated RNA using a cDNA synthesis kit (PCR Biosystems Ltd, London, 
UK) following manufacturer's instructions. 4 µL of 5x cDNA synthesis mix, 1 µL 
of 20x RTase and 4 µL of PCR-grade dH2O was added to the pretreated RNA 
sample. The reaction mixture was incubated in a heat block at 42 °C for 30 
minutes (step 1) and 85 °C for 10 minutes (step 2) to synthesise the cDNA and 
denature the RTase enzyme respectively. As a negative control, a non-reverse 
transcriptase sample was prepared using the pretreated RNA, mixed with 4 µL of 
5x cDNA synthesis mix and 5 µL of PCR-grade H2O and then incubated in the 
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heat block using the same protocol as stated above. The cDNA and the non-
reverse transcriptase samples were stored at -20 °C. 
2.3.3. Real-time polymerase chain reaction  
The mRNA expression levels of the genes of interest were analysed by real-time 
polymerase chain reaction (RT-PCR) using 2xqPCR BIO SyGreen kit (PCR 
Biosystems Ltd, London, UK) and primers (Table 2.1). Primers were obtained 
from Qiagen, UK or predesigned primer sequences were sent to Sigma-Aldrich 
where they were manufactured (Table 2.1). cDNA, 1.0 µL, was added to a 
reaction mix (containing 0.5 µL of PCR primer, 5.0 µL of SybraGreen and 3.5 µL 
of PCR-grade dH2O) in a 96-well plate. The non-reverse transcriptase negative 
control and the reaction mix alone were run on the same plate to confirm the 
absence of DNA contamination in the samples the reaction mix respectively. The 
PCR reaction set up was prepared according to the manufacturer’s instructions. 
The reaction was performed on a Light Cycler 96 instrument (Roche Diagnostics, 
East Sussex, UK) as follows: preincubation at 95 °C for 10 min, 3-step 
amplification consisting of: 95 °C for 10 s (step 1), 60 °C for 10 s (step 2) and 72 
°C for 10 s (step 3). A total of 35 or 45 cycles for the 3-step amplification were 
carried out followed by a melting stage consisting of 95 °C for 10 s, 60 °C for 60 
s and 97 °C for 1 s. The final condition of the melting stage was continuous, with 
five readings recorded per unit temperature. The data was analysed using the 
Light Cycler 96 analysis software and the relative quantification (Rel Quant) of 
the mRNA for each gene of interest to β-actin was taken as the mRNA expression 
levels.
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    Table 2.1. RT-PCR primers 
Primer name Cat. Number Forward Sequence Reverse Sequence 
Rat claudin 3 QT01169406 - - 
Rat claudin 4 QT00376726 - - 
Rat claudin 7 QT00400267 - - 
Rat claudin 8 QT00428617 - - 
Rat claudin 12 QT01607319 - - 
Rat claudin 15 QT01584604 - - 
Rat SGLT1 QT00001246 - - 
Rat GLUT2 - ACTCCGATTAGAAACGTCA CGTAAGGCCCGAGGAA 
Rat NaPi-IIb QT00188594 - - 
Mouse NaPi-IIb - ATCCACTCACGTTGGG CTGCGAACCAGCGATA 
Human NaPi-IIb QT00071883 - - 
Rat NHE3 QT00180985 - - 
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Mouse NHE3 QT01039829 - - 
Human NHE3 QT00095914 - - 
Rat/mouse PiT-1 - GGTGGGATGTGCAGTTTTCT CAAGAGAGGAGGTGGTGTCG 
Human PiT-1 QT00028763 - - 
Rat Cyp27b1 QT00386953 - - 
Rat VDR - AGGCTACAAAGGTTTCTTCA 
 
TAGCTTGGGCCTCAGACTGT 
Rat α-Klotho QT00185822 - - 
Rat DMT1 QT00182623 - - 
Mouse DMT1 QT01047368 - - 
Rat NaPi-IIa - AQTCTCATTCGGATTTGGT CACTTGTGCCTTGACG 
Rat NaPi-IIc QT00185633 - - 
Rat β-actin QT00193473 - - 
Mouse β-actin  QT00095242 - - 
Human β-Actin - AACAAGATGAGATTGGCATGG AGTGGGGTGGCTTTTAGGAT 
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2.4. Measurement of protein levels 
2.4.1. Intestinal brush border membrane vesicle preparation 
Intestinal BBM vesicles were prepared from snap frozen and stored duodenum 
and jejunum (at -80 °C) using the MgCl2 precipitation method 39. Mucosa tissue 
lining these segments was scraped off using glass slides and suspended in a 
buffer containing 50 mM mannitol, 2 mM HEPES (pH 7.1) and an EDTA free 
protease inhibitor cocktail tablet (Sigma-Aldrich, UK). The mucosa tissue was 
homogenised three times for 20 seconds with a 5-second interval after each 
homogenisation step, using an Ultra Turax homogeniser (Janke & Kunkel, FRG, 
UK) set at half speed. Following homogenisation, samples were collected for the 
assessment of whole cell protein concentration and alkaline phosphatase activity 
in the protein suspension or homogenate mixture, and MgCl2.6H2O was then 
added to a final concentration of 10 mM in the homogenate. The homogenate 
was stirred on ice for 20 minutes after which it was centrifuged at 4600 g for 10 
min to obtain a supernatant. The supernatant was centrifuged at 41600 g for 30 
min to obtain a pellet. The pellet was suspended in a buffer containing 300 mM 
mannitol, 20 mM HEPES and 0.1 mM MgSO4 (pH 7.2) and an EDTA free 
protease inhibitor cocktail tablet (Sigma-Aldrich, UK), by passing six times 
through a 21-gauge needle. The suspension was centrifuged at 9300 g for 15 
min, and the supernatant obtained was centrifuged for a further 30 minutes at 
41600 g to obtain the BBM pellet. The BBM pellet was resuspended in the latter 
buffer by passing six times through a 21-gauge needle. 
2.4.2. Kidney brush border membrane vesicle preparation 
Kidney BBM vesicles were prepared from snap frozen and stored kidneys (at -
80°C) using the double MgCl2 precipitation method 315. Kidney cortical slices were 
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homogenised in 30 ml buffer containing 300 mM mannitol, 5 mM EGTA and 12 
mM Tris-HCl (pH 7.4) for 2 min using an Ultra Turax homogeniser (Janke & 
Kunkel, FRG, UK) set at half speed. Cold deionized water, 42 ml, was added and 
briefly mixed. Samples were collected for the assessment of whole cell protein 
concentration and alkaline phosphatase activity, following which MgCl2.6H2O was 
added to make a final concentration of 12 mM. The solution was stirred on ice for 
15 minutes and then centrifuged at 2000 g for 15 minutes. The supernatant was 
re-centrifuged at 33000 g for 30 minutes to obtain a pellet, which was suspended 
in 20 ml buffer containing 150 mM mannitol, 2.5mM EGTA and 6mM Tris-HCl (pH 
7.4) and then homogenised using a hand operated Glass-Teflon homogeniser. A 
second precipitation using MgCl2.6H2O, low- and high-speed centrifugations as 
described above were repeated to obtain a pellet. The pellet was then re-
suspended in 20 ml buffer containing 300 mM mannitol, 2.5 mM EGTA and 12 
mM Tris-HCl (pH 7.4), homogenised and centrifuged at 33000 g for 30 minutes 
to obtain the purified BBM pellet. The appropriate volume of the latter buffer was 
added to re-suspend the BBM pellet using a 1 ml syringe and a 21-gauge needle, 
and the protein concentration of both renal and intestinal BBM was determined 
using a Bradford assay 316. To validate the purity of the BBM, alkaline 
phosphatase levels in the initial homogenate and the BBM were measured using 
the method of Forstner et al. 317 and the BBM vesicles were approximately 10-
fold enriched. All buffers used in the kidney BBM vesicle preparation contained 
0.25 mM PMSF and aprotinin (protease inhibitor). All the steps in the isolation of 
intestinal and kidney BBM vesicle were carried out at 4 °C. 
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2.4.3. Western blotting 
Intestinal and kidney BBM vesicles were mixed with Laemmli sample buffer, after 
which electrophoresis of the samples was carried out on a 10% SDS – 
polyacrylamide gel at 20 mA and the proteins transferred on to polyvinylidene 
difluoride (PVDF) membrane by electroblotting, run at 15V for 75 min. Following 
protein transfer, the PVDF membranes containing the separated proteins were 
incubated in PBS containing 0.1% Tween 20 (PBS-T) and 6% fat-free milk for 1 
hour at room temperature. The membranes were then incubated with antibodies 
(raised in rabbit or goat) to the protein of interest (Table 2.2) for 16 h at 4 °C. The 
membranes were washed with PBS-T four times (1 x for 15 min and 3 x for 5 min 
each), after which they were incubated with either an anti-rabbit antibody (1:2000 
dilution, GE Healthcare, Buckinghamshire, UK) or anti-goat antibody (1:1000 
dilution, Santa Cruz Biotechnology, Heidelberg, Germany) conjugated to 
horseradish peroxidase for 1 hour at room temperature. The membranes were 
washed with PBS-T as described above and the bound antibodies were 
visualized using a Flour-S Multi-Imager System (Biorad, Hemmel Hempstead, 
UK), governed by the chemiluminescent method of detection. 
The membranes were stripped of the antibodies using a blot restore buffer 
(Thermo Scientific, Hemmel Hempstead, UK) and non-specific protein binding 
was blocked with PBS-T containing 6% fat-free milk as described above. The 
membranes were then incubated with a mouse monoclonal antibody raised 
against Xenopus laevis β-actin (Table 2.2) for 1 hour at room temperature. The 
membranes were then washed and incubated with the anti-mouse antibody 
(1:5000 dilution, Sigma Ltd, Amersham, UK) for 1 hour at room temperature and 
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then visualized. The ratio of the protein of interest to β-actin band volumes was 
calculated for each sample and presented as arbitrary units (a.u).
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Table 2.2. Western blot antibodies  
Protein of interest Species  Source  Catalogue number  Dilutions  
NaPi-IIa Rabbit polyclonal Institute of Physiology-UZH              - 1:2000 
NaPi-IIb Rabbit polyclonal LSBio, Inc. LS-C37453 1:500 
NaPi-IIc Rabbit polyclonal Abcam ab155986 1:1000 
NHE3 Rabbit polyclonal StressMarq Biociences SPC-400 1:1000 
PiT-1 Rabbit polyclonal David’s Biotechnologie Custom antibody 1:100 
DMT1 Rabbit polyclonal Alpha Diagnostic Int. NRAMP24-A 1:500 
Claudin 3 Rabbit polyclonal Abcam ab199635 1:500 
SGLT1 Goat polyclonal Santa Cruz Biotechnology Sc-20584 1:1000 
GLUT2 Rabbit polyclonal Bio-rad 4670-1659 1:1000 
β-actin  Mouse monoclonal Santa Cruz Biotechnology Sc-69879 1:500 
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2.5. In vivo phosphate uptake experiments 
Measurement of transepithelial phosphate absorption in vivo was determined 
using the in situ intestinal loop technique 39,176. Animals were weighed and 
anaesthetized by an intraperitoneal injection of 45 mg/Kg pentobarbitone sodium 
(Pentoject; Animal care Ltd, Kent, UK), and maintained at 37 °C on a regulated 
heating blanket (Harvard Apparatus Ltd, Kent, UK). Following cannulation of the 
femoral artery in rats, a longitudinal abdominal incision was made and a 5-cm 
long segment of the duodenum (2 cm distal to the pylorus) or jejunum (5 cm distal 
to the ligament of Treitz) or ileum (5 cm proximal to the ileocecal junction) was 
cannulated, flushed with warm 0.9% saline and then flushed with air. Uptake 
solution (500 µl for rats or 200 µl for mice) containing 16 mM Na+-HEPES, 140 
mM NaCl, 3.5 mM KCl and 10 mM KH2PO4 (pH 7.4) and 0.37 MBq 33P 
(PerkinElmer, Bucks, UK) was instilled into the lumen of the cannulated segment 
and immediately tied off. For rats, blood (500 µl) was collected from the 
cannulated femoral artery at 10, 20 and 30 minutes after instilling the uptake 
solution. However, in mice, a single blood collection was done via cardiac 
puncture approximately 10 minutes after instilling the uptake buffer into the 
cannulated intestinal segment. Collected blood samples were centrifuged at 1500 
g for 15 min at 4 °C to obtain plasma. After 30 minutes, the cannulated intestinal 
segment was removed, blotted and the length was measured and recorded. The 
amount of phosphate transferred from the intestinal segment into 1 ml of plasma 
was calculated using the data obtained from the scintillation counting (Tri-Carb 
2900TR; Perkin Elmer) of 33P in plasma and the initial uptake solution. 
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2.6. In vitro phosphate uptake experiments 
Phosphate transport across the BBM was measured in vitro using the everted 
sleeve technique 45. Rats were weighed and anaesthetized as described above. 
Following a longitudinal abdominal incision, segments of the duodenum and 
jejunum (2-4 cm long) were removed, flushed with warm HEPES buffer containing 
16 mM Na+-HEPES, 3.5 mM KCl, 10 mM MgCl2, 1 mM CaCl2 and 125 mM NaCl 
(pH 7.4) and everted on a glass rod using a thread to hold the tissue in place. 
The everted tissue was incubated for 5 minutes in the HEPES buffer containing 
10 mM glucose, bubbled with 100% O2 and continuously stirred, with the 
temperature maintained at 37 °C. Following the 5-minute incubation, the tissue 
was transferred into a chamber containing the uptake solution, which was 
composed of the HEPES buffer, 10 mM KH2PO4 and 0.37 MBq 33P (PerkinElmer, 
Bucks, UK) for 2 minutes, with the solution gently stirred and bubbled with 100% 
O2. The tissue was then washed in a solution containing 150 mM NaCl and 100 
mM KH2PO4 (a 10-fold excess of non-radioactive phosphate in the uptake buffer) 
for 10 minutes, followed by another 5-minutes wash in PBS. The tissue 
(approximately 100 mg) was weighed and digested in 2 ml SOLVABLETM 
(PerkinElmer, Bucks, UK). Aliquots (100 µl) of the digested sample and initial 
uptake solution were counted as previously described, and the amount of 
phosphate transferred into the tissue was calculated and expressed as nmoles 
of phosphate/100 mg of intestinal tissue.  
2.7. Urine and Blood biochemistry 
Animals were put in metabolic cages overnight (16 hours) to collect urine samples 
before the in vivo or in vitro experiments. Blood samples were collected at the 
end of the experiment by either cardiac puncture or via femoral artery 
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cannulation. For plasma samples, blood was put in heparinised tubes, while for 
serum collection, blood was put in anticoagulant free containers to allow the 
formation of blood clots. Blood samples were then centrifuged at 7500 g for 10 
minutes at 4 °C to obtain serum and plasma. 
2.7.1. Measurement of iron levels - haematocrit levels and iron Assays 
Non-haemolysed blood samples were collected via the femoral artery cannulation 
into heparinised capillary tubes and spun using a micro-haematocrit centrifuge 
(Hawksley, England) for 5 minutes. The haematocrit levels were read using a 
micro-haematocrit reader.  
Serum samples were sent to the Chemical Pathology Department, at the Royal 
Free Hospital for measurement of iron levels. Samples were analysed using 
Randox reagents (Randox Laboratories, UK) using an RX series analyser, RX 
Daytona plus. 
Unsaturated iron-binding capacity (UIBC) and total iron-binding capacity (TIBC) 
were measured using a commercially available assay kit (Pointe Scientific Inc. 
Canton, MI, USA) following manufacturer’s instruction. For UIBC measurement, 
a known amount of ferrous ion was added to the serum sample in alkaline pH in 
order to bind to the transferrin binding sites. The unbound ferrous ions were 
measured by their reaction with ferrozine in the iron-colour reagent (Ferrozine 
reaction). The difference between the number of ferrous ions added and the 
unbound ions gives the UIBC. TIBC was obtained by the summation of the UIBC 
and the serum iron levels. For consistency, serum iron levels used for estimating 
the TIBC was measured using the ferrozine reaction. The iron buffer reagent 
releases ferrous ions from transferrin-bound ferric iron in acidic pH, and the 
ferrous ions react with ferrozine in the iron colour reagent to give a violet colour. 
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The absorbance of the reaction product was measured at 560 nm using a 
spectrophotometer.  
2.7.2. Measurement of phosphate levels 
Serum and urine phosphate levels were measured using a Phosphate 
Colorimetric Assay Kit (BioVision Inc, Milpitas, CA, USA) following 
manufacturer’s instruction. The assay utilises the reaction between phosphate 
ions with malachite green and ammonium molybdate. This reaction forms a 
chromogenic complex (green colour) and the absorbance of this complex is 
measured at a wavelength of 620 – 650 nm. 
2.7.3. Hormone assays 
All assays were carried out on serum or plasma samples following the 
manufacturer’s instructions. Serum intact FGF-23 concentrations were analysed 
using a commercially available enzyme-linked immunosorbent assay (ELISA) 
(Kainos Laboratories Inc., Tokyo, Japan), plasma c-term FGF-23 concentrations 
were assessed  using a rodent-specific c-term FGF-23 ELISA (Immutopics, Inc., 
San Clemente, CA, USA), serum 1,25 (OH)2D3 ELISA kit (LSBio Inc., Seattle, 
WA, USA) was used to measure 1,25 (OH)2D3 levels, and plasma PTH 
concentrations were assayed using rat bioactive intact PTH ELISA kit 
(Immutopics, Inc., San Clemente, CA, USA).  
2.7.3.1. Serum intact FGF-23 assay test principle 
The intact FGF-23 ELISA is governed by a two-step reaction principle. First, intact 
FGF-23 in the test sample binds to the immobilised antibody in the microtiter well 
to form an FGF-23/antibody complex. The second reaction step involves the 
binding of the FGF-23/antibody complex with horseradish peroxidase (HRP)-
labelled antibody to form a sandwich-like complex. The catalytic activity of the 
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peroxidase enzyme depends on the levels of intact FGF-23 in the sandwich-like 
complex. Activated peroxidase catalyses the reaction between 3,3’,5,5’-
Tetramethylbenzidine (TMBZ) and hydrogen peroxide (both in the substrate) to 
give a chromogenic product, whose absorbance at a wavelength of 450 nm 
reflects the level of intact FGF-23 in the sample.  
2.7.3.2. Plasma c-term FGF-23 assay test principle 
The wells in the c-term FGF-23 ELISA plate contain two affinity purified goat 
polyclonal antibodies that detect epitopes within the C-terminal region of mouse 
or rat FGF-23. One of the antibodies is conjugated with HRP, while the other is 
biotinylated for capturing FGF-23 in the sample. The c-term FGF-23 in the sample 
is bound to both antibodies in a streptavidin-coated microtiter well to form a 
sandwich-like complex. Like intact FGF-23, the activity of the peroxidase is 
directly proportional to the amount of c-term FGF-23 in the sample, and the 
absorbance of the chromogenic product, formed from the reaction between 
TMBZ and hydrogen peroxide in the substrate, gives the level of c-term FGF-23 
in the sample. 
2.7.3.3. Serum 1,25(OH)2D3 assay test principle 
Unlike the sandwich-ELISA assays described above, this assay is based on a 
competitive binding principle. Samples or standards were added to each well 
together with an HRP-conjugated target antigen. The free antigen in the sample 
competes with the HRP-conjugated antigen for binding to a capture antibody in 
each well of the microtiter assay plate. The antigen in the sample is able to 
displace the HRP-conjugated target antigen from binding with the capture 
antibody, thus reducing the activity of the peroxidase enzyme. Hydrogen peroxide 
and TMBZ in the substrate reacts to produce a chromogenic product whose 
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absorbance at 450 nm is inversely correlated with the concentration of 
1,25(OH)2D3 in the sample. Therefore, the higher the antigen (1,25(OH)2D3) in 
the sample, the lower the intensity of the colour generated or optical density from 
the experiment. 
2.7.3.4. Plasma intact PTH assay test principle 
Two affinity purified goat polyclonal antibodies present in the streptavidin-coated 
microtiter well detect full-length or intact PTH. One of the antibodies, which 
captures the antigen (PTH) is biotinylated and it recognises epitopes within the 
C-terminal portion of the peptide, while the other antibody recognises the N-
terminal epitope, and it is conjugated with the enzyme HRP for detection. Intact 
PTH in the sample binds to both antibodies to form a sandwich-like complex. Like 
other sandwich ELISA described above, the concentration of PTH in the samples 
is directly proportional to the absorbance of the chromogenic product of the HRP-
catalysed reaction. 
2.8. Statistical analysis 
Data are presented as mean ± SEM. Where possible, statistical analysis was 
performed using unpaired Student’s t-test, one-way ANOVA with Tukey’s post-
test or a two-way ANOVA with Bonferroni’s post-test to determine any statistical 
differences between groups. All analyses were performed using GraphPad Prism 
5.0 software, and statistical significance were depicted as follows: *P < 0.05, **P 
< 0.01 or ***P < 0.001. 
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Chapter Three 
3.0. Comparison of the mechanisms of intestinal phosphate absorption in 
mice, rats and humans 
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3.1. Introduction 
The quest for a safe and reliable management therapy for hyperphosphataemia 
in CKD patients is ongoing. Phosphate absorption in the small intestine is known 
to be the major target for controlling serum phosphate levels in patients with end-
stage renal disease (ESRD), and rodents are widely used as experimental 
models for the study of potential therapies for the control of intestinal phosphate 
absorption. As described in section 1.4, it is recognised that there are species 
differences in the major small intestinal segments responsible for phosphate 
absorption in rodents, and there is an ongoing debate concerning the relative 
contribution of the Na+-dependent and Na+-independent phosphate transport 
pathways. Using a physiological phosphate concentration, a previous report 
demonstrated that total transepithelial phosphate absorption in vivo was solely 
mediated by the Na+-independent pathway in the rat duodenum, while only 70% 
of jejunal phosphate transport was mediated by this pathway, with the remaining 
30% mediated by the Na+-dependent pathway 45. Interestingly, even though the 
Na+-independent pathway for phosphate absorption appears to be the 
predominant pathway under physiological conditions in rats, the administration of 
a novel NaPi-IIb inhibitor, ASP 3325, was shown to be beneficial in reducing 
plasma phosphate levels in normal rats and those with ESRD 76. In contrast, 
clinical studies in humans demonstrated that this inhibitor was ineffective in the 
treatment of hyperphosphataemia in ESRD patients 318. Whether these 
contradictory observations are as a result of differences in experimental 
conditions or highlight that NaPi-IIb plays no role in intestinal phosphate 
absorption in humans remains to be confirmed. 
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Emerging evidence suggests that NHE3 significantly contributes to small 
intestinal phosphate absorption. This is attributed to the findings that the 
administration of tenapanor, a competitive inhibitor of NHE3, significantly reduced 
intestinal phosphate absorption and serum phosphate levels in rats and humans 
with CKD, but plays an insignificant role in mice 77,247. It is therefore becoming 
apparent that the differences in intestinal phosphate transport mechanisms in 
various species may explain the discrepancies in the efficacy of both NaPi-IIb 
and NHE3 inhibitors on phosphate absorption in rats, mice and humans. 
Importantly, even though there is evidence suggesting that the proximal small 
intestine is the major segment for phosphate absorption in rats and humans 319, 
there is still a lack of information on the pattern of expression of the transcellular 
phosphate transporters, NaPi-IIb and PiT-1, and the mediator of paracellular 
phosphate absorption, NHE3, in humans. The aim of this chapter was to first 
compare the expression levels of NaPi-IIb, PiT-1 and NHE3 in the different 
segments of the small intestine of rat, mice and humans, and secondly, to confirm 
the contribution of NaPi-IIb, NHE3 and the Na+-independent pathway to overall 
phosphate absorption in rats and mice using physiological phosphate 
concentrations.  
3.2. Methods 
3.2.1. Animals and intestinal tissue collection 
Male Sprague Dawley rats and C57BL/6J mice, aged 6-8 weeks and intestinal 
specific NaPi-IIb knock-out and wild-type mice, aged 8-12 weeks, were used for 
this study. Animals were fed with RM1 diet, which contains 0.52% phosphate as 
described in section 2.1. For tissue collection, animals were anaesthetised by 
intraperitoneal injection with pentobarbitone sodium (40-50 mg/kg body weight, 
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Pentoject; Animalcare Ltd, York, UK) and mucosa scrapes were obtained from 
defined regions of the small intestine as described in section 2.2. The mucosa 
scrapes from the mouse duodenum and jejunum were pooled together to ensure 
that the tissues were enough for RNA and protein preparations, and were referred 
to as the proximal small intestine, while the ileum was taken as the distal small 
intestine. After tissue collection, cervical dislocation in mice and exsanguination 
(by cutting the heart) in rats were carried out to ensure animals were dead. The 
tissues were snap frozen in liquid nitrogen and stored at -80 °C until required. 
3.2.2. Human tissue collection 
As described in section 2.2, human intestinal tissue biopsies were obtained from 
healthy adult volunteers apparently consuming a normal phosphate diet. Tissue 
biopsies were collected from the duodenum (20 cm distal to the pylorus), jejunum 
(50 cm distal to the ligament of Treitz) and the ileum (50 cm proximal to the 
ileocecal junction). Tissues were snap frozen in liquid nitrogen and stored at -80 
°C until required. 
3.2.3. RT-PCR  
As described in section 2.3.1, RNA was extracted from thawed human tissue 
biopsies and the mucosa scrapes collected from rats and mice, using the Trizol 
method. cDNA was synthesised from 1 µg of RNA by reverse transcription 
reaction as described in section 2.3.2 and RT-PCR experiments were carried out 
as described in section 2.3.3 to test the levels of NaPi-IIb, PiT-1 and NHE3, using 
rat, mouse and human specific primers (Table 2.1). 
3.2.4. Western blot  
BBM proteins were prepared from thawed intestinal mucosa scrapes obtained 
from rats and mice using the MgCl2 precipitation method as described in section 
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2.4.1. Intestinal BBM protein (20-50 µg) were used for Western blotting to 
establish the protein levels of NaPi-IIb, PiT-1 and NHE3 as described in section 
2.4.3, using specific primary antibodies (Table 2.2) and their corresponding 
secondary antibodies. The ratio of NaPi-IIb, PiT-1 and NHE3 to β-actin was 
expressed as a.u.  
3.2.5. In vivo uptake 
In vivo phosphate uptake experiments were carried out in the jejunum and ileum 
of mice, using 8-10 mM phosphate solution in the uptake buffer as described in 
section 2.5. To test the relative contribution of the jejunum and ileum to overall 
phosphate absorption, the amount of phosphate transferred into blood after 10 
minutes per 5 cm of the cannulated jejunum or ileum was determined. In addition, 
the relative contribution of NaPi-IIb and NHE3 to phosphate absorption was 
investigated using a potent NaPi-IIb inhibitor, NTX9066, and an NHE3 inhibitor, 
tenapanor 77, both obtained from Ardelyx Inc. (Fremont, CA, USA). 
3.2.6. In vitro uptake  
In vitro phosphate uptake experiments were carried out using rat duodenal and 
jejunal segments to test the contribution of NaPi-IIb, NHE3 and Na+-independent 
mechanism to phosphate absorption in these intestinal segments as described in 
section 2.6. To test the contribution of NaPi-IIb to phosphate absorption, 10 mM 
PFA, a competitive inhibitor of NaPi-IIb was added to the uptake buffer. To 
investigate the contribution of NHE3, 10 µM tenapanor was added to the uptake 
buffer, while uptake buffer prepared using Na+ free HEPES and choline chloride, 
an iso-osmotic replacement for Na+, was used to test the contribution of the Na+-
independent pathway to phosphate absorption in these segments. The uptake 
buffer in all experiments contained physiological concentration of luminal 
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phosphate, 10 mM. The amount of phosphate transferred from the uptake buffer 
into the intestinal tissue (phosphate uptake) was expressed in nmoles/100mg of 
the intestinal segment. Phosphate uptake in the presence of PFA or tenapanor 
or the Na+-free uptake solution was expressed as a percentage of the total 
phosphate uptake using a normal physiological luminal solution containing Na+. 
3.2.7. Statistical analysis 
Data are presented as mean ± SEM using bar graphs. Statistical analysis was 
carried out as described in section 2.8, and statistical significance was depicted 
as follows: *P<0.05, **P<0.01 or ***P<0.001. 
3.3. Results 
3.3.1. Regional expression of the transcellular phosphate transporters in 
the small intestine of mice, rats and humans 
As previously described 38,39, in the mouse small intestine, NaP-IIb mRNA levels 
were significantly higher in the distal small intestine compared to the proximal 
small intestine (Figure 3.1A). In contrast, although NaPi-IIb mRNA has been 
reported in rat duodenum 39, its levels were very low compared to the jejunum, 
which is the segment that showed the highest expression of NaPi-IIb mRNA 
(Figure 3.1B). In contrast to rat and mouse NaPi-IIb profile, human NaPi-IIb 
mRNA was highest in the duodenum, followed by the jejunum, with very low 
levels in the ileum (Figure 3.1C).  
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Figure 3.1. RT-PCR quantification of NaPi-IIb in distinct regions of mouse, rat and 
human small intestine. Duplicate PCR reactions were performed for each sample and 
the mRNA expression of NaPi-IIb is given as the ratio of NaPi-IIb to β-actin. An unpaired 
t-test (A) and a one-way ANOVA with Tukey’s multiple comparisons post-tests (B and C) 
were used to compare results between groups (n=5-9). **P<0.01, ***P<0.001 
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Interestingly, intestinal PiT-1 mRNA also showed some variations in the regional 
expression profile between species. In mice, PiT-1 mRNA was significantly higher 
in the proximal small intestine compared to the distal small intestine (Figure 3.2A). 
However, in rats, PiT-1 mRNA was significantly higher in the jejunum compared 
to the duodenum (Figure 3.2B). Although PiT-1 mRNA expression was similar in 
the duodenum, jejunum and ileum of humans (Figure 3.2C), its contribution to 
phosphate absorption in this species is unclear. 
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Figure 3.2. RT-PCR quantification of PiT-1 in distinct regions of mouse, rat and 
human small intestine. Duplicate PCR reactions were performed for each sample and 
the mRNA expression of PiT-1 is given as the ratio of PiT-1 to β-actin. An unpaired t-test 
(A) and a one-way ANOVA with Tukey’s multiple comparisons post-tests (B and C) were 
used to compare results between groups (n=5-10). *P<0.05. 
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The detection of NaPi-IIb in the rat small intestine using a commercially available 
antibody against this protein has been a major challenge in phosphate research 
for many years. However, I have validated a commercially available antibody 
against NaPi-IIb (Source Bioscience, Cat. No.: LS-C37453) by carrying out 
Western blotting experiment using intestinal BBM protein prepared from NaPi-IIb 
knock-out and wild-type mice, and have used this antibody for the detection of 
NaPi-IIb protein in the current study. The presence of very weak bands in NaPi-
IIb knock-out mice at the predicted size for this protein, 100-105 kD (Figure 3.3), 
confirms that this antibody is specific for NaPi-IIb.  
 
Figure 3.3. Validation of NaPi-IIb antibody. Western blot image showing the protein 
levels of NaPi-IIb in wild-type and NaPi-IIb knock-out mice (n=2). 
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As previously reported 17,38,39 and like NaPi-IIb mRNA profile, its protein levels 
were significantly higher in the mouse distal small intestine compared to the 
proximal small intestine (Figure 3.4A), while rat NaPi-IIb protein was significantly 
higher in the jejunum compared to very low levels detected in the duodenum 
(Figure 3.4B). Since NaPi-IIb protein has been reported to be undetectable in the 
ileum of rats 17, its levels in this segment of rats were not investigated in this 
study. Moreover, it is interesting to note that NaPi-IIb protein was highly detected 
in the mouse small intestine and its levels were generally higher and more 
consistent in the mouse (detected in 20 µg BBM protein) compared to what was 
seen in the rat small intestine (detected only in 50 µg BBM protein) (Figure 3.4A 
and B). 
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Figure 3.4. Western blot analysis of NaPi-IIb protein in distinct regions of mouse 
and rat small intestine. Representative Western blot image and quantification of NaPi-
IIb protein relative to β-actin in the small intestine. The abundance of NaPi-IIb protein is 
given as the ratio of NaPi-IIb to β-actin, expressed in arbitrary units (a.u). An unpaired t-
test was used to compare results between groups (n= 4-6). *P<0.05, ***P<0.001. 
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The regional profile for PiT-1 protein in the mouse small intestine appears to be 
different from its mRNA levels. Unlike the mRNA profile, PiT-1 protein was similar 
in both proximal and distal small intestinal segments of mice (Figure 3.5A). In 
contrast, rat PiT-1 protein was significantly higher in the jejunum compared to the 
duodenum (Figure 3.5B), which is in agreement with the findings of Giral and 
colleagues 17. PiT-1 protein has been reported to be undetectable in the ileum of 
rats 17,146, thus, this protein was not investigated in the rat ileum in this study. 
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Figure 3.5. Western blot analysis of PiT-1 protein in distinct regions of mouse and 
rat small intestine. Representative Western blot image and quantification of PiT-1 
protein relative to β-actin in the small intestine. The abundance of PiT-1 protein is given 
as the ratio of PiT-1 to β-actin, expressed in arbitrary units (a.u). An unpaired t-test was 
used to compare results between groups (n=3-5). *P<0.05. 
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3.3.2. Regional expression of NHE3 in the small intestine of mice, rats and 
humans 
To gain more insight into the potential role of the recently reported NHE3-
regulated paracellular phosphate absorption in the small intestinal of mice, rats 
and humans 77, the mRNA levels of NHE3 were mapped using RT-PCR and its 
protein levels were tested using Western blotting. In mice, compared to the distal 
small intestine, NHE3 mRNA and protein levels were significantly higher in the 
proximal small intestine (Figure 3.6A and 3.7A), a segment known to contribute 
only a small proportion to intestinal phosphate absorption in this species. 
Although not statistically significant, the mRNA expression of NHE3 in the rat and 
human small intestine showed a similar trend, with the highest levels observed in 
the jejunum (Figure 3.6B and C), the major segment suggested to be responsible 
for intestinal phosphate absorption in these species. This suggests that the rat is 
a better animal model for studying the NHE3-regulated paracellular mechanism 
of phosphate absorption in the human small intestine. Surprisingly, in contrast to 
the RT-PCR data, NHE3 protein levels were significantly higher in the duodenum 
compared to the jejunum of rats (Figure 3.7B). Consistent with NHE3 protein 
profile in mice, this finding indicates that NHE3 protein is higher in the proximal 
segments compared to the distal segments of the small intestine of rodents. 
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Figure 3.6. RT-PCR quantification of NHE3 in distinct regions of mouse, rat and 
human small intestine. Duplicate PCR reactions were performed for each sample and 
the mRNA expression of NHE3 is given as the ratio of NHE3 to β-actin. An unpaired t-
test (A) and a one-way ANOVA with Tukey’s multiple comparisons post-tests (B and C) 
were used to compare results between groups (n=5-10).  **P<0.01.  
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Figure 3.7. Western blot analysis of NHE3 protein in distinct regions of mouse and 
rat small intestine. Representative Western blot image and quantification of NHE3 
protein relative to β-actin in the small intestine. The abundance of NHE3 protein is given 
as the ratio of NHE3 to β-actin, expressed in arbitrary units (a.u). An unpaired t-test was 
used to compare results between groups (n= 5-6). *P<0.05, ***P<0.001. 
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3.3.3. Mechanism of phosphate absorption in the mouse small intestine 
The ileum is known to be the major segment responsible for the absorption of 
phosphate in the mouse small intestine. To confirm the previously suggested 
relative contribution of the jejunum and ileum to intestinal phosphate absorption 
in mice, in vivo intestinal loop experiments were carried out in these segments, 
and the total transepithelial phosphate absorption in each segment was 
determined. The result showed that total transepithelial phosphate absorption 
was significantly higher in the ileum (Figure 3.8), which is the segment with the 
highest levels of NaPi-IIb, compared to the jejunum. This confirms the widely 
accepted dogma that the ileum is the major segment for phosphate absorption in 
mouse small intestine. 
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Figure 3.8. Total transepithelial phosphate absorption in distinct regions of the 
mouse small intestine. Values presented are the amount of phosphate transferred by 
5 cm of the small intestine into 1 ml of blood after 10 minutes of phosphate instillation 
into the intestine, using a normal buffer containing Na+. An unpaired t-test was used to 
compare results between the jejunum and ileum (n=6). *** P<0.001. 
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To test the contribution of mouse NaPi-IIb to total transepithelial phosphate 
absorption under normal intestinal phosphate condition, uptake buffer containing 
a physiological phosphate concentration of 10 mM, and increasing 
concentrations of a potent NaPi-IIb inhibitor, NTX9066, were used for in vivo 
uptake experiments. The result showed a concentration-dependent inhibition of 
transepithelial phosphate absorption in the mouse ileum in the presence of 
NTX9066, with approximately 88% inhibition observed at 100 µM (Figure 3.9). 
The inhibition of total transepithelial phosphate absorption by 100 µM of NTX9066 
was approximately the same as what was observed in NaPi-IIb knock-out mice 
77, suggesting that NaPi-IIb is the major phosphate transporter in the mouse small 
intestine under normal intestinal phosphate concentration. 
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Figure 3.9. Effect of NaPi-IIb inhibitor, NTX9066, on phosphate transport in the 
mouse ileum measured in vivo. Values presented are the amount of phosphate 
transferred by 5 cm of the small intestine into 1 ml of blood after 10 minutes of phosphate 
instillation into the intestine, using a normal buffer containing Na+ (control) and buffer 
containing Na+ + 10 or 100 µM of NTX9066. A one-way ANOVA with Tukey’s multiple 
comparisons post-tests was used to compare results between groups (n=5-10). *** 
P<0.001 compared to the control group and ##P<0.01 compared to NTX9066, 10 µM 
group. 
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Tenapanor, a potent NHE3 inhibitor, was also used to test whether there is any 
role for NHE3-regulated paracellular phosphate transport pathway in the jejunum 
and ileum of mice. Total transepithelial phosphate absorption in the mouse small 
intestine was investigated using buffers containing 8 mM phosphate, with or 
without 10 µM tenapanor. The results showed similar transepithelial phosphate 
absorption between normal (control) buffer and buffer containing tenapanor in 
both the jejunum and ileum (Figure 3.10A and B). This suggests that there is no 
significant role for the NHE3-dependent paracellular phosphate transport 
pathway in the mouse small intestine. 
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Figure 3.10. Effect of the NHE3 inhibitor, tenapanor, on phosphate transport in the 
mouse small intestine measured in vivo. Values presented are the amount of 
phosphate transferred by 5 cm of the intestinal segment into 1 ml of blood after 10 
minutes of phosphate instillation into the intestine, using a normal buffer containing Na+ 
(control) and buffer containing Na+ + 10 µM tenapanor. An unpaired t-test was used to 
compare results between groups (n=3-9).   
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3.3.4. Mechanism of phosphate absorption in the rat duodenum and 
jejunum 
To evaluate the relative contribution of the rat duodenum and jejunum to intestinal 
phosphate absorption, the capacity of phosphate absorption via these segments 
was assessed using the in vitro everted sleeve technique. The result showed that 
the jejunum has a significantly higher capacity to absorb phosphate compared to 
the duodenum (Figure 3.11A). Additionally, to compare the mechanisms of 
phosphate absorption in the duodenum and jejunum of rats, the contribution of 
the Na+-dependent and Na+-independent phosphate transport pathways in these 
segments were investigated using a physiological uptake buffer containing 10 
mM phosphate, in the presence or absence of Na+. As previously reported 45, 
phosphate absorption via the Na+-dependent pathway was higher in the jejunum, 
which is the intestinal segment with the highest levels of NaPi-IIb in the rat, 
compared to the duodenum (Figure 3.11B). In contrast, phosphate absorption via 
the Na+-independent pathway was higher in the duodenum compared to the 
jejunum (Figure 3.11C). It is worth noting that the Na+-independent mechanism 
mediated approximately 75% of duodenal phosphate transport (Figure 3.11C). 
These findings confirm that in the rat proximal small intestine, the jejunum is the 
major segment responsible for Na+-dependent phosphate absorption, while 
phosphate transport in the duodenum predominantly occurs via the Na+-
independent pathway.  
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Figure 3.11. Phosphate transport measured in vitro: a comparison between the 
duodenum and jejunum of rats. Total phosphate uptake is presented in nmoles 
transferred into 100 mg of intestinal tissue in 2 minutes (A). The proportion of Na+-
dependent phosphate uptake (B) and Na+-independent phosphate uptake (C) are 
presented as a percentage of the total phosphate uptake using normal uptake buffer 
containing Na+. The Na+-dependent phosphate uptake was determined by subtracting 
the Na+-independent phosphate uptake from the total phosphate uptake, while the Na+-
independent uptake was obtained from experiments carried out using a buffer in which 
Na+ has been replaced by iso-osmotic choline chloride. An unpaired t-test was used to 
compare results between groups (n=5-6). *P<0.05, ***P<0.001. 
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3.3.5. Role of NaPi-IIb and NHE3 as components of the Na+-dependent 
pathway of intestinal phosphate absorption in rats 
Using the in vitro everted sleeve technique, the proportion of the Na+-dependent 
phosphate transport pathway that is mediated by NaPi-IIb and NHE3 in the 
duodenum and jejunum of the rat was investigated. PFA, a well-known 
competitive inhibitor of NaPi-IIb and tenapanor were used to test the contribution 
of these transporters to phosphate absorption in the duodenum and jejunum of 
normal rats. In the duodenum, phosphate uptake was unaffected by PFA or 
tenapanor, suggesting that the PFA-sensitive NaPi-IIb and tenapanor-sensitive 
NHE3 have no significant contribution to the Na+-dependent component of 
phosphate absorption (approximately 25%) in this segment. In contrast, there 
was a significant contribution of NHE3, approximately 25%, to phosphate 
absorption in the jejunum (Figure 3.12B), with the PFA-sensitive NaPi-IIb 
pathway having a smaller contribution, approximately 13% (Figure 3.12B). In 
addition, the sum of the PFA-sensitive NaPi-IIb-mediated pathway and 
tenapanor-sensitive NHE3-regulated paracellular pathway in the jejunum was 
almost equal to the proportion of phosphate uptake via the Na+-dependent 
pathway, approximately 40% (Figure 3.11B and 3.12B). Interestingly, phosphate 
uptake in the presence of tenapanor was not significantly different from uptake 
via the Na+-independent pathway in the jejunum (Figure 3.12B), suggesting that 
NHE3-regulated paracellular phosphate transport may be the major Na+-
dependent phosphate absorption pathway that is detectable in the jejunum. 
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Figure 3.12. The contribution of the Na+-independent, NaPi-IIb and NHE3-
dependent mechanisms of phosphate transport in the rat proximal small intestine 
measured in vitro. Values presented are a percentage of the total phosphate transport 
in the presence of Na+ (control) using duodenal tissue (A) and jejunal tissue (B). Na+-
independent uptake (-Na+) was determined using a buffer in which Na+ has been 
replaced with iso-osmotic choline chloride; NaPi-IIb dependent uptake was determined 
using a buffer containing Na+ + 10 mM PFA, and NHE3 dependent uptake was 
determined using a buffer containing Na+ + 10 µM tenapanor. A one-way ANOVA with 
Tukey’s multiple comparisons post-tests were used to compare results between groups 
(n=6-26). **P<0.01, ***P<0.001 compared to the control group and ##P<0.01 compared 
to -Na group.  
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3.4. Discussion 
3.4.1. Comparison of the mechanism of intestinal phosphate absorption in 
mice, rats and humans 
Previous functional studies investigating the regional profile of phosphate 
absorption in the human small intestine 46,320 and findings from the comparison 
of the regional profile of NaPi-IIb have led to the assumption that the rat is a more 
appropriate animal model than the mouse to study new compounds for targeting 
intestinal phosphate absorption in CKD patients 39. However, recent clinical data 
in humans concerning the negative outcome of a novel NaPi-IIb inhibitor 318, 
which has been demonstrated to be effective in reducing intestinal phosphate 
absorption in rats 76 questions this assumption. Based on this finding, it is likely 
that the rat is not a good model to study NaPi-IIb-mediated phosphate absorption 
in humans. In addition, an inhibitor of NHE3, tenapanor, has recently been 
reported to be effective in reducing intestinal phosphate absorption in the small 
intestine of rats and humans, but not in mice 77,247. Thus, the mechanisms of 
intestinal phosphate absorption in different species seem to be more complex 
than previously thought. 
There is limited information on the segmental profile of the transcellular 
phosphate transporters and NHE3 in the human small intestine, therefore, one of 
the aims of the current study was to compare the regional profile of these 
transporters in rats, mice and humans. In addition, the contribution of NaPi-IIb- 
and NHE3-dependent phosphate transport mechanisms in the small intestine of 
rodents was investigated. The results showed that unlike in rats and mice, NaPi-
IIb mRNA was highest in the human duodenum, while the segmental profile of 
NHE3 in the human small intestine mirrored that of rats. Based on the similar 
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profile of NHE3 mRNA in the small intestine of rat and humans, the rat appears 
to be a more appropriate model than the mouse to study the NHE3-regulated 
paracellular mechanism of phosphate absorption in humans. A limitation of this 
study is that there was a lack of human tissue biopsies for BBM protein 
preparation in order to investigate the protein levels of the transcellular phosphate 
transporters and the NHE3 using Western blotting. However, I attempted to 
investigate this using immunohistochemistry on paraffin-embedded human 
intestinal tissues, but the studies were unsuccessful because the antibodies were 
unable to detect NaPi-IIb, PiT-1 or NHE3 in the human tissues. Nevertheless, the 
profile of NaPi-IIb mRNA is consistent with previous findings that the human 
duodenum exhibits the highest levels of NaPi-IIb mRNA transcripts 253. 
Compared with the other small intestinal segments, the duodenum is known to 
have a shorter length, and therefore, the sojourn time of chyme in this region is 
short. For example, the duodenum of adult rat is approximately 8 cm in length, 
with a transit time of chyme along this segment of 3 minutes 243. In comparison, 
the jejunum is approximately 36 cm in length, with a transit time of 43 minutes, 
while the ileum is also approximately 36 cm in length, with a transit time of 141 
minutes 243. Therefore, the short length and transit time of chyme in the 
duodenum, where NaPi-IIb is most highly expressed, may be responsible for the 
recently reported lack of therapeutic effect of NaPi-IIb inhibitors for the treatment 
of hyperphosphataemia in humans 318. Based on these findings, the importance 
of duodenal NaPi-IIb in phosphate absorption in humans remains uncertain.  
3.4.2. Mechanism of phosphate absorption in the mouse small intestine 
In this study, the regional profile of mouse intestinal NaPi-IIb and NHE3 was 
investigated and the contribution of these proteins to phosphate absorption 
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examined. Consistent with previous studies 31,39, the evidence from the current 
study showed a positive relationship between NaPi-IIb levels and the capacity of 
phosphate absorption in specific intestinal segments. In this regard, low mRNA 
and protein levels of NaPi-IIb in the proximal segments of the mouse small 
intestine were associated with a low capacity of phosphate absorption in these 
segments, while high NaPi-IIb levels were associated with a high capacity of 
phosphate absorption in the mouse ileum. In contrast, high levels of NHE3 were 
detected in the proximal small intestine, a segment associated with relatively 
lower phosphate absorption compared to the distal small intestine. While these 
findings suggest a role for NaPi-IIb in intestinal phosphate absorption in mice, it 
looks as though NHE3 may not be playing any role. Previous studies investigating 
the role of NaPi-IIb in intestinal phosphate absorption in mice have carried out 
uptake experiments in vitro, using BBM proteins or everted gut sacs, and have 
employed uptake buffers with low phosphate concentrations (≤ 1.2 mM), a 
condition that favours NaPi-IIb transport 31,222. Even though these studies 
demonstrated that NaPi-IIb accounts for approximately 90-95% of Na+-
dependent phosphate transport across the BBM of the mouse ileum 31,222, it has 
been speculated that NaPi-IIb is only important in mice maintained on a low 
phosphate diet (≤ 0.1% phosphate) 145,319,321. These authors hypothesised that at 
physiological phosphate concentration, NaPi-IIb would have a minor contribution 
to transepithelial phosphate absorption and that paracellular phosphate transport 
would predominate. Based on the findings that the physiological concentration of 
phosphate in the gastrointestinal tract of mice fed a normal phosphate diet is at 
least 4 mM and may be as high as 35 mM 251,319, 8-10 mM of phosphate was 
used in the current study. Using a physiological technique that measures 
transepithelial phosphate absorption in vivo, the result of this study showed that 
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NaPi-IIb contributes approximately 90% of total transepithelial phosphate 
absorption in the ileum of mice maintained on a normal diet. Interestingly, the 
NaPi-IIb inhibitor, NTX9066 caused a dose-dependent inhibition of transepithelial 
phosphate absorption in the ileum, and at 100 µM, the inhibition of phosphate 
absorption by this inhibitor was the same as what was recently reported in NaPi-
IIb knock-out mice 77. Additionally, recent findings from uptake experiments using 
tenapanor in NaPi-IIb knock-out mice 77 and the finding of this study, 
demonstrated that the inhibition of NHE3 had no effect on transepithelial 
phosphate absorption in the jejunum and ileum of mice. This suggests that under 
physiological phosphate concentration, NHE3-regulated paracellular phosphate 
transport has little or no contribution to intestinal phosphate absorption in mice. 
Taken together, these findings support the claim that NaPi-IIb is the major 
phosphate transporter responsible for transepithelial phosphate absorption in the 
mouse small intestine under normal dietary phosphate condition.  
Contrary to this hypothesis is the study by Sabbagh et al in NaPi-IIb knock-out 
mice 31, suggesting that NaPi-IIb only accounts for 50% of total transepithelial 
phosphate absorption in vivo. It is worth noting that the authors gavaged a 
solution containing superphysiological phosphate concentration (500 mM) and 
measured serum phosphate levels at 30 minutes and 60 minutes following 
phosphate gavage. The discrepancy between the findings of Sabbagh et al 31 and 
the findings of the current study may be because of the differences between the 
phosphate concentration in the uptake buffers and techniques employed in these 
studies. In contrast to the 10 mM of phosphate used in the current study, a 
phosphate load of 500 Mm used by Sabbagh et al 31 will generate a tremendous 
concentration gradient and may be sufficient to completely saturate the high 
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levels of NaPi-IIb in the mouse small intestine. Therefore, this would favour 
paracellular phosphate diffusion that may not be attainable under a physiological 
condition. Alternatively, using the above experimental set up of Sabbagh et al 31, 
there is no evidence that the changes in serum phosphate in both NaPi-IIb knock-
out and wild-type mice were solely due to intestinal phosphate absorption. 
Phosphate exchange between serum and bone minerals may have contributed 
to the levels of phosphate detected in the serum of NaPi-IIb knock-out mice 
gavaged 500 mM of phosphate. To rule out the contribution of bone phosphate, 
this experiment could be repeated using radioactive phosphorus (32P or 33P) to 
accurately measure the amount of phosphate absorbed across the intestinal 
epithelium. Using this method, the potential contribution of bone phosphate in the 
current study was ruled out as 33P transferred from the uptake buffer into the 
circulation is taken as a direct measure of only the phosphate absorbed by the 
small intestine.  
Other studies speculating that intestinal NaPi-IIb plays a minor role under normal 
or high dietary phosphate condition have employed the investigation of faecal 
phosphate levels 31,145,222,251, an approach that is crude and only measures 
apparent phosphate absorption. These studies showed that NaPi-IIb knock-out 
mice maintained on either a normal or high phosphate diet exhibited only a 
moderate increase or no significant increase in faecal phosphate excretion 
compared to wild-type mice 31,222,251. However, the importance of NaPi-IIb was 
demonstrated by the observation that there was approximately 45% increase in 
faecal phosphate excretion when NaPi-IIb knock-out mice were chronically fed a 
phosphate-deficient diet 145. Although these findings suggest that NaPi-IIb plays 
a lesser role in intestinal phosphate absorption under normal or high dietary 
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phosphate conditions, the potential contribution of secreted phosphate, for 
example, salivary and intestinal phosphate secretion 322–326, to faecal phosphate 
levels were not considered. Early studies investigating phosphate absorption in 
the small and large intestines revealed that faecal phosphate levels represent the 
summation of both absorption and secretion of phosphate 326. Approximately 7 
mmol of phosphate is secreted into the gastrointestinal tract per day, and some 
of this phosphate is reabsorbed in addition to the absorption of dietary phosphate 
327. Based on these reports, the contribution of NaPi-IIb cannot be ascertained 
from the fact that faecal phosphate excretion was unchanged or showed only a 
moderate increase in NaPi-IIb knock-out mice maintained on a normal or a high 
phosphate diet. The in situ intestinal loop technique and buffers containing 8-10 
mM of phosphate used by King et al 77 and in the current study, remain the most 
direct physiological approach to investigate the transport mechanisms underlying 
transepithelial phosphate absorption in the small intestine. Therefore, based on 
the evidence of this study and the findings of King et al. in NaPi-IIb knock-out 
mice 77, NaPi-IIb is the major transporter responsible for intestinal phosphate 
absorption in mice. Interestingly, the importance of mouse NaPi-IIb in intestinal 
phosphate absorption is confirmed by the fact that renal phosphate excretion is 
significantly adjusted to maintain serum phosphate levels in NaPi-IIb knock-out 
mice maintained on a normal phosphate diet 31,251,328. 
3.4.3. Mechanism of phosphate absorption in the rat small intestine 
In rats, the high levels of jejunal NaPi-IIb mRNA and protein are consistent with 
the widely accepted dogma that the jejunum is the major segment responsible for 
NaPi-IIb-mediated Na+-dependent transcellular phosphate transport. Conversely, 
even though low levels of duodenal NaPi-IIb mRNA and protein were observed 
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in the current study, a considerable amount of phosphate absorption was 
observed in this segment. These findings suggest the presence of multiple 
phosphate transport pathways in the rat proximal small intestine. Moreover, in the 
rat ileum, even though NaPi-IIb and PiT-1 protein have not been detected 17, a 
significant contribution of the Na+-dependent  phosphate transport mechanism to 
total transepithelial transport has been reported in this segment 45. Whether an 
unknown Na+-dependent transporter is responsible for this phosphate transport 
mechanism or there is a Na+-dependent passive phosphate transport pathway in 
the ileum as speculated by McHardy and Parsons 240, remains to be confirmed.  
3.4.3.1. Duodenum 
In the rat duodenum, the fact that very low levels of NaPi-IIb were detected, and 
the lack of effect of PFA on phosphate uptake in vitro, suggest that there is no 
NaPi-IIb-mediated transcellular phosphate transport pathway in this segment. In 
agreement with this, duodenal phosphate uptake using a physiological phosphate 
concentration of 10 mM in vivo has been shown to have no Na+-dependent 
component 45, suggesting no role for NaPi-IIb in duodenal phosphate absorption 
in the rat. To support the finding that NaPi-IIb has no significant role in the 
duodenum, previous findings in rats treated with 1,25(OH)2D3, a major regulator 
of NaPi-IIb function, have shown that this hormone has no effect on duodenal 
phosphate absorption 39,329. However, contrary to the findings that NaPi-IIb plays 
no role in duodenal phosphate absorption is the in vitro data by Giral et al., which 
demonstrated that the duodenum exhibited the highest Na+-dependent 
phosphate transport activity compared to other segments of the small intestine 
17. They showed that increased phosphate uptake in duodenal BBM vesicles of 
rats switched from a chronic low phosphate diet to an acute high phosphate diet 
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was associated with increased NaPi-IIb levels 17. Although these findings suggest 
a role for duodenal NaPi-IIb, it is important to note that these experiments were 
carried out using 0.1 mM phosphate in the uptake buffer, a concentration that 
favours active NaPi-IIb-mediated transport activity. Based on the kinetics of NaPi-
IIb, it is currently known that this transporter functions optimally at a Km of 0.05–
0.1 mM and that at higher phosphate concentrations its transport function does 
not increase accordingly 20,70. Importantly, the concentration of free phosphate in 
the rat intestine after a standard phosphate diet has been reported to be much 
higher than the Km of NaPi-IIb, ranging from approximately 6–12 mM 45. Evidence 
from the current study using a phosphate concentration within this range indicates 
that NaPi-IIb has no contribution to total transepithelial phosphate absorption in 
the duodenum.  
Although recent evidence indicated that the NHE3-regulated paracellular 
phosphate transport pathway significantly contributes to total transepithelial 
phosphate absorption in the jejunum of rats 77, there is no evidence suggesting 
the presence of this pathway in the rat duodenum. Therefore, the contribution of 
NHE3 in duodenal phosphate absorption was investigated in this study. Even 
though high levels of NHE3 protein was detected in the duodenum, the finding 
that tenapanor had no effect on duodenal phosphate transport indicates that this 
transporter plays no significant role in mediating phosphate absorption in this 
segment. The reason for this lack of effect of NHE3 inhibition on duodenal 
phosphate transport is not known. However, it is possible that NHE3 is already 
partially inhibited by the acidic environment of the duodenal enterocyte, and 
further inhibition by tenapanor may result in only a moderate change in phosphate 
transport in this segment as seen in this study. Surprisingly, based on the 
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evidence that NaPi-IIb and NHE3 have no significant contribution to duodenal 
phosphate transport, and because low levels of PiT-1 were detected in this 
segment, the contribution of the Na+-dependent phosphate transport pathway 
observed in vitro (approximately 25%), cannot be completely explained by these 
transporters. Thus, further studies are required to identify the transporter(s) 
responsible for the Na+-dependent component of phosphate absorption in the 
duodenum of rats. 
The finding from this study that the Na+-independent mechanism of phosphate 
transport is the predominant pathway for phosphate absorption in the duodenum 
is in agreement with previous data 45,246. Interestingly, the previously reported 
increase in phosphate uptake in vitro in the duodenum of rats switched from a 
chronically low phosphate diet to an acutely high phosphate diet was preserved 
when the experiment was conducted using a Na+-free buffer 246. This indicates 
that rather than duodenal NaPi-IIb that was suggested by Giral et al. 17, the Na+-
independent phosphate transport pathway appears to be responsible for this 
effect 246. Candeal and colleagues 246 showed a significantly higher Na+-
independent phosphate uptake in BBM vesicles prepared from the duodenum of 
rats acutely switched to a high phosphate diet for 4 hours compared to those 
maintained on a low phosphate diet 246. Therefore, it is possible that dietary 
phosphate levels, particularly high phosphate diet, regulate the Na+-independent 
phosphate transport pathway. In addition, studies in Caco-2 BBE cells have 
shown that the Na+-independent phosphate transport pathway is also regulated 
by pH, with reduced phosphate transport via this pathway observed at low pH 
and vice versa 246. In contrast, recent findings suggest that the Na+-dependent 
mechanism of phosphate absorption in the proximal small intestine increases 
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with decreasing pH 146. These differential effects of pH on the Na+-dependent and 
Na+-independent phosphate transport pathways could be explored to unravel the 
nature of the Na+-independent phosphate transport pathway. 
Reports from early studies on the mechanism of intestinal phosphate absorption 
in rodents and mammals (reviewed in 252) showed that the Na+-independent 
phosphate transport pathway is characterised by a non-saturable concentration-
dependent phosphate transport process. Although Candeal and colleagues 
observed a similar Na+-independent phosphate transport mechanism in Caco-2 
BBE cells 246, the identity of the transporters involved in this pathway was not 
determined and it is still unknown. Whether this Na+-independent mechanism 
involves an unknown passive transcellular phosphate carrier protein or is 
mediated via the paracellular pathway remains to be seen. Interestingly, cell 
culture studies have shown that the concentration-dependent increase in 
phosphate transport via the Na+-independent pathway requires gene 
transcription and synthesis of new proteins 246. The identity of these genes or 
proteins is yet to be reported. 
3.4.3.2. Jejunum 
In this study, unlike the duodenum where NaPi-IIb and NHE3 were demonstrated 
to have no significant contribution to phosphate absorption, these transporters 
were responsible for the Na+-dependent phosphate transport pathway observed 
in the jejunum, contributing approximately 40% of total phosphate absorption in 
this segment. Since the discovery of NaPi-IIb 40, most of the studies investigating 
phosphate absorption in the rat small intestine have focused on this protein, 
which mediates a saturable Na+-dependent phosphate transport mechanism 
45,126,245,320. Based on the relatively higher expression of jejunal NaPi-IIb 
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compared to other intestinal segments, this protein was later suggested to be the 
major transporter responsible for Na+-dependent phosphate absorption in the rat 
jejunum 17,39,144,248, with 1,25(OH)2D3 known to be a key regulator 39,48,126. 
Interestingly, evidence from the current study indicates that in the presence of a 
physiological phosphate concentration of 10 mM in the jejunum, NaPi-IIb only 
contributes approximately 13% to total phosphate absorption, with the bulk of the 
Na+-dependent phosphate transport occurring via the recently reported NHE3-
regulated paracellular pathway. Previous uptake studies in rats that have 
demonstrated evidence to support a key role for NaPi-IIb in jejunal phosphate 
absorption have carried out uptake experiments using uptake solution containing 
phosphate concentrations close to the Km of NaPi-IIb 17,255. However, a 
phosphate concentration of 10 mM, which would likely saturate the relatively low 
levels of rat NaPi-IIb compared to that of the mouse, was used in the current 
study, and at this concentration, NaPi-IIb was shown to play a minor role in 
mediating Na+-dependent phosphate transport in the rat jejunum. Nevertheless, 
in vivo studies in normal rats and those with CKD have shown that the inhibition 
of NaPi-IIb by nicotinamide or ASP3325 resulted in a significant inhibition of 
jejunal NaPi-IIb-mediated phosphate absorption and consequently reduced 
serum phosphate levels 76,248. The discrepancy between these studies 76,248 and 
the current study  in the contribution of NaPi-IIb to jejunal phosphate absorption 
in rats requires further clarification.  
It has recently been shown that NHE3-regulated paracellular phosphate transport 
significantly contributes to total transepithelial phosphate absorption in both rat 
and human small intestine and that the inhibition of this pathway significantly 
impacts systemic phosphate levels in uremic rats and CKD patients 77,247. In 
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agreement with the findings of King et al 77, the result of this study indicates that 
NHE3-regulated paracellular phosphate transport pathway is the major Na+-
dependent phosphate mechanism in the rat jejunum. Surprisingly, in comparison 
to the duodenum (where NHE3 protein was high, but no NHE3-regulated 
phosphate transport was observed), significantly lower levels of NHE3 protein 
were observed in the jejunum of rats, yet inhibition occurred. This expression 
profile could be because NHE3 protein is required in the duodenum to 
physiologically secrete H+ to protect the duodenal enterocytes from gastric acid 
and the potential intracellular H+ toxicity. The discrepancy in the relative inhibition 
of NHE3-regulated phosphate transport by tenapanor may be as a result of the 
fact that duodenal transepithelial electrical resistance (TEER) is significantly 
higher than that of the jejunum 77, thus inhibiting NHE3 may not be as effective in 
reducing paracellular phosphate absorption in the duodenum in comparison to 
the jejunum.  
Moreover, like the duodenum, the Na+-independent pathway appears to be the 
predominant pathway in the jejunum, accounting for approximately 60% of total 
phosphate absorption in vitro. This finding is consistent with previous in vivo data 
showing that at physiological phosphate concentration, the Na+-independent 
phosphate transport pathway contributes more than 60% of total transepithelial 
phosphate absorption 45. The Na+-independent phosphate transport pathway in 
the jejunum shares similar concentration-dependent passive transport features 
with the duodenum. Findings from early studies have ruled out the contribution of 
solvent drag as a mediator of this pathway since it appears to be unaffected by 
water movement in response to the movement of solutes with varying tonicities 
like mannitol, urea and glucose 240. Like the duodenum, the molecular candidate 
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responsible for the Na+-independent phosphate transport pathway is still unclear. 
However, it is currently speculated that this transport pathway involves the 
diffusion of phosphate through paracellular pores 45,145,319,330. Since claudins are 
known to be the major determinants of the permeability of the paracellular 
pathway to various electrolytes, these proteins may play significant roles in 
mediating Na+-independent phosphate transport in the duodenum and jejunum. 
It is also possible that an unknown transcellular Na+-independent phosphate 
transporter is responsible for this transport pathway 45,330. Further studies are 
required to clarify the transporters or tight junction proteins involved in mediating 
the Na+-independent transcellular or paracellular phosphate transport process in 
the jejunum. 
3.5. Conclusion 
There are significant variations in the regional expression profile of the 
transcellular phosphate transporters in the small intestine of mice, rats and 
humans. The finding that NaPi-IIb expression is highest in the human duodenum, 
a segment that is short and has a rapid transit time for chyme, may explain the 
lack of therapeutic efficacy of NaPi-IIb inhibitors in treating hyperphosphatemia 
in CKD patients. In contrast, the efficacy of tenapanor in inhibiting intestinal 
phosphate absorption in both rats and humans is consistent with the similar 
expression profile of NHE3 in these species. Using a physiological phosphate 
concentration of 10 mM, the results of this study suggest that while NaPi-IIb is 
the major phosphate transporter in mice, it plays little or no significant role in 
mediating phosphate absorption in the rat duodenum and jejunum. Interestingly, 
NHE3-regulated phosphate transport is likely responsible for the majority of the 
Na+-dependent component of phosphate absorption in the rat jejunum. The 
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findings of this study confirm that the Na+-independent component of phosphate 
absorption is the predominant pathway for phosphate absorption in the rat 
duodenum and jejunum under physiological phosphate concentration in the 
lumen. 
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Chapter Four 
4.0. Effect of diet-induced iron deficiency on phosphate homeostasis in 
rats 
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4.1. Introduction 
Systemic iron homeostasis is controlled by the peptide hormone hepcidin, which 
inhibits intestinal iron absorption in the duodenum via the downregulation of the 
basolateral iron transporter, ferroportin 331,332 and the BBM divalent metal 
transporter type 1 (DMT1) 333. Iron deficiency, characterised by low systemic iron 
levels and depleted iron stores, is known as the most common nutrient deficiency 
globally, affecting more than 25% of the world population 334–336. In addition to 
reports associating iron deficiency with decreased bone mineralisation and 
osteoporosis 337–341, increasing evidence suggests a link between iron deficiency 
and phosphate homeostasis (discussed in section 1.6). In normal individuals, iron 
deficiency has been shown to increase the transcription of the major phosphate 
regulator, FGF-23, in osteocytes, an observation that is in contrast to reduced 
FGF-23 transcription following intravenous iron administration 305. Moreover, iron 
deficiency anaemia and hyperphosphataemia are commonly seen in CKD 
patients, and the treatment of iron deficiency anaemia by iron supplementation in 
these patients has been shown to affect the levels of FGF-23 342.  
Furthermore, there is evidence that other regulators of phosphate homoeostasis, 
PTH and 1,25(OH)2D3, also interact with the regulator of iron balance 306,343,344. 
Notably, an interaction between 1,25(OH)2D3 and hepcidin has recently been 
reported 344,345. In patients with CKD, 1,25(OH)2D3 insufficiency is inversely 
associated with serum hepcidin concentrations 345 and in healthy individuals, high 
dose 1,25(OH)2D3 administration significantly decreases plasma hepcidin levels 
344. Therefore, in keeping with these novel interactions between hepcidin and the 
regulators of phosphate homeostasis, the aim of this chapter was to determine 
whether diet-induced iron deficiency affects the mechanisms of phosphate 
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homeostasis, with a particular focus on how intestinal and renal phosphate 
transport are impacted. Changes in serum levels of the recognised regulators of 
phosphate homeostasis were also investigated to test if diet-induced iron 
deficiency alters intestinal or renal phosphate transport via any of these 
regulators.  
4.2. Methods 
4.2.1. Animals and diet 
Male Sprague-Dawley rats, aged 6 – 8 weeks, were either fed a control iron diet 
(TD. 80394) containing 48 ppm of iron or an iron deficient group diet (TD. 80396) 
containing 2-6 ppm of iron for 2 weeks. Other than the iron content, both diets 
had the same composition and contained 0.6% phosphate. All diets were 
purchased from Harlan Laboratories, Inc. Madison, WI, USA. For urine collection, 
following the 2-week period of diet administration, animals were individually 
housed in metabolic cages overnight (16 hours).  
4.2.2. In vitro uptake experiments 
Rats were weighed and anaesthetized as described in section 2.5. In vitro 
phosphate uptake experiments were carried out using 2-4 cm long duodenal or 
jejunal segments as described in section 2.6. To determine the effect of diet-
induced iron deficiency on total phosphate uptake across the BBM, uptake buffer 
containing Na+ and a physiological phosphate concentration of 10 mM was used. 
The amount of phosphate transferred from the uptake buffer into the intestinal 
tissue (phosphate uptake) after 2 minutes was expressed in nmoles/100mg of the 
intestinal segment. 
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4.2.3. In vivo uptake experiments 
Phosphate uptake experiments in the duodenum or jejunum were carried out as 
described in section 2.5. To test the effect of diet-induced iron deficiency on total 
transepithelial phosphate absorption, uptake buffer containing Na+ and a 
physiological phosphate concentration of 10 mM was instilled into the intestinal 
segments. The amount of phosphate transferred into blood per 5 cm of the 
cannulated duodenum or jejunum after 10, 20 and 30 minutes of instilling 
phosphate into the segment was determined and expressed in nmoles/5 cm. 
4.2.4. Blood and urine biochemistry 
Blood samples were collected at the end of the experiment by cardiac puncture 
and haematocrit measured using a micro-haematocrit reader. Serum and plasma 
were obtained from whole blood as described in section 2.7. Serum iron and other 
markers of iron deficiency were measured using commercially available assay 
kits as described in section 2.7.1. Serum and urine phosphate levels were 
measured using a colorimetric phosphate assay kit (Biovision Inc., Milpitas, CA, 
USA) as described in section 2.7.2. Urine volume was measured using a 
graduated cylinder, and the urine flow rate (V̇) was estimated by: urine volume 
(mL)/ time (minutes). 
Urinary phosphate excretion (UPi) was calculated using the equation below:  
UPi (µmol/min)  = urinary phosphate concentration x V̇  
Serum intact FGF-23 (Kainos Laboratories Inc., Tokyo, Japan), c-term FGF-23 
(Immutopics, Inc., San Clemente, CA, USA), 1,25(OH)2D3 (LSBio Inc., Seattle, 
WA, USA) and plasma intact PTH (Immutopics, Inc., San Clemente, CA, USA) 
were measured by ELISA as described in section 2.7.3.1 - 2.7.3.4. 
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4.2.5. RT-PCR experiment 
Total RNA was isolated from the whole kidney and from intestinal mucosa 
scrapes obtained from the duodenum and jejunum as described in section 2.3.1. 
cDNA was synthesised from the extracted RNA as described in section 2.3.2. 
RT-PCR experiment was carried out as described in section 2.3.3 to test the 
relative mRNA expression of renal NaPi-IIa, NaPi-IIc, α-Klotho, 25-
Hydroxyvitamin D3 1-alpha-hydroxylase (Cyp27b1), and duodenal and jejunal 
VDR, with reference to β-actin. Rat specific primers (Table 2.1) were used for RT-
PCR experiments. 
4.2.6. Western blotting experiment 
Kidney BBM vesicles were prepared as described in section 2.4.2. Kidney BBM 
protein (20µg) was used for Western blotting experiments to establish the protein 
levels of NaPi-IIa and NaPi-IIc as described in section 2.4.3, using specific 
antibodies (Table 2.2). The ratio of these proteins to β-actin was expressed as 
a.u.  
4.2.7. Statistical analysis 
Data are presented as mean ± SEM, statistical analysis was carried out as 
described in section 2.8, and statistical significance was depicted as follows: 
*P<0.05, **P<0.01 or ***P<0.001. 
4.3. Results 
4.3.1. Validation of iron deficient rat models 
To confirm that 2-week administration of an iron deficient diet induces iron 
deficiency, the markers of iron deficiency: haematocrit, serum iron, UIBC and 
TIBC were measured. Rats administered an iron deficient diet had significantly 
decreased serum iron and haematocrit, and significantly increased UIBC and 
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TIBC, compared with rats fed a control iron diet (Table 4.1). This indicates that 
the administration of an iron deficient diet for 2 weeks significantly induced iron 
deficiency in the animals used for this study. Weight gain during the 2-week 
dietary regime was similar in both groups (Table 4.1).  
Table 4.1. Effect of diet-induced iron deficiency on markers of iron status and 
animal weight. Data are presented as mean ± SEM (n = 5-13) and analysed using an 
unpaired t-test. ***P<0.001 compared with control. 
 Control Iron deficient 
Haematocrit (%) 42.38 ± 0.45 37.08 ± 0.75 *** 
Serum iron (µmol/l) 36.50 ± 2.82 9.22 ± 1.15 *** 
Serum UIBC (µg/dl) 353.30 ± 19.86 473.30 ± 12.91 *** 
Serum TIBC (µg/dl) 412.60 ± 20.03  530.20 ± 17.12 *** 
Animal weight (g) 345.00 ± 13.41  333.60 ± 13.85 
 
4.3.2. Effect of diet-induced iron deficiency on intestinal phosphate 
absorption  
Using the in vitro phosphate uptake technique and a physiological concentration 
of luminal phosphate in the uptake buffer, the effect of diet-induced iron deficiency 
on phosphate absorption across the BBM of the duodenum and jejunum was 
investigated. The result demonstrated that diet-induced iron deficiency 
significantly inhibited phosphate uptake across duodenal and jejunal BBM in vitro 
(Figure 4.1A and B). In the duodenum, iron deficiency resulted in approximately 
70% inhibition of phosphate uptake across the BBM (Figure 4.1A), while 
approximately 50% of phosphate uptake was inhibited in the jejunum (Figure 
4.1B), measured after 2 minutes. To test if this effect occurs in vivo, in situ 
intestinal loop technique was employed, using the same phosphate concentration 
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in the uptake buffer as in the in vitro uptake experiment. Consistent with the 
phosphate uptake results in vitro, diet-induced iron deficiency significantly 
inhibited total transepithelial phosphate absorption in the duodenum 
(approximately 65% inhibition) and jejunum (approximately 40% inhibition), 
measured in vivo after 10 minutes of instilling phosphate into the segment (Figure 
4.1C and D). However, this inhibition of phosphate absorption was more 
prominent in the duodenum and was still present when measured after 30 
minutes (Figure 4.1C), in contrast to the jejunum, where the inhibition of 
phosphate absorption decreased with time and at 30 minutes, phosphate 
absorption was similar in both groups (Figure 4.1D). This finding suggests that 
unlike the duodenum, there may be a potential compensation for the iron 
deficiency-induced inhibition of phosphate absorption in the jejunum. Other 
phosphate transport pathways that are not affected by iron deficiency may be 
responsible for this potential compensatory mechanism.  
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Figure 4.1. Diet-induced iron deficiency inhibits intestinal phosphate absorption. 
Phosphate uptake was determined in vitro (A and B) in control and iron deficient rats, 
using a buffer containing 10mM phosphate and Na+. An unpaired t-test was used to 
compare results between groups (n=6). ***P<0.001. Phosphate uptake at different time 
points was determined in vivo (C and D), in control and iron deficient rats, using a buffer 
containing 10mM phosphate and Na+. A two-way ANOVA with Bonferroni’s multiple 
comparisons post-test was used to compare differences between groups (n=7-8). 
*P<0.05, ***P<0.001. 
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4.3.3. Effect of diet-induced iron deficiency on serum phosphate levels and 
renal phosphate excretion 
To examine whether the inhibition of phosphate absorption in the duodenum and 
jejunum significantly impacts serum phosphate levels, phosphate assay 
experiment was carried out to measure the levels of phosphate in the animals. 
Similar serum phosphate levels were observed in control and iron deficient 
animals (Figure 4.2A). This indicates that even though diet-induced iron 
deficiency significantly inhibited intestinal phosphate absorption, this effect had 
no impact on systemic phosphate levels. To understand the physiological 
mechanism responsible for the lack of change in serum phosphate levels 
observed in the iron deficient animals, the effect of diet-induced iron deficiency 
on renal phosphate excretion was investigated. Although not significant, the 
result showed a trend for a decrease in urinary phosphate excretion (P=0.1; 
Figure 4.2B). Additionally, the effect of diet-induced iron deficiency on the mRNA 
and protein levels of the renal phosphate transporters; NaPi-IIa and NaPi-IIc were 
tested using RT-PCR and Western blotting. The result showed a trend for 
upregulation of NaPi-IIa protein in the iron deficient group (P=0.07; Figure 4.3C), 
while NaPi-IIa and NaPi-IIc mRNA, as well as NaPi-IIc protein, were unchanged 
(Figure 4.3A, B and D). Taken together, these findings suggest that there may be 
a renal compensation for the reduced intestinal phosphate absorption seen in the 
iron deficient rats and this likely accounts for the unchanged serum phosphate 
levels. 
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Figure 4.2. Effect of diet-induced iron deficiency on serum phosphate and urinary 
phosphate excretion. Changes in serum phosphate levels (A) and urinary phosphate 
excretion (B) in control and iron deficient rats were analysed using an unpaired t-test 
(n=4-6). 
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Figure 4.3. Effect of diet-induced iron deficiency on renal NaPi-IIa and NaPi-IIc.   
RT-PCR quantification of mRNA levels of NaPi-IIa and NaPi-IIc (A and B). Duplicate 
PCR reactions were performed for each sample and the mRNA expression of NaPi-IIa 
and NaPi-IIc is given as their ratio to β-actin. Representative Western blot image and 
quantification of NaPi-IIa and NaPi-IIc protein (C and D) in control and iron deficient rats. 
The abundance of NaPi-IIa and NaPi-IIc protein is given as the ratio of their band density 
to β-actin, expressed in arbitrary units (a.u). An unpaired t-test was used to compare 
results between groups (n=5-6). 
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4.3.4. Effect of diet-induced iron deficiency on regulators of phosphate 
homeostasis 
To gain more insight into the underlying mechanisms responsible for the inhibition 
of intestinal phosphate absorption by diet-induced iron deficiency and the 
potential renal compensation, the levels of the systemic regulators of phosphate 
homeostasis, FGF-23, PTH and 1,25(OH)2D3 were examined. The results 
showed that these regulators were unchanged in the iron deficient group 
compared to control (Figure 4.4A-D). Using RT-PCR, the mRNA levels of 
Cyp27b1, the gene encoding the enzyme that catalyses the rate limiting-step for 
1,25(OH)2D3 synthesis and FGF-23 co-receptor, α-klotho, were also shown to be 
unchanged in response to diet-induced iron deficiency (Figure 4.5A and B). 
These findings suggest that the systemic regulators of phosphate homeostasis 
are unaffected by diet-induced iron deficiency, and thus, play no role in the 
inhibition of intestinal phosphate absorption seen in the iron deficient animals. To 
further rule out any potential contribution of 1,25(OH)2D3 signalling to the 
mechanism underlying the inhibition of intestinal phosphate absorption by diet-
induced iron deficiency, RT-PCR experiment was used to test the mRNA 
expression of VDR in the duodenum and jejunum. Surprisingly, VDR mRNA 
expression was significantly increased in the duodenum (Figure 4.5C), where the 
inhibition of phosphate absorption by diet-induced iron deficiency was more 
prominent, while jejunal VDR was unaffected (Figure 4.5D). Since 1,25(OH)2D3 
signalling is known to increase intestinal phosphate and Ca2+ absorption, the 
exact significance of this upregulated duodenal VDR is unclear.  
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Figure 4.4. Effect of diet-induced iron deficiency on systemic regulators of 
phosphate homeostasis. Serum levels of c-term FGF-23, Intact FGF-23, 1,25(OH)2D3 
and plasma levels of intact PTH were determined in control and iron deficient animals 
using ELISA. An unpaired t-test was used to compare differences between groups (n=6-
11). 
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Figure 4.5. Effect of diet-induced iron deficiency on renal Cyp27b1 and Klotho, and 
intestinal VDR. RT-PCR quantification of the mRNA levels of Cyp27b1, klotho, duodenal 
VDR and jejunal VDR (A-D). Duplicate PCR reactions were performed for each sample 
and the mRNA expression of Cyp27b1, klotho, duodenal VDR and jejunal VDR is given 
as their respective ratio to β-actin. An unpaired t-test was used to compare results 
between groups (n=6). **P<0.01 
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4.4. Discussion 
Based on the evidence linking iron deficiency with phosphate imbalance 
(reviewed in section 1.6) and bone disease 337–341, the effect of diet-induced iron 
deficiency on the intestinal and renal mechanisms of phosphate homeostasis was 
examined. Using in vitro and in vivo techniques, diet-induced iron deficiency was 
shown to significantly inhibit intestinal phosphate absorption in normal rats, but 
this effect had no impact on serum phosphate levels. A trend for increased renal 
NaPi-IIa protein levels in iron deficient rats and a consequent reduction in renal 
phosphate excretion, although not significant, may be responsible for the normal 
phosphate balance observed in iron deficient animals. In addition, the bone 
phosphate buffering mechanism, which was not investigated in the current study, 
may also contribute to the maintenance of phosphate homeostasis in iron 
deficient rats.  Evidence from the current study indicated that the effect of diet-
induced iron deficiency on the intestinal and renal mechanisms of phosphate 
transport were not dependent on the recognised systemic phosphate regulators, 
FGF-23, PTH and 1,25(OH)2D3.  
Intestinal absorption of phosphate via the transcellular pathway is widely 
considered to be mediated by NaPi-IIb. Previous findings using gene chip 
analysis and quantitative PCR techniques have shown that in response to diet-
induced iron deficiency in rats, the NaPi-IIb gene, SLC34A2, is significantly 
downregulated in the duodenum and jejunum, with a more prominent decrease 
observed in the duodenum compared to the jejunum 346,347. In keeping with these 
findings, the observation that the inhibition of phosphate absorption by diet-
induced iron deficiency was stronger in the duodenum compared to the jejunum 
in the current study suggests that the effect of iron deficiency on intestinal 
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phosphate absorption may have been due to changes in NaPi-IIb levels. 
However, the evidence presented in chapter 3 and previous reports in rats 45,246 
indicate that NaPi-IIb plays no significant role in duodenal phosphate absorption 
while contributing only a small proportion to jejunal phosphate absorption at 
physiological phosphate concentration. These findings make it unlikely that the 
downregulation of duodenal NaPi-IIb mRNA by iron deficiency (presented in 
chapter 5, Figure 5.3A) is responsible for the robust inhibition of phosphate 
absorption observed in this study. Based on the in vitro phosphate uptake data 
(Figure 3.11), it is interesting to note that the Na+-independent pathway appears 
to be the predominant phosphate transport mechanism, mediating approximately 
75% and 60% of total phosphate transport in the duodenum and jejunum 
respectively. These overall proportions of Na+-independent phosphate transport 
are comparable to the proportion of phosphate transport inhibition in the 
duodenum and jejunum in response to iron deficiency. Since the Na+-
independent phosphate transport pathway contributes a higher proportion of 
phosphate transport in the duodenum compared to the jejunum in vivo 45, it is 
possible that this phosphate transport pathway is affected by iron deficiency and 
this may be the reason for the stronger and long-lasting phosphate inhibition 
observed in the duodenum. Taken together, these findings indicate that instead 
of NaPi-IIb, the Na+-independent pathway is the phosphate transport mechanism 
that is likely affected in iron deficiency. Additional experiments to test this 
hypothesis are discussed in chapter 5. 
There is however data from the investigation of the 1,25(OH)2D3 – VDR signalling 
in the current chapter that supports the hypothesis that NaPi-IIb is not involved in 
the inhibitory effect of diet-induced iron deficiency on intestinal phosphate 
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absorption. NaPi-IIb-mediated phosphate absorption in the rat small intestine is 
known to be regulated by the 1,25(OH)2D3 – VDR signalling pathway, with the 
effect of this hormonal pathway occurring only in the jejunum 39,126,329,348. 
However, in the current study, iron deficiency inhibited phosphate absorption in 
the duodenum and jejunum, with a more striking effect in the duodenum, a 
segment where 1,25(OH)2D3 has been reported to have no effect on phosphate 
absorption 39,329. The iron deficiency-induced inhibition of jejunal phosphate 
absorption does not correlate with the fact that iron deficiency had no effect on 
circulating 1,25(OH)2D3 levels and VDR mRNA expression in this segment. Based 
on this finding and since 1,25(OH)2D3 has been demonstrated to increase NaPi-
IIb-mediated phosphate absorption in the jejunum 39,48, it is therefore apparent 
that the effect of iron deficiency on phosphate absorption may not be dependent 
on changes in NaPi-IIb function. Moreover, even though 1,25(OH)2D3 has not 
been reported to affect NaPi-IIb-mediated phosphate absorption in the duodenum 
of rats 39,329, the significantly upregulated mRNA levels of duodenal VDR in iron 
deficiency would have been expected to increase phosphate absorption in this 
segment. In contrast to this expected increase in phosphate absorption, was the 
finding that phosphate absorption was inhibited in the duodenum of iron deficient 
rats in the current study. This further supports the hypothesis that the 
downregulation of NaPi-IIb mRNA (Figure 5.3A) 346,347 in iron deficient animals is 
not responsible for the inhibition of intestinal phosphate absorption. Interestingly, 
the upregulated VDR in the duodenum in response to iron deficiency may be 
associated with duodenal Ca2+ absorption. Iron deficiency has been reported to 
inhibit intestinal Ca2+ absorption 338,349, with emerging evidence in our laboratory 
suggesting that this effect may be due to the reduction in calbindin D9K-mediated 
transcellular Ca2+ transport (unpublished data). Because the duodenum is known 
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to be involved in 1,25(OH)2D3-sensitive Ca2+ absorption, the upregulated VDR 
may be a component of a possible compensatory mechanism in response to a 
potential inhibition of transcellular Ca2+ absorption in this segment. In line with 
this hypothesised compensatory mechanism for Ca2+ absorption, the 
upregulation of a 1,25(OH)2D3-sensitive Ca2+ pore, claudin 2, has previously been 
reported in the duodenum in response to diet-induced iron deficiency 347. To 
understand the exact significance of the iron deficiency-induced upregulation of 
VDR in the duodenum, further studies are required to examine the effect of iron 
deficiency on the mechanisms of intestinal Ca2+ absorption. 
Interestingly, in the jejunum, the observation that the magnitude of iron 
deficiency-induced inhibition of phosphate absorption in vivo decreased over a 
period of 30 minutes suggests the activation of a potential compensatory 
mechanism for this inhibition of phosphate absorption. Since my findings suggest 
that iron deficiency inhibits the Na+-independent phosphate absorption pathway 
in the rat small intestine, there may be a potential increase in the activity of the 
transcellular Na+-dependent phosphate transporters in the jejunum, NaPi-IIb and 
PiT-1, both known to be most highly expressed in this segment (discussed in 
chapter 3). It is worth noting that like the duodenum that is known to be 
responsible for transcellular 1,25(OH)2D3-VDR-dependent Ca2+ transport, the 
jejunum is the segment involved in transcellular phosphate absorption, mediated 
by the 1,25(OH)2D3-VDR signalling pathway. Surprisingly, the unchanged levels 
of 1,25(OH)2D3 or jejunal VDR in response to iron deficiency, suggests that the 
potential compensatory mechanism for the inhibited phosphate absorption over 
time in the jejunum may not be dependent on the function of this hormonal 
pathway.  
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In animals with normal renal function, the kidney is known to be the major 
regulator of phosphate homeostasis, therefore, the effect of iron deficiency on 
phosphate balance and renal phosphate handling was investigated. In diet-
induced iron deficiency, even though there was a significant inhibition of intestinal 
phosphate absorption, serum phosphate levels were unchanged. This may have 
been due to the trend for upregulation of renal NaPi-IIa and a moderate decrease 
in urinary phosphate excretion observed in this study. In agreement with this 
suggestion, the inhibition of intestinal phosphate absorption in NaPi-IIb knock-out 
mice maintained on a normal phosphate diet has been shown to be associated 
with reduced urinary phosphate excretion. Interestingly, changes in renal 
phosphate excretion in NaPi-IIb knock-out mice are not always associated with 
changes in FGF-23 and NaPi-IIa levels 31,222,251,328. For example, when NaPi-IIb 
knock-out mice are maintained on 0.63% phosphate diet, the decreased urinary 
phosphate excretion is associated with reduced intact FGF-23 levels and 
increased renal NaPi-IIa protein expression 31. However, when these mice were 
maintained on a 0.9% phosphate diet, the reduced urinary phosphate excretion 
was not associated with changes in NaPi-IIa and intact FGF-23 251. In addition, 
studies have shown that intestinal phosphate absorption following gastric 
phosphate loading or instillation of a phosphate bolus into the small intestine of 
rats is associated with significant renal phosphate wasting, which was 
demonstrated to be a consequence of increased circulating levels of phosphate 
and PTH 23,24. Therefore, in the current study, the lack of change in FGF-23, the 
trend for NaPi-IIa upregulation and the moderate reduction in urinary phosphate 
excretion in response to iron deficiency may be due to the magnitude of inhibition 
of intestinal phosphate absorption. The relatively smaller inhibition of phosphate 
absorption observed in the jejunum (the major segment for phosphate absorption 
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in rats) in response to iron deficiency, may explain the lack of significant change 
in urinary phosphate excretion and renal NaPi-IIa levels. 
Age and sex have been identified to be among the causes of the inconsistent 
renal adaptation to reduced intestinal phosphate absorption in rodents 222,328. For 
example, to maintain phosphate balance during a period of low intestinal 
phosphate absorption in NaPi-IIb knock-out mice, reduced urinary phosphate 
excretion has been reported in both 4-week and 20-week old mice 328. However, 
while this renal phosphate adaptation occurs as a result of reduced circulating 
levels of FGF-23 and NaPi-IIa upregulation in 4-week old NaPi-IIb knock-out 
mice, no change in both NaPi-IIa and FGF-23 was seen in the 20-week old mice 
328. Hernando and colleagues reported that changes in the circulating levels of 
phosphate regulators in response to the inhibition of intestinal phosphate 
absorption by the loss of NaPi-IIb was less apparent in adult males compared to 
females, where NaPi-IIa upregulation and reduced intact FGF-23 levels were 
seen 222. Based on these reports, the age and sex of the animals used in the 
current study may have affected the renal adaptation to the reduced intestinal 
phosphate absorption seen in the iron deficient animals.  
Importantly, the degree of renal adaptation in response to intestinal phosphate 
absorption seems to vary with the amount of phosphate absorbed in the small 
intestine, which is determined by the levels of phosphate in the diet. For example, 
intact FGF-23, PTH and urinary phosphate levels in both NaPi-IIb knock-out and 
wild-type mice have been shown to be lowest in mice maintained on a 0.1% 
phosphate diet, compared to those maintained on a 0.8% or 1.2% phosphate diet 
145. These findings, in addition to those discussed in the previous two paragraphs, 
suggest that diet-induced iron deficiency does not have a direct effect on NaPi-
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IIa function or renal phosphate excretion and that the adaptation of the renal 
system to maintain phosphate balance in iron deficiency occurs in response to 
the reduced intestinal phosphate absorption.  
Previous reports in mice and humans have shown that iron deficiency affects 
FGF-23 transcription and processing in osteocytes, leading to increased 
circulating c-term FGF-23 and unchanged intact FGF-23 levels under normal 
physiological conditions 305,309,310. However, in the current study, the levels of c-
term FGF-23 were unchanged in response to diet-induced iron deficiency. The 
discrepancy between the current study and previous findings on the levels of c-
term FGF-23 in response to iron deficiency may be as a result of the previously 
reported blood collection time-dependent variation in the levels of c-term FGF-23 
in normal rats 311. A study involving repeated blood collection from normal 
anaesthetised or non-anaesthetised rats at 3 different time points has shown that 
c-term FGF-23 is an unstable hormone 311. In the current study, the time of blood 
collection from animals was different as blood was collected after phosphate 
uptake experiment from each animal. In contrast to the unstable levels of c-term 
FGF-23, the levels of intact FGF-23 have been reported to be stable over a similar 
period of time 311. Importantly, in the current study, diet-induced iron deficiency 
had no effects on the levels of biologically active intact FGF-23, which is 
consistent with previous findings 305,309,310. Reports on the biology of FGF-23 have 
shown that the levels of intact FGF-23 are regulated by FGF-23 gene 
transcription and intracellular cleavage of newly synthesised intact FGF-23 to c-
term FGF-23 within osteocytes, with both forms released into the circulation 350. 
Only the intact FGF-23 is thought to be involved in phosphate homeostasis, with 
the role of the c-term FGF-23 currently unknown. It has been hypothesised that 
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continuous FGF-23 production and cleavage to c-term FGF-23 fragments provide 
osteocytes with the innate ability to increase or decrease the secretion of intact 
FGF-23 more rapidly by adjusting the rate of cleavage 306. In phosphate 
homeostasis, one of the roles of intact FGF-23 is to decrease the levels of a major 
regulator of intestinal phosphate absorption, 1,25(OH)2D3, by inhibiting the mRNA 
expression of Cyp27b1 enzyme and increasing that of Cyp24a1 306,351. The 
mRNA expression of Cyp27b1 and the levels of 1,25(OH)2D3 in response to diet-
induced iron deficiency were tested in this study. Consistent with the unchanged 
levels of intact FGF-23, the results showed that both Cyp27b1 mRNA and 
1,25(OH)2D3 levels were unaffected in the iron deficient animals. Interestingly, it 
is noteworthy that age interferes with the impact of iron deficiency on FGF-23 and 
1,25(OH)2D3. In normal mice that are less than 6 weeks old and healthy children, 
previous studies have reported changes in intact FGF-23 and 1,25(OH)2D3 levels 
in response to iron deficiency 306,307,312. Thus, the fact that adult rats were used 
for the current study may explain the discrepancy between my findings and these 
reports. 
PTH and α-klotho are also considered important regulators of phosphate balance, 
as both have been shown to affect the levels or actions of FGF-23 and 
1,25(OH)2D3 10,95,116. Recent clinical data in 6-10-year old children with beta-
thalassemia have shown that iron overload in this condition is associated with low 
PTH levels, and these children were shown to have higher phosphate levels 
compared to healthy children 352. In the current study, the investigation into 
whether changes in PTH and α-klotho were associated with the inhibition of 
phosphate absorption in iron deficiency revealed that these regulators were 
unchanged in adult animals. This finding, therefore, suggests that in normal adult 
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animals, like intact FGF-23 and 1,25(OH)2D3, PTH and α-klotho levels are not 
linked to the inhibition of intestinal phosphate absorption or the moderate 
changes in renal phosphate excretion in diet-induced iron deficiency.  
4.5. Conclusion 
In summary, the findings of this chapter demonstrate that diet-induced iron 
deficiency inhibits phosphate absorption in the duodenum and jejunum of rats, 
with a more prominent effect in the duodenum. The results indicate that the 
inhibition of intestinal phosphate absorption by diet-induced iron deficiency is not 
dependent on the circulating levels of recognised phosphate regulators, 
suggesting that this impact on phosphate absorption may be mediated via 
mechanisms within the enterocytes. The mechanisms underlying the inhibition of 
intestinal phosphate absorption by iron deficiency is reported in the next chapter. 
Importantly, based on the evidence discussed in this chapter in relation to 
previous findings (described in section 1.6), it is now known that abnormal iron 
metabolism interferes with the mechanisms of phosphate homeostasis, and a 
complete understanding of this link may improve clinical outcomes in patients 
with impaired iron and phosphate metabolism. In addition, since iron deficiency 
is highly prevalent globally, a proper understanding of the link between iron, FGF-
23 and other regulators of phosphate homeostasis will be essential in preventing 
the development of bone disease in iron deficient individuals. 
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Chapter Five 
5.0. Effect of diet-induced iron deficiency on the mechanisms of intestinal 
phosphate absorption 
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5.1. Introduction 
As demonstrated in chapter 3, intestinal phosphate absorption in the rat proximal 
small intestine occurs mainly via a Na+-dependent NHE3-regulated paracellular 
pathway and a Na+-independent pathway. While the findings of chapter 4 indicate 
that diet-induced iron deficiency significantly inhibited intestinal phosphate 
absorption, it is not known whether one or both these mechanisms of phosphate 
absorption are affected. The results do however suggest that the underlying 
mechanisms are independent of the systemic regulators of phosphate 
homeostasis, and of particular interest, do not involve 1,25(OH)2D3, which is 
known to regulate NaPi-IIb levels. Until recently, NaPi-IIb has been considered to 
be the rate-limiting step for intestinal phosphate absorption 353, however, as 
discussed in chapter 3, it is now known that under normal physiological 
phosphate concentration, NaPi-IIb becomes saturated and that the Na+-
independent phosphate transport mechanism, thought to be mediated via the 
paracellular pathway is predominantly responsible for phosphate absorption in 
rats 45,145. 
Paracellular absorption of solutes and ions from the intestinal lumen into the 
circulation is influenced by the composition and architectural organisation of tight 
junction complexes. Numerous integral membrane proteins and scaffolding 
proteins combine to form tight junctions, but it is recognised that the claudin 
protein family plays a key role in the function of these complexes (reviewed in 
354). Claudins have been shown to form either epithelial barriers (pore-sealing 
claudins) or paracellular channels (pore-forming claudins), and like NaPi-IIb 
(described in chapter 3), these claudins also have a distinct regional profile in the 
intestine 268. The most highly expressed pore-sealing claudins, claudin 3 and 4, 
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have been demonstrated to be higher in the rat duodenum compared to the 
jejunum, and the pore-forming claudins 2 and 12 are higher in the jejunum 
(described in section 1.5.1). While numerous studies have reported a role for 
claudins in the paracellular transport of Na+, K+, Ca2+ and Cl- 257,258,267,269, there 
is as yet no evidence linking claudins to paracellular phosphate transport.  
Recently, NHE3 has been demonstrated to regulate paracellular phosphate 
absorption in the small intestine of rats and humans 77,247.  Inhibition of NHE3 by 
tenapanor has been shown to reduce paracellular phosphate absorption 77. In 
intestinal stem cell-derived monolayers, NHE3 inhibition results in a reduction in 
intracellular pH, which causes an increase in TEER, and this mechanism has 
been suggested to be responsible for the inhibition of paracellular phosphate 
absorption following tenapanor treatment 77. Interestingly, there is evidence that 
the TEER increases in iron deficient Caco-2 cells, a response shown to involve 
changes in the localisation of claudin 4 355. Whether this increase in the TEER in 
iron deficient Caco-2 cells occurs in intact enterocytes and whether this results in 
changes in paracellular phosphate absorption is yet to be determined. Therefore, 
the aim of this chapter was to investigate the cellular mechanisms underlying the 
inhibition of phosphate absorption in iron deficient rat model. Firstly, the effect of 
diet-induced iron deficiency on the Na+-dependent (NaPi-IIb- and NHE3-
regulated phosphate transport pathways) and the Na+-independent mechanisms 
of phosphate absorption were investigated, and the levels of intestinal claudins 
in response to diet-induced iron deficiency were examined. 
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5.2. Methods 
5.2.1. Animals 
Male Sprague Dawley rats and C57BL/6J mice, aged 6-8 weeks, were used for 
this study. As described in section 4.2.1, animals were either fed a control iron 
diet (TD. 80394) containing 48 ppm added iron or an iron deficient group diet (TD. 
80396) containing approximately 2-6 ppm added iron for 2 weeks. Following the 
dietary regime, animals were weighed and anaesthetised as described in section 
2.5. For haematocrit and serum phosphate measurement, blood was collected 
via femoral artery cannulation or via cardiac puncture, and haematocrit and 
phosphate levels were measured as described in section 2.7.1 and 2.7.2 
respectively. Mucosa scrapes were then obtained from defined regions of the 
small intestine of the animals as described in section 2.2, snap frozen in liquid 
nitrogen and stored at -80 °C until required. 
5.2.2. In vitro phosphate uptake 
As described in section 2.6, in vitro phosphate uptake experiments were carried 
out using rat duodenal and jejunal segments to test the contribution of NaPi-IIb, 
NHE3 and the Na+-independent pathway to the inhibition of phosphate absorption 
in rats fed an iron deficient diet. To test the role of NaPi-IIb in response to iron 
deficiency, 10 mM PFA was added to the uptake buffer. Similarly, to test the role 
of NHE3, 10 µM tenapanor was added to the uptake buffer, while uptake buffer 
prepared using Na+ free HEPES and choline chloride was used to test whether 
the Na+-independent mechanism was responsible for the iron deficiency-induced 
inhibition of phosphate absorption. The uptake buffer in all experiments contained 
a physiological phosphate concentration of 10 mM. Phosphate uptake in the 
presence of PFA or tenapanor or the Na+-free uptake solution was expressed as 
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a percentage of the total phosphate uptake using normal physiological uptake 
solution containing Na+. 
5.2.3. In vivo phosphate uptake 
As described in section 2.5, in vivo phosphate uptake experiments were carried 
out in the jejunum and ileum of mice to test the effect of diet-induced iron 
deficiency on intestinal phosphate absorption using an uptake buffer containing 
Na+ and 10 mM phosphate. The amount of phosphate transferred into the blood 
in 10 minutes per 5 cm of the cannulated jejunum or ileum was determined and 
expressed in nmoles/5 cm. 
5.2.4. RT-PCR  
As described in section 2.3.1, RNA was extracted from thawed intestinal mucosa 
scrapes collected from rats, using the Trizol method. cDNA was synthesised from 
1 µg of RNA by reverse transcription reaction as described in section 2.3.2. and 
RT-PCR experiments were carried out to test the mRNA expression of NaPi-IIb, 
NHE3, DMT1, claudins 3,4,7,8,12 and 15, SGLT1 and GLUT2 using rat-specific 
primers (Table 2.1). 
5.2.5. Western blotting 
Intestinal BBM vesicles were prepared as described in section 2.4.1. Intestinal 
BBM protein (20-50 µg) was used for Western blotting experiments to establish 
the protein levels of NaPi-IIb in rats and mice, and the protein levels of NHE3, 
DMT1, claudin 3, SGLT1 and GLUT2 in rats, as described in section 2.4.3. using 
specific antibodies (Table 2.2). The ratio of the band densities of these proteins 
to β-actin was expressed as a.u. 
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5.2.6. Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was carried out as 
described in section 2.8, and statistical significance was depicted as follows: 
*P<0.05, **P<0.01 or ***P<0.001. 
5.3. Results 
5.3.1. Validation of iron deficient animal models 
As described in section 4.3.1, the significantly reduced haematocrit and serum 
iron levels confirm that the rat used for the experiments described in this chapter 
were iron deficient. In mice, the 2-week administration of an iron deficient diet 
significantly reduced the haematocrit levels compared to control (Table 5.1). The 
dietary regime had no impact on the weight of either the rats or mice (Table 4.1 
and 5.1). In addition, as observed in rats (Figure 4.3), serum phosphate levels in 
control and iron deficient mice were similar (Table 5.1). 
Table 5.1. Effect of diet-induced iron deficiency on haematocrit, serum phosphate 
and the weight of mice. Data are presented as mean ± SEM (n = 5-11) and 
analysed using an unpaired t-test. *P<0.05 compared with control. 
 Control Iron deficient 
Haematocrit (%) 44.56 ± 0.96 40.55 ± 1.09 * 
Serum phosphate (mmol/l) 3.64 ± 0.15 3.41 ± 0.13 
Animal weight (g) 25.04 ± 0.48 24.35 ± 0.53 
 
5.3.2. Effect of diet-induced iron deficiency on the mechanisms of 
phosphate absorption in rats 
Using the in vitro everted sleeve technique, the contribution of NaPi-IIb, NHE3 
and the Na+-independent pathway to the inhibitory effect of diet-induced iron 
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deficiency on intestinal phosphate absorption were tested. As described in 
chapter 3, using 10 mM phosphate in the uptake buffer, this technique has 
previously been used to show the presence of a significant Na+-dependent 
component of phosphate absorption in the duodenum and jejunum of rats 45. 
While the data presented in chapter 3 showed that NaPi-IIb- and NHE3-regulated 
phosphate transport pathways accounted for the Na+-dependent component of 
phosphate absorption in the jejunum, these transporters had no contribution in 
the duodenum. In this chapter, the uptake experiments using PFA are difficult to 
interpret given the relatively low contribution of PFA-sensitive NaPi-IIb pathway 
to overall phosphate transport in control animals (Figure 5.1A and B). In contrast, 
in the jejunum where there is a significant contribution of NHE3 to phosphate 
absorption in control animals, this component was not inhibited by tenapanor in 
the iron deficient animals, suggesting that iron deficiency impacts NHE3 activity 
in this segment (Figure 5.2B). In addition, the fact that the proportion of jejunal 
phosphate absorption inhibited by iron deficiency was significantly more than the 
proportion of phosphate absorption mediated by NHE3 (Figure 5.2B), suggests 
that iron deficiency may be impacting another phosphate transport pathway in 
this segment. In the duodenum, tenapanor has no significant effect on transport 
in control animals, therefore, ruling out any impact of iron deficiency on this 
pathway of phosphate absorption in this segment (Figure 5.2A). Western blotting 
and RT-PCR experiments were performed to test if there were any changes in 
the protein and mRNA levels of NaPi-IIb and NHE3 in response to diet-induced 
iron deficiency. In the duodenum, while NaPi-IIb mRNA levels were significantly 
downregulated (Figure 5.3A), NaPi-IIb protein was not detected (Figure 3.4B, 
chapter 3), which could be because duodenal NaPi-IIb mRNA is 10-fold lower 
than jejunal NaPi-IIb mRNA levels. The very low levels or lack of NaPi-IIb protein 
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in the duodenum raises the question of whether there is any physiological 
relevance of the downregulation of NaPi-IIb mRNA by iron deficiency in this 
segment. In contrast, NaPi-IIb mRNA and protein levels were unchanged in the 
jejunum in response to iron deficiency (Figure 5.3B and C). Similarly, NHE3 
mRNA and protein levels were unchanged in the duodenum and jejunum in 
response to iron deficiency (Figure 5.4A-D). Taken together, these findings 
suggest that while NaPi-IIb function and NHE3-regulated paracellular phosphate 
transport pathway were unaffected by diet-induced iron deficiency in the 
duodenum, NHE3-regulated phosphate transport appears to be affected in the 
jejunum, but this is not associated with altered transporter levels. Additionally, in 
comparison to the jejunum, the duodenum was shown to exhibit a more striking 
effect of iron deficiency on phosphate absorption. The observation that the 
duodenum has low levels of NaPi-IIb and PiT-1, and that phosphate transport is 
unaffected by PFA or tenapanor in this segment highlight that the Na+-
independent pathway is likely to be most affected by iron deficiency.  
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Figure 5.1. Effect of iron deficiency on NaPi-IIb-mediated phosphate transport in 
the rat proximal small intestine measured in vitro. Phosphate uptake in the 
duodenum (A) and jejunum (B). Values presented are a percentage of the total 
phosphate transport using a buffer containing Na+ in the control group (control). NaPi-
IIb-dependent uptake was determined using a buffer containing Na+ + 10 mM PFA. A 
one-way ANOVA with Tukey’s multiple comparisons post-tests was used to compare 
differences between the control and iron deficient groups (n=6). ***P<0.001 compared 
with control, ##P<0.01 and ###P<0.001 compared with control + PFA. 
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Figure 5.2. Effect of iron deficiency on NHE3-regulated paracellular phosphate 
transport in the rat proximal small intestine measured in vitro. Phosphate uptake in 
the duodenum (A) and jejunum (B). Values presented are a percentage of the total 
phosphate transport using a buffer containing Na+ in the control group (control). NHE3-
regulated phosphate uptake was determined using a buffer containing Na+ + 10 µM 
tenapanor. A one-way ANOVA with Tukey’s multiple comparisons post-tests was used 
to compare differences between the control and iron deficient groups (n=5-6). ***P<0.001 
compared with control; and #P<0.05, ##P<0.01 and ###P<0.001 compared with control + 
tenapanor. 
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Figure 5.3. Effect of iron deficiency on NaPi-IIb mRNA and protein in the proximal 
small intestine of the rat.  RT-PCR was used to determine NaPi-IIb mRNA in the 
duodenum (A) and jejunum (B) in response to iron deficiency. Duplicate PCR reactions 
were performed for each sample and the mRNA expression of NaPi-IIb is given as the 
ratio of NaPi-IIb to β-actin. Representative Western blot image and quantification of 
NaPi-IIb protein levels in the jejunum (C) in control and iron deficient animals. The 
abundance of NaPi-IIb protein is given as the ratio of NaPi-IIb band density to β-actin, 
expressed in arbitrary units (a.u). An unpaired t-test was used to compare results 
between groups (n= 5-6). *P<0.05. 
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Figure 5.4. Effect of iron deficiency on NHE3 mRNA and protein in the proximal 
small intestine of the rat. RT-PCR was used to determine NHE3 mRNA in the 
duodenum (A) and jejunum (B) in response to iron deficiency. Duplicate PCR reactions 
were performed for each sample and the mRNA expression of NHE3 is given as the ratio 
of NHE3 to β-actin. Representative Western blot image and quantification of NHE3 
protein levels in the duodenum (C) and jejunum (D) in control and iron deficient animals. 
The abundance of NHE3 protein is given as the ratio of NHE3 band density to β-actin, 
expressed in arbitrary units (a.u). An unpaired t-test was used to compare results 
between groups (n= 4-6) 
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Furthermore, phosphate uptake experiments using a Na+-free buffer was used to 
examine the role of the Na+-independent mechanism in the inhibition of 
phosphate absorption by iron deficiency. Interestingly, in the duodenum where 
the Na+-independent component of phosphate transport is most predominant in 
the rat small intestine 45 (Figure 3.11 and 3.12, chapter 3), iron deficiency 
significantly inhibited phosphate uptake via this pathway (Figure 5.5A). This result 
indicates that the Na+-independent mechanism of intestinal phosphate absorption 
is the pathway affected by diet-induced iron deficiency in the duodenum. 
Surprisingly, phosphate uptake via the Na+-independent pathway in the jejunum 
was not significantly different between the control and iron deficient animals, but 
approximately 14% inhibition of phosphate transport via this pathway was 
observed in response to iron deficiency (% phosphate uptake; control - Na, 57.1 
± 4.7% Vs iron deficient - Na, 43.1 ± 5.3%, Figure 5.5B). In addition, the significant 
Na+-dependent component of phosphate absorption seen in the jejunum of 
control animals was not present in the iron deficient animals (Figure 5.5B). Taken 
together, these findings suggest that the effect of diet-induced iron deficiency on 
jejunal phosphate absorption have both Na+-dependent and Na+-dependent 
component, with a more significant effect on the Na+-dependent component. 
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Figure 5.5. Effect of iron deficiency on the Na+-independent phosphate transport 
in the rat proximal small intestine measured in vitro. Phosphate uptake in the 
duodenum (A) and jejunum (B). Values presented are a percentage of the total 
phosphate transport using a buffer containing Na+ in the control group (control). Na+-
independent uptake (-Na+) was determined using buffer in which Na+ has been replaced 
with iso-osmotic choline chloride. A one-way ANOVA with Tukey’s multiple comparisons 
post-tests was used to compare differences between the control and iron deficient 
groups (n=5-6). **P<0.01 and ***P<0.001 compared with control, and ###P<0.001 
compared with control - Na+. 
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5.3.3. Effect of diet-induced iron deficiency on phosphate absorption in 
mice 
To confirm that NaPi-IIb function does not contribute to the iron deficiency-
induced inhibition of phosphate absorption in the rat small intestine, in vivo 
phosphate uptake experiments were conducted in the mouse jejunum and ileum. 
Like the experiments in rats, uptake experiments were carried out using a buffer 
containing 10 mM phosphate to test if intestinal phosphate absorption is affected 
in iron deficient mice, and whether any changes in phosphate absorption is 
associated with NaPi-IIb protein levels. In the jejunum of mice, iron deficiency 
significantly downregulated NaPi-IIb protein levels (Figure 5.7A) but had no effect 
on transepithelial phosphate absorption (Figure 5.6A). As shown in chapter 3 
(Figure 3.1A and 3.4A), the mouse jejunum is known to exhibit low levels of NaPi-
IIb 38,39 and because iron deficiency had no impact on phosphate uptake in this 
segment, the downregulation of NaPi-IIb protein in response to iron deficiency 
may be physiologically irrelevant. Interestingly, in the ileum where NaPi-IIb has 
been demonstrated to be highest in mice 38,39 (Figure 3.1A and 3.4A), iron 
deficiency had no effect on phosphate uptake (Figure 5.6B) and NaPi-IIb protein 
levels (Figure 5.7B), thus, confirming that NaPi-IIb function is unaffected by diet-
induced iron deficiency.   
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Figure 5.6. Effect of iron deficiency on phosphate transport in the small intestine 
of mice measured in vivo. Values presented are the amount of phosphate transferred 
by 5 cm of the jejunum (A) and ileum (B) into 1 ml of blood after 10 minutes of phosphate 
instillation into the intestine, using a normal buffer containing Na+. An unpaired t-test was 
used to compare results between groups (n=6).   
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Figure 5.7. Effect of iron deficiency on NaPi-IIb protein levels in the small intestine 
of mice. Representative Western blot image and quantification of NaPi-IIb protein levels 
in the jejunum (A) and ileum (B) in control and iron deficient animals. The abundance of 
NaPi-IIb protein is given as the ratio of NaPi-IIb band density to β-actin, expressed in 
arbitrary units (a.u). An unpaired t-test was used to compare results between groups 
(n=6). *P<0.05. 
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5.3.4. Diet-induced iron deficiency inhibits duodenal phosphate absorption 
in rats by a mechanism involving DMT1 and claudin 3  
To gain more insight into the underlying cellular mechanisms responsible for the 
inhibition of intestinal phosphate absorption by diet-induced iron deficiency in 
rats, the expression of the pore-forming and pore-sealing claudins, known to 
control paracellular ion transport, was examined using RT-PCR. The results 
demonstrated that claudin 3 was the most abundant pore-sealing claudin 
transcript in the proximal small intestine of rats (Figure 5.8A and 5.8B), 
particularly in the duodenum, and that diet-induced iron deficiency significantly 
upregulated its expression in this segment (Figure 5.8A). In contrast, mRNA 
levels of the other duodenal pore-sealing claudins 4 and 8, duodenal pore-
forming claudins 7, 12 and 15, and all jejunal claudins investigated in this study 
were unchanged (Figure 5.8B, 5.9A and B). Western blotting revealed that 
duodenal claudin 3 protein levels were significantly upregulated by diet-induced 
iron deficiency, confirming that increased mRNA levels translated to elevated 
claudin 3 protein levels in the rat model (Figure 5.10A). Surprisingly, even though 
jejunal phosphate absorption was also significantly inhibited by diet-induced iron 
deficiency, there were no changes in the mRNA or protein levels of claudin 3 in 
this segment (Figure 5.8B and 5.10B).  
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Figure 5.8. RT-PCR quantification of pore-sealing claudins in the proximal small 
intestine of rats. The effect of iron deficiency on each claudin was determined in the 
duodenum (A) and jejunum (B). Duplicate PCR reactions were performed for each 
sample and the mRNA expression of each claudin is given as the ratio of the claudin to 
β-actin. An unpaired t-test was used to compare results between the control and iron 
deficient group for each claudin (n=6). *P<0.05. 
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Figure 5.9. RT-PCR quantification of pore-forming claudins in the proximal small 
intestine of rats. The effect of iron deficiency on each claudin was determined in the 
duodenum (A) and jejunum (B). Duplicate PCR reactions were performed for each 
sample and the mRNA expression of each claudin is given as the ratio of the claudin to 
β-actin. An unpaired t-test was used to compare results between the control and iron 
deficient group for each claudin (n=6). 
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Figure 5.10. Claudin 3 protein levels are increased in the duodenum, but not 
jejunum, by iron deficiency. Representative Western blot image and quantification of 
claudin 3 protein levels in the duodenum (A) and jejunum (B) of control and iron deficient 
animals. The abundance of claudin 3 protein is given as the ratio of claudin 3 band 
density to β-actin, expressed in arbitrary units (a.u). An unpaired t-test was used to 
compare results between groups (n=6). *P<0.05. 
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Iron is primarily absorbed in the duodenum, the first step of which utilises the 
BBM ferrous iron transporter DMT1. As expected in rats, there was a significant 
upregulation of duodenal DMT1 mRNA and protein levels in the iron deficient 
group compared to control (Figure 5.11A and 5.11C). Iron deficiency had no 
significant effect on jejunal DMT1 mRNA expression (Figure 5.11B), although 
very low levels were detected in this segment. However, like the duodenum, iron 
deficiency significantly upregulated jejunal DMT1 protein levels (Figure 5.11D). 
Consistent with the widely accepted dogma that iron is mainly absorbed in the 
duodenum, it is noteworthy that in iron deficient rats, the levels of DMT1 protein 
in the duodenum (a.u. 0.3825 ± 0.05895, n=6; Figure 5.11C) was approximately 
three times more than that in the jejunum (a.u. 0.1399 ± 0.01861, n=5; Figure 
5.11D). In keeping with the finding that the inhibition of phosphate absorption is 
more prominent in the duodenum compared to the jejunum, it is speculated that 
changes in DMT1 function may contribute to the underlying mechanisms 
responsible for this inhibition of phosphate absorption. DMT1 is known to be an 
H+-dependent cotransporter of ferrous iron. Therefore, in addition to increased 
iron absorption, upregulation of this transporter also results in an increase in H+ 
uptake and intracellular acidification of the enterocyte 356–358. There is also 
evidence that DMT1 functions as a uniporter for H+ in the absence of iron when 
the extracellular pH is acidic 357,358. This function of DMT1 as an H+ uniporter may 
be more predominant in the duodenum since pH in this segment has been 
previously reported to be 6.6 compared to the jejunum with pH greater than 6.6 
243. Based on this variation in luminal pH and the relatively higher expression of 
DMT1 in the duodenum, the possibility of DMT1-induced H+ accumulation 
occurring in response to diet-induced iron deficiency may be higher in the 
duodenum compared to the jejunum. 
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Figure 5.11. DMT1 levels are increased in the proximal small intestine of rat by iron 
deficiency. RT-PCR quantification of mRNA levels of DMT1 (A and B). Duplicate PCR 
reactions were performed for each sample and the mRNA expression of DMT1 is given 
as the ratio of DMT1 to β-actin. Representative Western blot image and quantification of 
DMT1 protein levels in the duodenum (C) and jejunum (D) of control and iron deficient 
animals. The abundance of DMT1 protein is given as the ratio of DMT1 band density to 
β-actin, expressed in arbitrary units (a.u). An unpaired t-test was used to compare results 
between groups (n= 4-6). **P<0.01, ***P<0.001. 
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Finally, to test if diet-induced iron deficiency impacts other nutrient absorption 
pathways in the duodenum and jejunum, mRNA and protein levels of the Na+-
dependent glucose cotransporter, SGLT1, and the facilitative glucose 
transporter, GLUT2, were investigated. The results showed that diet-induced iron 
deficiency had no effect on the mRNA (Figure 5.12) and protein levels (Figure 
5.13) of these glucose transporters. 
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Figure 5.12. Intestinal glucose transporter mRNA levels are unaffected by iron 
deficiency. RT-PCR quantification of mRNA levels of SGLT1 and GLUT2 was assessed 
by RT-PCR in the duodenum (A and B) and jejunum (C and D) of control and iron 
deficient animals. Duplicate PCR reactions were performed for each sample and the 
mRNA expression of SGLT1 and GLUT2 is given as the ratio of these transporters to β-
actin. An unpaired t-test was used to compare the differences between groups (n=5-6). 
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Figure 5.13. Intestinal glucose transporter protein levels are unaffected by iron 
deficiency. Representative Western blot image and quantification of SGLT1 and GLUT2 
protein levels in the duodenum (A and B) and jejunum (C and D) of control and iron 
deficient animals. The abundance of SGLT1 and GLUT2 protein is given as the ratio of 
the band density of each protein to β-actin, expressed in arbitrary units (a.u). An unpaired 
t-test was used to compare the differences between groups (n=5-6). 
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5.4. Discussion 
In this study, the effect of diet-induced iron deficiency on the mechanisms of 
phosphate transport in the rat duodenum and jejunum was investigated, and 
phosphate uptake experiments in iron deficient mice were used to determine the 
role of NaPi-IIb. Interestingly, while NaPi-IIb function was unaffected by diet-
induced iron deficiency, the results demonstrated that the mechanisms 
underlying the inhibition of phosphate absorption in response to iron deficiency 
are different in the duodenum and jejunum of rats. In iron deficiency, the Na+-
independent phosphate transport pathway was inhibited in the duodenum by a 
mechanism likely involving DMT1 and claudin 3, while the NHE3-regulated 
paracellular pathway for phosphate transport appears to be the mechanism 
mainly affected in the jejunum. 
In agreement with the evidence from early studies investigating intestinal 
phosphate absorption 46,126,240 and more recent findings 45,246,318, it is now 
recognised that in the rat and human small intestine, NaPi-IIb likely plays a minor 
role in intestinal phosphate absorption when physiological phosphate 
concentrations are present in the intestinal lumen. Even though diet-induced iron 
deficiency has previously been reported to downregulate the expression of the 
NaPi-IIb gene in the duodenum 346,347, evidence that very low levels of NaPi-IIb 
are present in this segment (discussed in chapter 3) suggests that this transporter 
may not be responsible for the significantly inhibited intestinal phosphate 
absorption caused by iron deficiency in rats. Consistent with this suggestion, the 
inhibition of phosphate absorption by iron deficiency in the rat duodenum and 
jejunum was unaffected by PFA. In addition, in the mouse ileum where NaPi-IIb 
is most highly expressed and plays a major role in phosphate transport in the 
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presence of 10 mM luminal phosphate (discussed in chapter 3), transepithelial 
phosphate transport or NaPi-IIb protein levels was not affected by iron deficiency. 
Like the rat duodenum, the jejunum of mice is known to have low levels of NaPi-
IIb, and in this segment of mice, diet-induced iron deficiency was demonstrated 
to downregulate NaPi-IIb in the current study. Interestingly, the downregulation 
of NaPi-IIb in the proximal small intestine of mice in response to iron deficiency 
had no impact on transepithelial phosphate transport. Taken together, these 
findings suggest that iron deficiency-induced downregulation of NaPi-IIb has no 
physiological relevance in intestinal segments where this protein is undetected or 
lowly expressed (e.g. duodenum of rat and the proximal small intestine of mice). 
These findings confirm that the inhibition of phosphate absorption by diet-induced 
iron deficiency does not involve NaPi-IIb. However, the significantly 
downregulated NaPi-IIb mRNA levels in the duodenum of rats in response to iron 
deficiency may prevent any potential compensation by the NaPi-IIb-mediated 
transcellular phosphate absorption pathway in this segment. 
Recent reports indicate that NHE3 plays a key role in mediating intestinal 
phosphate absorption in rats 77,247, and this role of NHE3 has been demonstrated 
to involve changes in intracellular pH and TEER, both affecting paracellular 
phosphate transport 77. In the current study, the contribution of the NHE3-
regulated paracellular phosphate transport mechanism in response to iron 
deficiency was investigated. The finding that the NHE3-regulated paracellular 
pathway for phosphate transport has no contribution to phosphate absorption in 
the duodenum (discussed in chapter 3), suggests that the effect of iron deficiency 
on phosphate absorption in this segment is unlikely to involve NHE3. Consistent 
with this hypothesis, the inhibition of phosphate absorption by iron deficiency was 
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unaffected by tenapanor in the duodenum. In contrast, using tenapanor, the 
finding that iron deficiency abolished the significant NHE3-regulated paracellular 
phosphate transport pathway in the jejunum, suggests that this phosphate 
transport mechanism is inhibited at least in part by iron deficiency in this segment. 
Based on this finding, the fact that iron deficiency had no effect on either the 
mRNA or protein levels of NHE3 suggests that rather than expression levels, iron 
deficiency impacts the activity of this transporter in the jejunum. Taken together, 
while the NHE3-regulated paracellular pathway for phosphate transport appears 
to be inhibited by iron deficiency in the jejunum, the inhibition of phosphate 
absorption in the duodenum does not involve this transport pathway. 
The Na+-independent phosphate transport pathway is now known to be the 
predominant pathway in the duodenum (discussed in chapter 3), and this 
pathway is suggested to involve a non-saturable concentration-dependent 
phosphate transport process, which is a key feature of simple diffusion 252. Given 
that the proximal small intestine is known to be a leaky epithelium, with high 
permeability to ions and water 252,359,360, it is likely that the Na+-independent 
phosphate absorption is mediated by paracellular diffusion. In the current study, 
to investigate if iron deficiency affects this Na+-independent mechanism, 
phosphate uptake was conducted using a Na+-free buffer containing a phosphate 
concentration of 10 mM to favour passive diffusion. As described in section 4.3.2, 
in the duodenum, approximately 70% of phosphate transport was inhibited by 
iron deficiency in vitro, this being similar to the proportion of phosphate transport 
mediated by the Na+-independent pathway. To support the speculation in the 
previous chapter, the findings of the current chapter indicated that iron deficiency 
inhibits the Na+-independent phosphate transport pathway in the duodenum. 
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However, the result of the Na+-free uptake experiment in the jejunum did not show 
the same effect as observed in the duodenum. The fact that phosphate uptake in 
the jejunum of control and iron deficient animals were not statistically different 
when Na+ was removed from the uptake buffer supports the hypothesis that iron 
deficiency may be affecting a Na+-dependent phosphate transport mechanism, 
suggested to be the NHE3-regulated paracellular pathway. Nevertheless, 
evidence from this study suggests that the inhibition of jejunal phosphate 
absorption by iron deficiency is not entirely due to changes in NHE3-regulated 
paracellular phosphate transport. A small proportion of the Na+-independent 
phosphate transport pathway appears to be inhibited by iron deficiency in the 
jejunum. Taken together, these findings suggest that iron deficiency inhibits 
paracellular phosphate transport through the Na+-independent pathway in the 
duodenum, and via both NHE3-regulated and Na+-independent pathways in the 
jejunum.  
Previous studies have shown that similar to phosphate absorption, intestinal Ca2+ 
absorption in the duodenum and jejunum is mediated by multiple transport 
mechanisms 361,362. Thus, to understand phosphate absorption clues can be 
taken from the cellular mechanisms underlying intestinal Ca2+ absorption. While 
transcellular Ca2+ absorption has been studied extensively, paracellular Ca2+ 
transport mechanisms are now gaining prominence. Transcellular and 
paracellular Ca2+ transport mechanisms are known to occur in both the 
duodenum and jejunum, however, the relative contribution of these pathways in 
each segment varies depending on dietary Ca2+ content 363. In the duodenum, 
during dietary Ca2+ restriction, the transcellular pathway contributes 
approximately 80%, while under high dietary Ca2+ conditions, paracellular Ca2+ 
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transport accounts for more than 90% of total transepithelial Ca2+ absorption 363. 
Similarly, in the jejunum, paracellular Ca2+ absorption accounts for more than 
80% of total Ca2+ absorption under normal or high dietary Ca2+ conditions 363. 
Therefore, analogous to Ca2+ absorption, a drive towards understanding the 
relative contribution of these pathways to intestinal phosphate absorption under 
different dietary conditions, and the mechanism(s) involved in paracellular 
phosphate absorption, is underway. It is now recognised that pore-sealing 
claudins are involved in the control of intestinal membrane permeability by virtue 
of their role in maintaining tight junction integrity, and therefore, affect the 
paracellular diffusion of ions 277. Consequently, differences in the regional 
expression pattern, together with alterations in the levels of these claudins may 
have an impact on paracellular phosphate transport in defined segments of the 
intestine. In keeping with previous reports 267, the results of this study 
demonstrated that pore-sealing claudins, in particular, claudin 3, were higher in 
the duodenum than jejunum and that this in combination with an absence of NaPi-
IIb, may explain the lower levels of transepithelial phosphate absorption seen in 
this region.  In addition, the inhibitory effect of diet-induced iron deficiency on 
duodenal phosphate absorption may be a consequence of increased claudin 3 
protein levels sealing the paracellular pathway. Interestingly, 1,25(OH)2D3, the 
main systemic regulator of intestinal phosphate absorption has been reported to 
reduce claudin 3 expression levels 285, although the functional consequence of 
this on paracellular phosphate transport has not been investigated. It is also of 
interest that in addition to the well-known effect of 1,25(OH)2D3 on the 
transcellular Ca2+ transport pathway 364, the hormone also affects the expression 
of the pore-forming claudins, 2, 12 and 15 257,294, which mediate paracellular Ca2+ 
transport. However, although there is evidence for the role of 1,25(OH)2D3 in the 
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regulation of paracellular Ca2+ and phosphate transport processes 257,364, the 
results of this study indicate that the upregulation of duodenal claudin 3 in 
response to diet-induced iron deficiency is not associated with changes in 
1,25(OH)2D3 or its regulators, PTH and FGF-23.  
Ideas as to the possible cellular mechanism that may be involved in the inhibition 
of paracellular phosphate absorption by diet-induced iron deficiency can be taken 
from evidence linking NHE3 and hepcidin-enhanced duodenal Ca2+ absorption 
365. In β-thalassemic mice, iron hyperabsorption via DMT1 was hypothesised to 
increase the H+ concentration within the enterocyte, resulting in reduced 
transcellular Ca2+ absorption 365. Hepcidin administration in these mice 
decreased iron hyperabsorption and subsequently enhanced transcellular Ca2+ 
transport 365. The authors reported that although paracellular Ca2+ absorption per 
se was unaffected, the effect of iron hyperabsorption on mineral transport was 
not restricted to the transcellular Ca2+ pathway since paracellular absorption of 
Zn2+ was also inhibited in β-thalassemic mice 365,366. In addition, tenapanor was 
shown to abolish the hepcidin enhanced transcellular Ca2+ transport in these 
mice, further confirming that changes in H+ concentration within the enterocyte 
affect mineral absorption 365. Importantly, tenapanor administration has recently 
been demonstrated to inhibit intestinal phosphate absorption in rats fed a normal 
phosphate diet via a pH-mediated inhibition of the paracellular pathway 77. The 
current study, and previous studies in both rodents and Caco-2 cells, consistently 
show that duodenal DMT1 mRNA and protein levels are upregulated under iron 
deficient conditions 356,367. Since DMT1 is an H+-coupled iron cotransporter, its 
upregulation by iron deficiency may result in intracellular accumulation of H+ 
within the enterocyte and subsequent intracellular acidification 356–358. Based on 
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these findings, it is hypothesised that in iron deficiency, this DMT1-mediated 
increase in intracellular acidification stimulates the upregulation of claudin 3 
protein levels within the duodenal enterocyte tight junctions, leading to the sealing 
of the paracellular pathways and the subsequent inhibition of paracellular 
phosphate absorption in this segment.  
The potential intracellular signalling mechanisms underlying this hypothesised 
effect of intracellular acidification on claudin 3 are unknown but may involve the 
regulatory role of intracellular protein kinases on tight junctions. PKA and PKC 
have both been reported to control paracellular permeability by phosphorylating 
pore-sealing claudins within the tight junctions of enterocytes 265. PKA–mediated 
phosphorylation of claudin 3 has been shown to affect its anchoring to tight 
junctions 296, while PKC-δ-induced phosphorylation of claudin 4 has been 
demonstrated to facilitate the assembly of this pore-sealing claudin into intestinal 
epithelial tight junctions 297. However, to date, there is no evidence reporting that 
iron deficiency or intracellular acidification of the enterocyte affects PKA or PKC 
levels or activity. Interestingly, the previously reported finding that metabolic 
acidosis upregulates claudin 3 mRNA expression 368 suggests that increased 
intracellular H+ may directly alter claudin 3 gene transcription.  
Although it is speculated in the current study that DMT1-induced changes in 
intracellular pH result in claudin 3 upregulation in the duodenum, this mechanism 
is unlikely to explain the inhibition of transepithelial phosphate absorption in the 
jejunum of iron deficient rats. Even though a significant upregulation of DMT1 
protein in jejunum was observed in response to iron deficiency in the current 
study, relatively low levels of DMT1 mRNA and protein were detected in this 
segment compared to the duodenum. Therefore, it is unlikely that DMT1 will have 
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any significant impact on intracellular pH in the jejunum. Recent findings in the 
jejunum have shown that tenapanor-induced increase in intracellular H+ did not 
affect the protein levels or trafficking of claudin 3 and that the inhibition of 
phosphate absorption may instead be due to a pH-sensitive conformational 
change in the tight junction 77. Thus, the inhibition of phosphate absorption that 
was observed in the jejunum in iron deficiency may be a result of dynamic 
remodelling or enhanced stability of claudin 3 protein already present within the 
tight junction (reviewed in 283), rather than the increase in expression levels seen 
in the duodenum. Additionally, recent findings have shown that the H+-coupled 
peptide cotransporter 1 (PEPT1), which is localised on the apical membrane 
throughout the rat small intestine 369, is also involved in intestinal iron absorption 
370. Therefore, it is possible that this transporter is also upregulated during diet-
induced iron deficiency, and that this leads to intracellular H+ accumulation as 
documented for DMT1 and therefore, potentially affects the expression or 
dynamic remodelling of claudin 3. While changes in claudin 3 mRNA and protein 
levels in the duodenum are responsible for the inhibition of paracellular 
phosphate absorption in this segment, this was not seen in the jejunum and thus, 
may explain why there was a less striking effect of diet-induced iron deficiency in 
the jejunum.  
Alternatively, the inhibition of phosphate absorption in the duodenum and jejunum 
may be independent of changes in intracellular pH. Recent evidence indicates 
that intracellular Zn2+ depletion decreases claudin 3 gene transcription and 
protein levels 286. Therefore, because DMT1 has also been demonstrated to 
mediate BBM Zn2+ transport 358, it is plausible that DMT1-induced increase in 
intracellular Zn2+ levels in enterocytes may cause the upregulation of claudin 3 
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expression in the duodenum or changes in tight junction permeability in the 
jejunum. In addition, increased intracellular iron levels have also been linked to 
reduced TEER and a consequent increase in tight junction permeability, an effect 
reported to be a result of claudin 4 internalisation due to apoptosis and necrosis 
355. Therefore, it is possible that intracellular iron levels of duodenal and jejunal 
enterocytes may directly affect the localisation of pore-sealing tight junction 
proteins, leading to changes in the paracellular permeability of these intestinal 
segments to phosphate.  
5.5. Conclusion 
In summary, this is the first study to show that diet-induced iron deficiency inhibits 
transepithelial phosphate absorption in the duodenum and jejunum of rats via 
mechanisms that likely involve the paracellular pathway. The findings of this study 
suggest that in the duodenum, a DMT1-induced increase in intracellular H+ 
concentration enhances claudin 3 levels in the tight junction and that this 
mechanism may be responsible for the inhibition of paracellular phosphate 
absorption. In the jejunum, the inhibition of NHE3 activity by iron deficiency may 
result in a pH-sensitive conformational change in the tight junction, leading to the 
inhibition of paracellular phosphate transport. A detailed understanding of the 
intracellular signalling pathways involved in regulating the conformation and 
protein levels of claudin 3 may be beneficial in the identification of novel 
therapeutic targets for the management of hyperphosphataemia in CKD and 
patients with dysfunctional mineral metabolism. 
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Chapter Six 
6.0. General discussion 
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6.1. Aims of the experiments described in this thesis 
Early studies investigating the mechanisms of intestinal phosphate absorption 
identified two transport mechanisms; a passive paracellular process, mediated 
by the simple diffusion of phosphate and an active transcellular mechanism, 
known to be Na+-dependent and regulated by 1,25(OH)2D3 46,126,239–241,244,371–373. 
Following the discovery and characterisation of NaPi-IIb in 1998 40, this protein 
was thought to be the rate-limiting step in intestinal phosphate absorption 353 and 
using nicotinamide, it was subsequently targeted to reduce intestinal phosphate 
absorption in CKD patients 249. However, emerging clinical data using a potent 
NaPi-IIb inhibitor, which was effective in rats 76, but not in humans 318, indicated 
that NaPi-IIb might not be the major phosphate transporter in humans. 
Interestingly, recent findings using tenapanor demonstrated a vital role for NHE3 
in mediating intestinal phosphate absorption in rats and humans, but not in mice 
77. Because of these discrepancies in the efficacy of both NaPi-IIb and NHE3 
inhibitors on intestinal phosphate absorption in mice, rats and humans, the 
suitability of rodents as experimental models to study intestinal phosphate 
absorption needed further clarification. Therefore, one of the aims of the 
experiments described in this thesis was to understand the mechanisms of 
intestinal phosphate absorption in mice, rats and humans. 
Secondly, recent reports have shown that alterations in serum iron levels affect 
bone mineral metabolism in rodents, healthy individuals and in patients with 
genetic phosphate disorders like ADHR 337–341,374–376. Although changes in Ca2+ 
absorption in iron deficiency have been reported in the small intestine of rats 
338,349, there are conflicting reports concerning intestinal phosphate absorption 
349,377. Therefore, the other aim of the experiments described in this thesis was to 
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investigate the effect of diet-induced iron deficiency on phosphate homeostasis, 
with a particular focus on the effect of iron deficiency on intestinal phosphate 
absorption and the underlying mechanisms. 
6.2. Mechanism of intestinal phosphate absorption in mice, rats and 
humans 
In mice, the phosphate uptake data confirmed previously reported findings 38,39 
that the ileum is the major segment responsible for NaPi-IIb-mediated phosphate 
absorption, and the higher capacity of phosphate absorption in this segment in 
comparison to the jejunum was consistent with the expression levels of NaPi-IIb. 
Additionally, complete inhibition of NaPi-IIb by 100 µM NTX9066 or loss of NaPi-
IIb in knock-out animals 77 resulted in 85-90% inhibition of transepithelial 
phosphate absorption in the ileum, with NHE3-regulated paracellular phosphate 
absorption mediating the remaining 10-15%. Unlike the mouse ileum, the 
proximal small intestine is characterised by lower levels of NaPi-IIb and higher 
levels of NHE3. Even with the high levels of NHE3 in the proximal small intestine 
of mice, its contribution to transepithelial phosphate absorption in this segment 
was less than 10% of total phosphate absorption. Based on this finding, it appears 
that phosphate absorption in the proximal small intestine of mice is mainly 
mediated by NaPi-IIb as its low levels are consistent with low phosphate transport 
in this segment. Although the contribution of PiT-1 protein to phosphate 
absorption in mice was not investigated, the similar expression profile of this 
protein in the proximal and distal small intestinal segments is not consistent with 
the different transport capacities between these segments. These findings 
suggest that PiT-1 plays a minor role in intestinal phosphate absorption in mice. 
Based on these findings, phosphate absorption in the mouse small intestine is 
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mainly mediated by NaPi-IIb, with PiT-1 and NHE3-regulated paracellular 
transport playing only a minor role (Figure 6.1). 
 
 
Figure 6.1. Mechanism of phosphate absorption in the mouse ileum. Under normal 
dietary phosphate condition, phosphate absorption is mainly mediated by NaPi-IIb, while 
PiT-1 and the paracellular pathway play a small role. 
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Interestingly, even though the findings of this study indicate that NaPi-IIb is the 
major phosphate transporter in the mouse small intestine, there is evidence 
suggesting that NaPi-IIb is not the predominant phosphate transport pathway 
under physiological conditions 31,145,251,321. Most of the studies speculating that 
NaPi-IIb-mediated phosphate transport pathway in mice is not the major pathway 
put this hypothesis forward following the analysis of the levels of faecal phosphate 
in NaPi-IIb knock-out mice without considering the potential contribution of 
phosphate secretory pathways in the gastrointestinal tracts 322–326 and phosphate 
absorption in the colon 239. It is possible that phosphate transport in the large 
intestine is mediated by passive paracellular diffusion, and this may potentially 
compensate for the loss of NaPi-IIb-mediated phosphate transport in the small 
intestine of NaPi-IIb knock-out mice. Therefore, the speculation against a 
predominant role for NaPi-IIb in the small intestine requires further clarification. 
Future studies are required to investigate the contribution of gastrointestinal 
phosphate secretion to faecal phosphate levels. This will provide more insights 
into the validity of the analysis of faecal phosphate levels as a measure of 
intestinal phosphate absorption. To investigate the rate of gastrointestinal 
phosphate secretion, 33P-labelled phosphate solution could be injected 
intravenously into NaPi-IIb knock-out and wild-type mice, and the levels of 33P 
should be measured in intestinal content or faeces obtained from these mice. 
Additionally, the contribution of passive paracellular phosphate transport in the 
large intestine of NaPi-IIb knock-out mice should also be investigated to 
determine the contribution of the large intestine to overall phosphate absorption. 
This could be done by oral gavage of a phosphate load labelled with 33P, followed 
by measuring the amount of 33P transferred into the circulation at different time 
points. Using the documented duration of chyme in different intestinal segments 
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243, the rate of absorption of phosphate in the large intestine can be identified and 
its contribution to total phosphate absorption could be determined. 
In rats, the expression of the transcellular phosphate transporters, NaPi-IIb and 
PiT-1, was highest in the second part of the proximal small intestine, the jejunum, 
as previously reported by Giral and colleagues 17. In addition to previous findings 
in our laboratory 45, the results of this study showed that the jejunum has the 
highest capacity for phosphate transport and therefore, it is the major segment 
responsible for intestinal phosphate absorption in rats. Unlike in mice, phosphate 
absorption in the rat proximal small intestine is known to be mediated by both 
Na+-dependent and Na+-independent phosphate transport mechanisms. 
Evidence from the regional profiling of rat NaPi-IIb and PiT-1 in this study 
indicated that in comparison to the jejunum, the duodenum is characterised by 
very low levels of these Na+-dependent phosphate transporters. The fact that 
duodenal NaPi-IIb and PiT-1 are very low indicates that these transporters play 
no role in duodenal phosphate absorption in rat. In contrast, higher levels of 
another Na+-dependent BBM transporter involved in paracellular phosphate 
absorption, NHE3, was detected in the duodenum.  
The uptake data of this study showed that the Na+-dependent phosphate 
transport pathway in the duodenum mediates approximately 25% of total 
phosphate transport, with phosphate uptake via the NHE3-regulated pathway 
accounting for approximately 10% of this 25% of total phosphate transport. Since 
NaPi-IIb and PiT-1 play no role in this segment, an unknown Na+-dependent 
phosphate transporter is likely responsible for the remaining 15% of phosphate 
absorption via the Na+-dependent pathway. Using uptake buffer containing 50 
µM phosphate, Candeal and colleagues recently characterised an unknown PFA-
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sensitive Na+-dependent phosphate transporter in the proximal small intestine 
that preferentially mediates the transport of monovalent phosphate and its 
transport activity was shown to be higher at low luminal pH 146. Since PFA 
inhibited less than 5% of duodenal phosphate uptake in the current study (using 
10 mM phosphate), it is unlikely that this recently characterised and yet unknown 
Na+-dependent phosphate transporter is responsible for the remaining 15% of 
phosphate absorption via the Na+-dependent pathway. Moreover, previous 
findings in our laboratory 45 and the results of the current study indicated that the 
Na+-independent phosphate transport pathway is the major pathway responsible 
for duodenal phosphate absorption, accounting for approximately 75% of overall 
phosphate transport (Figure 6.2A) 
In comparison to the duodenum, the Na+-independent pathway mediated 
approximately 60% of the total phosphate transport in the jejunum, with the 
remaining 40% mediated by the Na+-dependent pathway (Figure 6.2B). NHE3 
and NaPi-IIb are the transporters responsible for Na+-dependent phosphate 
transport in the jejunum, with NHE3 mediating more than 25% of total phosphate 
absorption, while NaPi-IIb mediates less than 15% (Figure 6.2B). While the 
mechanism underlying the Na+-dependent phosphate absorption in the jejunum 
involves NaPi-IIb and NHE3, the physiological mechanism or the transporter 
responsible for the predominant Na+-independent pathway in both the duodenum 
and jejunum is yet to be identified.  
Early studies investigating intestinal phosphate absorption demonstrated a 
significant concentration-dependent passive transport process in the duodenum 
and jejunum (reviewed in 252). There are however conflicting reports as to whether 
this passive phosphate transport process is Na+-dependent 46,240 or Na+-
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independent 126,245. While a Na+-dependent NHE3-regulated passive paracellular 
phosphate transport mechanism has been reported in the jejunum 77, previous in 
vivo data in the duodenum showing similar amounts of transepithelial phosphate 
transport in the presence or absence of Na+ 45 suggests that the passive 
phosphate transport process in the duodenum is Na+-independent. In keeping 
with this suggestion, it is worth noting that no significant NHE3-regulated passive 
paracellular phosphate transport was seen in the duodenum in the current study, 
while both the NHE3-regulated and the Na+-independent passive phosphate 
transport pathways were observed in the jejunum.  
The passive Na+-independent phosphate transport pathway has been speculated 
to be mediated by paracellular diffusion 45,319. The finding of this study supports 
the hypothesis that diet-induced iron deficiency results in the inhibition of Na+-
independent phosphate transport in the duodenum of rats, likely due to claudin 3 
upregulation. Increased levels of this claudin have been reported to reduce the 
paracellular permeability of the small intestine to all ions 277. However, it is also 
possible that a Na+-independent transcellular phosphate transporter exists in the 
small intestine 45,319,330. Future studies are required to clarify the exact 
mechanism underlying the Na+-independent phosphate transport pathway in the 
duodenum and jejunum of rats under physiological luminal phosphate 
concentration. In summary, the mechanism of duodenal phosphate absorption is 
predominantly mediated by a Na+-independent paracellular phosphate transport 
process, with a smaller role for a Na+-dependent phosphate transport process 
that is not entirely mediated by NaPi-IIb, PiT-1 and NHE3. However, in the 
jejunum, phosphate absorption is mediated by a NaPi-IIb pathway, an NHE3-
regulated paracellular pathway, and a Na+-independent paracellular pathway, 
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with the latter demonstrated in the current study to have the highest contribution 
(Figure 6.2B). 
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Figure 6.2. Mechanism of phosphate absorption in the proximal small intestine of rats. (A) Phosphate absorption in the duodenum is 
predominantly mediated by the Na+-independent paracellular pathway (~ 75%), with less than 10% of phosphate absorption mediated by NHE3 and a 
yet to be identified (?) Na+-dependent phosphate transporter mediating ~ 15%. (B) Phosphate absorption in the jejunum is predominantly mediated by 
a Na+-independent (~ 60%) and an NHE3-regulated (~ 25%) paracellular pathway, with NaPi-IIb playing a minor role. 
A B 
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Unlike rodents, the segmental profile of NaPi-IIb in the human small intestine 
showed that the duodenum exhibits the highest levels of this active phosphate 
transporter. Interestingly, the similar segmental expression of NHE3 in rats and 
humans suggests that the rat is a better model than the mouse to study NHE3-
regulated paracellular phosphate transport, which has been shown to be a key 
phosphate transport pathway in humans 77,247. Like rodents, intestinal phosphate 
absorption in humans is thought to be mediated by both NaPi-IIb-mediated active 
transport and concentration-dependent passive phosphate transport. The 
functional profile of phosphate absorption in humans has been reported to be 
similar to that of rats, mainly occurring in the duodenum and jejunum, with little 
absorption seen in the ileum 39,45. Although previous studies in humans have not 
directly compared the capacity of phosphate absorption between the duodenum 
and jejunum, there is evidence that the capacity of phosphate transport in the 
jejunum is high 46,320,378. Based on this evidence, in addition to its relatively long 
length, the jejunum has been speculated to absorb the majority of dietary 
phosphate 379. Interestingly, the segmental profile of NaPi-IIb observed in this 
study showing that NaPi-IIb levels are highest in the duodenum could explain the 
lack of effect of NaPi-IIb inhibitors in inhibiting overall phosphate absorption in 
humans 318. This may be because of the relatively shorter length of the duodenum 
and consequently shorter transit time of chyme along this segment 243. In addition, 
it may also be because of the fact that normal phosphate concentration in the diet 
is considerably higher than the Km of NaPi-IIb. In keeping with this suggestion, 
studies investigating the mechanism of phosphate absorption in patients with 
CKD have revealed that this process is mediated by an active transcellular 
pathway that becomes saturated when luminal phosphate concentration exceeds 
2 mM, and a passive phosphate transport pathway that increases linearly with 
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luminal phosphate concentration 371. Because the concentration of phosphate in 
the lumen of the small intestine of these patients ranges from 3.0-12.2 mM 371, it 
is very likely that passive phosphate transport pathway is mainly responsible for 
phosphate absorption in the human small intestine.  
There is evidence that this passive phosphate transport process in humans is 
dependent on intestinal luminal Na+ concentration 46,77. Consistent with this 
evidence, recent cell culture studies and clinical data have shown that NHE3 
inhibition leads to a reduction in passive paracellular phosphate transport 77,247. 
This transport pathway is speculated to be particularly present in the jejunum of 
humans, a segment demonstrated in this study to have the highest levels of 
NHE3. Although NaPi-IIb-mediated active transport and NHE3-regulated 
paracellular pathway for phosphate transport have previously been studied in 
humans, there is limited information concerning the role of the Na+-independent 
pathway. In vitro phosphate uptake studies using human Caco-2 BBE cells 246 
suggest that the Na+-independent transport pathway exhibits similar 
concentration-dependent passive phosphate transport characteristics like the 
Na+-independent passive transport mechanism reported in the human small 
intestine in vivo 245. The exact contribution of the Na+-independent phosphate 
transport pathway in humans remains to be determined. In summary, NaPi-IIb 
plays a small role in phosphate absorption in the human small intestine under 
normal luminal phosphate concentration, with both the NHE3-regulated and Na+-
independent passive paracellular transport pathway likely playing a major role 
(Figure 6.3). 
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Figure 6.3. Mechanism of phosphate absorption in the human small intestine. The 
Na+-independent and NHE3-regulated paracellular pathway for phosphate transport is 
the major pathway in humans, with NaPi-IIb playing a minor role. 
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6.3. Effect of diet-induced iron deficiency on phosphate homeostasis 
The most striking finding of this study was that diet-induced iron deficiency inhibits 
phosphate absorption in the duodenum and jejunum of normal rats, with a more 
prominent effect in the duodenum. The known systemic regulators of phosphate 
homeostasis played no role in the inhibition of phosphate absorption by iron 
deficiency caused by a 2-week administration of an iron deficient diet. Although 
this is the first study showing that diet-induced iron deficiency significantly inhibits 
intestinal phosphate absorption, there was no impact on phosphate balance. This 
may be because the kidney, which is known to be the major regulator of 
phosphate homeostasis under physiological conditions, could adjust phosphate 
excretion to match the amount of phosphate absorbed from the diet. In line with 
this suggestion, a moderate decrease in renal phosphate excretion was 
observed, which was consistent with a modest increase in renal NaPi-IIa levels 
seen in this study. Moreover, the bone phosphate pool is also known to contribute 
to the maintenance of phosphate balance, and since the dietary iron regime 
lasted for only 2 weeks, this homeostatic mechanism may have contributed to the 
unchanged serum phosphate levels in response to diet-induced iron deficiency 
observed in the current study. In comparison, chronic iron deficiency in humans 
337,380 and severe iron deficiency in rats following a 4-week administration of an 
iron deficient diet 338 have been associated with loss of bone mineral and 
osteoporosis. This effect of iron deficiency on bone health may be a consequence 
of increased osteoclast activity to break down bone minerals in order to release 
phosphate into the circulation, in response to reduced intestinal phosphate 
absorption. Although previous findings in neonatal mice, children, and patients 
with genetic mineral disorders and CKD have linked iron deficiency with the 
regulators of phosphate homeostasis 305–308,310,312,376,381, iron deficiency in normal 
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adult animals did not affect phosphate regulators in this study, which is consistent 
with previous findings in healthy adults 305,309. The moderate changes in renal 
NaPi-IIa and urinary phosphate levels observed in this study, in addition to reports 
on changes in renal phosphate excretion following reduced intestinal phosphate 
absorption in NaPi-IIb knock-out mice 31,145,251, suggest that the impact of iron 
deficiency on phosphate homeostasis depends on the degree of inhibition of 
intestinal phosphate absorption. Therefore, it is possible that chronic or a more 
severe iron deficiency than what was observed in the current study, may result in 
a long-term and a more prominent inhibition of intestinal phosphate absorption in 
the proximal small intestine. This may therefore lead to a significant fall in 
postprandial phosphate levels in the circulation, serum PTH and urinary 
phosphate excretion, which were not seen in this study. This speculation is in 
agreement with previous data showing that 4-week administration of an iron 
deficient diet resulted in a moderate decrease in the levels of PTH and 
1,25(OH)2D3 338. Although the levels of active intact FGF-23 following a 4-week 
administration of an iron deficient diet was not investigated in these animals 338, 
its levels might be affected via the previously reported regulatory feedback 
pathways involving dietary phosphate absorption, PTH and 1,25(OH)2D3 7,382–384. 
Future experiments to investigate the effect of long-term administration of an iron 
deficient diet will be required to ascertain whether serum phosphate levels are 
affected under this dietary condition and whether the regulators of phosphate 
homeostasis are significantly altered. 
In summary, iron deficiency induced by a 2-week dietary regime inhibits intestinal 
phosphate absorption by mechanisms that are independent of the systemic 
phosphate regulators, FGF-23, PTH and 1,25(OH)2D3. The moderate increase in 
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renal NaPi-IIa and a consequent fall in the rate of renal phosphate excretion 
observed in this study, in addition to the release of phosphate from bone mineral 
via bone resorption, are both speculated to be responsible for the maintenance 
of normal phosphate homeostasis observed in the iron deficient animals (Figure 
6.4).  
    
Figure 6.4. Effect of diet-induced iron deficiency on phosphate homeostasis. Iron 
deficiency causes the inhibition of intestinal phosphate absorption, which results in a 
potential fall in postprandial serum phosphate levels. This fall in serum phosphate levels 
stimulates the release of phosphate from bone mineral and also stimulates the kidneys 
to conserve phosphate, thus, restoring phosphate balance. 
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6.4. Effect of diet-induced iron deficiency on the mechanisms of intestinal 
phosphate absorption 
Evidence from this study demonstrates for the first time that diet-induced iron 
deficiency inhibits phosphate absorption in the duodenum and jejunum via 
different mechanisms. Iron deficiency inhibited phosphate absorption via the Na+-
independent phosphate transport pathway in the duodenum, while both NHE3-
regulated phosphate transport and the Na+-independent phosphate transport 
pathways were inhibited in the jejunum. Since previous reports suggest that the 
Na+-independent phosphate transport mechanism and NHE3-regulated 
phosphate transport are both mediated via the paracellular pathway 45,77,319,330, it 
is likely that iron deficiency inhibits paracellular phosphate absorption. To support 
this hypothesis, the result of this study showed that the upregulation of DMT1 in 
the duodenum may be responsible for the increased levels of claudin 3, and this 
may reduce the permeability of tight junctions since claudin 3 is a pore-sealing 
claudin. Unlike the duodenum, reduced NHE3 activity in the jejunum of iron 
deficient rats may inhibit paracellular phosphate absorption via the alteration of 
tight junction conformation in the jejunum as suggested by King et al. 77. Changes 
in duodenal claudin 3 levels or jejunal tight junction conformation are speculated 
to inhibit paracellular phosphate absorption in iron deficiency in the current study. 
In addition, the iron deficiency-induced upregulation of claudin 3 levels in the 
duodenum may be contributing to the more striking inhibition of paracellular 
phosphate absorption in this segment, in comparison to the less striking effect 
observed in the jejunum where claudin 3 levels were unchanged.  
Interestingly, evidence from this study suggests that iron deficiency had no impact 
on NaPi-IIb-mediated transcellular phosphate transport in the rat proximal small 
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intestine and in the mouse small intestine. In iron deficiency, even though 
changes in NaPi-IIb mRNA was observed in the duodenum of rats, uptake 
experiments using PFA showed that NaPi-IIb-mediated phosphate transport 
pathway was not affected. Similarly, in the proximal small intestine of mice, iron 
deficiency downregulated NaPi-IIb protein levels, but had no effect on phosphate 
absorption in this segment. Even though changes in NaPi-IIb mRNA or protein 
was observed in the proximal small intestine of mice and duodenum of rats, 
evidence from chapter 3 and previous findings on intestinal NaPi-IIb profile 38,39 
have demonstrated low levels of NaPi-IIb mRNA and protein in these intestinal 
regions. The low levels of NaPi-IIb in these intestinal segments of rats and mice, 
and the unchanged NaPi-IIb mediated phosphate uptake data in response to iron 
deficiency, indicate that the changes in the mRNA or protein levels of NaPi-IIb in 
response to iron deficiency are not physiologically relevant. Importantly, in the rat 
jejunum and mouse ileum where NaPi-IIb is highly expressed, iron deficiency had 
no effect on both NaPi-IIb levels and NaPi-IIb-mediated phosphate uptake. These 
findings confirm that NaPi-IIb plays no role in the inhibition of phosphate 
absorption by iron deficiency in the rat proximal small intestine. 
In comparison to NaPi-IIb, NHE3-regulated phosphate absorption appears to be 
responsible for most of the phosphate absorption via the Na+-dependent pathway 
in the rat jejunum. However, unlike in the jejunum, evidence from this study 
showed that the NHE3-regulated pathway has no contribution to phosphate 
absorption in the duodenum. Based on the lack of contribution of NHE3 to 
duodenal phosphate absorption, it is very likely that NHE3 plays no role in the 
marked inhibition of phosphate absorption by iron deficiency in this segment. In 
contrast, the inhibition of jejunal phosphate absorption by iron deficiency involves 
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at least in part the Na+-dependent NHE3-regulated phosphate transport pathway. 
The inhibition of this phosphate transport pathway in the rat jejunum by tenapanor 
has recently been reported to involve changes in intracellular pH and TEER, both 
affecting paracellular phosphate diffusion 77. Although changes in intracellular pH 
and TEER were not monitored in the current study, it is possible that iron 
deficiency affects paracellular phosphate absorption via similar mechanisms in 
the rat jejunum.  
In response to iron deficiency, the Na+-independent phosphate transport 
mechanism was demonstrated to be inhibited mostly in the duodenum where 
dietary iron is mainly absorbed, with only a minor inhibition of this pathway 
observed in the jejunum. This finding indicates that the adaptation of the rat 
proximal small intestine to low dietary iron content interferes with phosphate 
absorption. In this regard, the upregulation of duodenal and jejunal DMT1 was 
seen in the iron deficient animals and this is speculated to impact the Na+-
independent mechanism of phosphate transport in these segments. As 
previously described in the jejunum following tenapanor inhibition, it is possible 
that increased DMT1 levels result in changes in intracellular pH, claudin 3 levels 
or TEER and these mechanisms may be responsible for the inhibition of the Na+-
independent paracellular phosphate transport pathway in the proximal small 
intestine of iron deficient rats.  
It is worth noting that the relatively higher levels of DMT1 in the duodenum 
compared to the jejunum may be the reason for the substantial inhibition of the 
Na+-independent pathway in the duodenum in comparison to the moderate 
inhibition of this pathway in the jejunum in response to iron deficiency. Based on 
the higher levels of DMT1 protein in the duodenum and the fact that NHE3 
211 
 
inhibition had no effect on duodenal phosphate absorption in this study, increased 
iron and H+ transport by DMT1 in the duodenum potentially caused the 
upregulation of claudin 3. In contrast, the inhibition of NHE3 activity possibly 
resulted in changes in claudin 3 conformation at jejunal tight junctions as reported 
by King et al. 77 rather than expression levels. These findings implicate NHE3 
activity, DMT1 and claudin 3 as potential regulators of the paracellular pathway 
for phosphate transport in the rat proximal small intestine. 
Based on the findings of this study that increased DMT1 function in iron deficiency 
affects intestinal phosphate absorption in rats, and since DMT1-induced iron 
absorption occurs in both the duodenum and jejunum of rats 385,386 and humans 
387, iron absorption via DMT1 may affect phosphate absorption in humans. 
Therefore, increased intestinal iron absorption following oral intake of ferric citrate 
388 or iron-containing phosphate binders 389–391 by CKD patients may be affecting 
claudin 3 and other tight junction proteins and this might result in reduced 
paracellular phosphate absorption. This mechanism may potentially be 
responsible for the enhanced efficacy of ferric citrate and other iron-containing 
phosphate binders in the inhibition of intestinal phosphate absorption in CKD 
patients, even though these therapies are thought to chelate phosphate to reduce 
its absorption 392. 
The hypothesis of the current study is that DMT1-induced iron and H+ 
hyperabsorption in the duodenum of iron deficient rats leads to an increase in 
intracellular acidification, which stimulates increased claudin 3 expression within 
the tight junctions between enterocytes, leading to the sealing of the paracellular 
pores and subsequent inhibition of Na+-independent paracellular phosphate 
absorption (Figure 6.5). To test this hypothesis, future studies could be designed 
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to investigate the role of claudin 3 in paracellular phosphate transport, and 
whether iron deficiency-induced changes in claudin 3 affect phosphate uptake in 
epithelial monolayers, for example, in Caco-2 cells, rat small intestinal epithelial 
cell line (IEC-6) 393 or the recently described intestinal epithelial stem cell 
monolayers 77. Additionally, to test the role of DMT1 in the hypothesised pH-
induced inhibition of intestinal phosphate absorption in iron deficiency, the effect 
of DMT1 overexpression or knockdown on intracellular pH could be monitored 
and this could be correlated with changes in phosphate transport across the 
monolayers. Further experiments to measure the TEER following DMT1 
overexpression or knockdown could also be carried out, and whether changes in 
TEER are linked to the expression of pore-sealing claudins (e.g. claudin 3 and 4) 
could be assessed. It is also possible that changes in claudin 3 levels occur in 
iron deficient enterocytes by a mechanism that is independent of DMT1. This 
possibility could be investigated to completely unravel the cellular mechanisms 
underlying the inhibition of paracellular phosphate transport in iron deficient 
enterocytes.  
Of note in the current study is the fact that diet-induced iron deficiency impacts 
NHE3 activity only in the jejunum, a segment where the inhibition of this 
transporter has been demonstrated to inhibit paracellular phosphate absorption 
via a pH-sensitive conformational change within the tight junction 77,247. Reduced 
NHE3 activity in the jejunum in response to iron deficiency is speculated to mainly 
impact intracellular pH, with a smaller contribution by DMT1, due to the low 
expression profile of this transporter in the jejunum. Therefore, in iron deficiency, 
the combined effect of reduced NHE3 activity and the upregulation of DMT1 is 
speculated to increase intracellular H+ and this results in the reduction of 
paracellular phosphate absorption in the jejunum (Figure 6.6). Unlike the jejunum, 
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the high levels of duodenal DMT1 and the unchanged duodenal NHE3 activity in 
response to iron deficiency, suggest that there is a major difference between the 
mechanisms underlying paracellular phosphate absorption in these segments of 
the proximal small intestine of rats. Further studies are required to better 
understand the segmental differences that exist in the mechanisms of 
paracellular phosphate absorption in the rat duodenum and jejunum.  
Importantly, while the current study speculates that iron deficiency affects 
different mechanisms (DMT1 and NHE3) in the duodenum and jejunum - both 
generating increased intracellular H+, the cellular signalling pathway linking 
intracellular H+ and paracellular phosphate transport requires further 
investigation. To identify potential cellular contributors to the signalling pathway 
underlying the effect of iron deficiency and/or intracellular H+ on paracellular 
phosphate transport via tight junctions, proteomic analysis of cell lysates obtained 
from the duodenum and jejunum of iron deficient and tenapanor-treated rats 
could be carried out. These experiments will identify differentially expressed tight 
junction proteins in both segments in response to the different treatments, and 
may identify protein enzymes that are known to regulate tight junction 
permeability, for example; PKA, PKC-theta and Rho-activated protein kinases.  
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Figure 6.5. Proposed model depicting the effect of diet-induced iron deficiency on 
duodenal phosphate absorption in rats. Increased expression of DMT1 in response 
to iron deficiency causes intracellular acidification because of increased transport of H+ 
into the enterocyte. This leads to increased claudin 3 expression resulting in the sealing 
of the paracellular pathway, thus, inhibiting phosphate absorption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
215 
 
 
 
Figure 6.6. Proposed model depicting the effect of diet-induced iron deficiency on 
jejunal phosphate absorption in rats. Reduced NHE3 activity in response to iron 
deficiency is the major cause of intracellular acidification due to the reduction in the 
transport of H+ out of the enterocyte. In addition, the upregulated DMT1 is likely to play 
a minor role in the accumulation of intracellular H+ due to its low expression profile in this 
segment. The resultant acidification of the intracellular compartment leads to changes in 
tight junction conformation and the consequent inhibition of paracellular phosphate 
absorption. 
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6.5. Conclusion 
The findings of this thesis provide evidence that intestinal NaPi-IIb is the major 
transporter responsible for transepithelial phosphate absorption in mice, while in 
rats, this transporter plays little or no role. NHE3-regulated and the Na+-
independent paracellular mechanisms for phosphate transport are likely to be 
mainly responsible for phosphate absorption in the proximal small intestine of 
rats. Since tenapanor is known to be effective in inhibiting intestinal phosphate 
absorption in humans, NHE3-regulated paracellular phosphate absorption is 
therefore likely to be a key mechanism in mediating Na+-dependent phosphate 
absorption in humans. Moreover, the similar regional expression profile of 
intestinal NHE3 in rats and humans, and the fact that tenapanor inhibits 
phosphate absorption only in these species, suggest that the rat is a better model 
than the mouse to study phosphate absorption in the human small intestine. 
Additionally, this is the first study to provide evidence that diet-induced iron 
deficiency inhibits phosphate absorption in the duodenum and jejunum of rats, an 
effect that is not dependent on NaPi-IIb or the recognised systemic regulators of 
phosphate homeostasis. The results of this study suggest that increased DMT1 
function mainly in the duodenum and reduced NHE3 activity in the jejunum may 
be responsible for the inhibition of phosphate absorption in iron deficient rats. 
This inhibition of intestinal phosphate absorption may be the cause of bone 
disease in individuals with chronic iron deficient conditions. 
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